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S. Louise Pay 
A Systemically-Delivered Stem Cell Therapy for Dry Age-Related Macular 
Degeneration  
Dry age-related macular degeneration (AMD) is a progressive neurodegenerative 
disorder characterized by geographical atrophy of the retinal pigment epithelium 
(RPE), causing irreversible central vision loss. Systemically-delivered bone 
marrow-derived cells (BMDCs), programmed to RPE-like cells via expression of 
human RPE65, regenerate damaged RPE and preserve vision in murine models 
of retinal degeneration. RPE65 rapidly activates adenylate cyclase (AC), which 
then activates endogenous Rpe65 and RPE-associated marker Cralbp. Previous 
studies expressed RPE65 from an integrating lentiviral vector (ILV), which is an 
unnecessary safety risk due to the potential for insertional mutagenesis, as long- 
term expression of RPE65 is not required for BMDC programming. Here, we 
developed a 3rd generation integrase-defective lentiviral vector (IDLV) for 
programming both murine and human BMDCs to RPE-like cells, reducing 
insertional mutagenesis risk and expanding the protocol to include human cells. 
We enhanced IDLV3-RPE65 infection of murine and human BMDCs by preloading 
concentrated vector on RetroNectin at MOI 50, and infecting with low-speed 
centrifugation, increasing RPE65 mRNA levels from ~12-fold to ~25-fold (p<0.05). 
IDLV3-RPE65 infection initiates expression of endogenous Rpe65 mRNA 
expression in murine BMDC and Cralbp/CRALBP mRNA in both murine and 
human BMDCs, indicating programming to RPE-like cells. Inhibiting AC in RPE65-
infected BMDCs abrogated expression of the endogenous genes, confirming the 
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role of AC activation in programming. Critically, IDLV3-RPE65-infected murine 
BMDCs are recruited to and incorporate into to the RPE layer, and preserve vision 
in murine models of retinal degeneration. We conclude that BMDCs programmed 
with IDLV3-RPE65 successfully prevent retinal degeneration progression and are 
appropriate for testing in human cells, with a view to move into human clinical trial 
for the treatment of dry AMD. This approach significantly increases the safety of 
the therapy and is, to the best of our knowledge, the first application of a single 
IDLV in the generation of therapeutic cells from adult stem cells. 
            
 Michael E. Boulton, PhD., Co-Chair 
 
    Maria B. Grant, M.D., Co-Chair 
 
 
 
 
 
 
 
 
 
 
 
 
v 
 
DEDICATION 
 
Susan Montez 
You made me miss my plane. 
“Dante named names”. 
 
Kimberly Quaid 
Thank you. It was an honor to be your friend.  
I couldn’t have done this without you.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
vi 
 
ACKNOWLEDGEMENTS 
 
I would like to express my sincere gratitude to my advisor, Dr. Michael E. Boulton, 
for his guidance and input throughout my graduate career. Working for Dr. Boulton 
has been an enlightening experience, and has given me invaluable insight into 
how best to handle a wide range of challenging situations. He has taught me the 
value of perseverance and patience when things are not working out as intended. 
Secondly, I would like to thank my co-PI, Dr. Maria B. Grant, for her support and 
advice throughout my project, and my research committee members, Drs. Hal E. 
Broxmeyer, Nuria Morral, and Janaiah Kota for keeping me on track and 
encouraging me.  
 
I would also like to thank my advisory committee members, Drs. Kenneth Cornetta, 
Brenda Grimes, Rebecca Chan, Scott Witting, and Brittney-Shea Herbert for their 
support and advice in my early career as a PhD student, and my previous advisor, 
Dr. Helmut Hanenberg, who taught me everything I know about lentiviral vectors, 
along with former colleagues Libby Virts and Stephanie Kelich.   
 
None of the work presented in this study would have been possible without my 
colleagues in the Boulton lab. In particular, Dr. Xiaoping Qi, who taught me how to 
measure mouse vision and analyze all my data, Judith Quigley who flat-mounted 
eyes and took the OCT images of my animals, and Sayak Mitter who taught me 
how to do qRT-PCR and helped prevent my research from making me crazy (well, 
vii 
 
at least no more so than I already was at the start). I am also indebted to the 
undergraduate interns who worked with me over the past few years, Kavya 
Sankhavaram, Jeffery Franklin Willard, Ranier Horton, and Sam Macro, and the 
rest of the Boulton/Grant lab members past and present: Kevin Qian, Zhigang Cai, 
Ahmed Gomaa, Juliana Godoy, Hongmei Gu, Amanda Fisher, Colin IP, Sunu 
Mathew, Mark Morrisson, Eleni Beli, Sergio LiCalzi, Yaqian Duan, Thao Trinh, 
Jimmy Dominguez, Rehae Miller, Tatiana Salazar, and Leni and Nicanor 
Moldovan. 
 
I would like to thank my department, Medical and Molecular Genetics, for always 
being encouraging and supportive. In particular, academic advisor Dr. Brittney-
Shea Herbert and Department Chair Dr. Tatiana Foroud for helping me get through 
the program, Dr. Steve Dlouhy for making the coursework engaging and 
interesting, Dr. Gail Vance, for helping me stay focused,  Dr. Kimberly Quaid, who 
knows why she’s on this list; Joan Charlesworth and her predecessor Peggy 
Knople for handling all our administrative requirements and making sure I never 
forgot to register for anything, and the department in general for being a wonderful 
collection of people who I am grateful to have had the opportunity to train with.  
 
Thank you to Susan Rice for sorting millions of cells for me and teaching me about 
flow cytometry, Keith Condon for sectioning all of my eyes, and Tony Sinn for 
helping with tail vein injections. Simon Curling, Callum Hill, Clare Taylor and 
Douglas Fraser-Pitt for their help in preparing me to start a PhD; my friends from 
viii 
 
the 2011 IBMG cohort Emrin Horgusluoglu, Esther Bolanis, Baindu Bayon, Rania 
Sulaiman, without whom I would never have passed my first year, and my 
qualifying exam study buddies James Butler and Meghan Schellinger.  
 
Thank you to my wonderful parents and family, who have been supportive and 
encouraging and helpful throughout my entire academic career (and life!). I 
wouldn’t be here without you. My church ‘family’, Becky, Ed, Rachel & Sarah Chan, 
and Doug, Valerie, Dan & Jessie Beaver, and friends Nicole Brockmann, Tom 
Beevers, Stuart Learmonth, Nikki Thompson, Brandi Baros, Debbie Seltzer, Cass 
Muesing, Angela Gilham, Alanna Cotch, everyone in the BRT Club, Meaghan and 
Jasper Randall, and Michelle Hamilton-Hibler.  
 
Finally, I would like to thank Aaron Sorkin. 
 
 “What’s next?” 
 
 
 
 
 
 
 
  
ix 
 
TABLE OF CONTENTS 
 
List of Tables…………………………………………………………….....................xii 
List of Figures…………………………………………………………………..……...xiii 
List of Abbreviations………………………………………………………………..…xvi 
Chapter I: Introduction…………………………………………………...……...…......1 
 Introduction………………………………………………………………………1 
 The Retinal Pigment Epithelium………………………………………............7 
  Overview of the Eye………………………………………...................7 
  Structure and Function of the RPE…………………………………..13 
  Regional Variations in the RPE………………………………………30 
  Normal Aging Changes in the RPE………………………………….31 
 Dry Age-Related Macular Degeneration…………………………………….32 
  Overview……………………………………..…………………………32 
  Normal Aging Changes in the Retina………………………………..34 
  Risk Factors for Dry AMD……………………………………..……...35 
  Pathology of Dry AMD……………………………………..………….36 
  Therapies for Dry AMD………………………………………………..49 
 Stem Cell-Based Therapy for Dry AMD……………………………………..52 
  Stem Cells in the Normal Retina/RPE……………………………….54 
  Stem Cells in Dry AMD………………………………………………..56 
 Lentiviral Vectors……………………………………..………………………..65 
  Lentiviral Vector Structure…………………………………………….67 
x 
 
  Integrase-Defective Lentiviral Vectors………………………………69 
 Project Summary……………………………………..………………………..71 
Chapter II: Materials and Methods…………………………………………………..75 
 In Vitro Methods……………………………………..…………………………75 
 In Vivo Methods……………………………………..……… ……………….101 
  
Chapter III: Improving the Infection of Bone Marrow-Derived Cells with an 
Integrase-Defective Lentiviral Vector………………………………………….…...107 
 Introduction……………………………………………………………………107 
 Results…………………………………………………………………...……109 
 Discussion…………………………………………………………………….131 
 
Chapter IV: Murine Bone Marrow-Derived Cells Programmed with 3rd  
Generation Integrating and Integrase-Deficient Lentiviral Vectors Prevent  
Retinal Degeneration…..…………………………………………………………….136 
 Introduction……………………………………………………………………136 
 Results………………………………………………………………………...140 
 Discussion…………………………………………………………………….173 
Chapter V: Pharmacological Treatment of Murine and Human Bone Marrow-
Derived Cells Induces Differentiation to RPE-Like Cells In Vitro and Provides 
Insights into the Mechanism of Programming…………………………………….179 
 Introduction……………………………………………………………………179 
 Results………………………………………………………………………...181 
xi 
 
 Discussion…………………………………………………………………….206 
Chapter VI: Discussion………………………………………………………………211 
Appendices……………………………………………………………………………224 
References……………………………………………………………………………231 
Curriculum Vitae
xii 
 
LIST OF TABLES 
Chapter I: 
Table 1: Life Expectancy and Leading Causes of Death from 1901 to 2014. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
xiii 
 
LIST OF FIGURES 
Chapter I: 
Figure 1.1: The Structure of the Human Eye. 
Figure 1.2: The Structure of the Retina. 
Figure 1.3: The Retinal Pigment Epithelium. 
Figure 1.4: Fundus Photograph of a Normal Human Eye.  
Figure 1.5: Diagrammatic Representation of the Location of Drusen in Dry 
AMD.  
Figure 1.6: Fundus Photographs of Dry AMD Progression. 
Figure 1.7: Foveal Sparing in Human AMD. 
Chapter II: 
 Figure 2.1: Quantification of Cells in a RPE Flat Mount. 
 Figure 2.2: Plasmid Maps  
 Figure 2.3: The Structure of the SOD2-KD Model Ribozymes and Vector 
Chapter III: 
Figure 3.1: IDLVs Infect Murine BMDCs and Induce Expression of 
Endogenous mRNA, and Infect HT1080 Cells with Minimal Integration. 
Figure 3.2: Optimization of the Use of RetroNectin to Infect BMDCs. 
Figure 3.3: Enhancing the Infection of BMDCs with IDLV3-RPE65. 
Figure 3.4: In Vitro Differentiation of Murine and Human BMDCs with IDLV3-
RPE65. 
Chapter IV:  
xiv 
 
Figure 4.1: ILV3-RPE65-MITF and IDLV3-RPE65-MITF Express Human 
RPE65 and MITF, and Initiate Expression of Endogenous Rpe65 and 
Cralbp mRNA in Murine BMDCs. 
Figure 4.2: BMDC-ILV3-RPE65 Incubated Overnight Following Infection Do 
Not Preserve Vision or Are Recruited to the RPE Layer. 
Figure 4.3: BMDC-ILV3-RPE65 Are Recruited to the RPE Layer and 
Preserve Vision in Sodium Iodate-Treated Mice. 
Figure 4.4: BMDCs Programmed with IDLV3 Vectors Preserve Vision in 
Sodium Iodate-Treated Mice. 
Figure 4.5: BMDCs Programmed with ILV3 or IDLV3 Vectors Are Recruited 
to and Integrate at the RPE Layer in SOD2-KD Mice.  
Figure 4.6: BMDCs Programmed with ILV3 or IDLV3 Vectors Preserve 
Retinal Integrity in SOD2-KD Mice. 
Figure 4.7: BMDCs Programmed with ILV3 or IDLV3 Vectors Preserve 
Visual Function in SOD2-KD Mice. 
Figure 4.8: Improvement in Visual Function in SOD2-KD Mice Treated with 
ILV3 or IDLV3 Vectors Persists for At Least Six Months.  
Chapter V: 
Figure 5.1: Forskolin and Rolipram Induce Expression of Rpe65 and Cralbp 
mRNA in Murine BMDCs. 
Figure 5.2: Forskolin and Rolipram Induce Expression of RPE65 and 
CRALBP mRNA in Human BMDCs. 
xv 
 
Figure 5.3: Adenylate Cyclase Inhibitors Inhibit Expression of Rpe65 and 
Cralbp mRNA in Forskolin and Rolipram-Treated Murine BMDCs. 
Figure 5.4: Adenylate Cyclase Inhibitors Inhibit Expression of RPE65 and 
CRALBP mRNA in Forskolin and Rolipram-Treated Human BMDCs. 
Figure 5.5: Adenylate Cyclase Inhibitors Inhibit Expression of Rpe65 and 
Cralbp/CRALBP in Murine and Human BMDCs Infected with ILV3-RPE65.  
Figure 5.6: Forskolin and Rolipram-Treated Murine BMDCs Do Not 
Preserve Retinal Morphology in Murine Models of Retinal Degeneration.  
 
 
Chapter VI:  
Figure 6.1: An Overview of the Treatment of Retinal Degeneration with 
BMDCs.  
 
 
 
 
 
 
 
 
 
 
xvi 
 
LIST OF ABBREVIATIONS 
AMD:    Age-Related Macular Degeneration 
BMDC:  Bone Marrow-Derived Cell 
CRALBP/Cralbp: Cellular Retinaldehyde Binding Protein 
IDLV:    Integrase-Defective Lentiviral Vector 
ILV:   Integrating Lentiviral Vector 
MITF:   Micropthalmia Associated Transcription Factor 
RPE:   Retinal Pigment Epithelium 
RPE65/Rpe65: Retinal Pigment Epithelium Specific Protein 65 kDa 
 
 
 
 
 
 
 
 
 
 
 
 
 
A SYSTEMICALLY-DELIVERED STEM CELLTHERAPY FOR DRY 
AGE-RELATED MACULAR DEGENERATION 
 
 
 
S. Louise Pay 
 
 
 
 
 
 
Submitted to the faculty of the University Graduate School  
in partial fulfillment of the requirements 
for the degree Doctor of Philosophy 
in the Department of Medical and Molecular Genetics,  
Indiana University 
 
 
August 2017 
ii 
 
Accepted by the Graduate Faculty, Indiana University, in partial 
fulfillment of the requirements for the degree of Doctor of Philosophy.  
 
Doctoral Committee 
                                                                  
               Michael E. Boulton, PhD., Co-Chair 
                                                             
    Maria B. Grant, M.D., Co-Chair 
 
                                      
     Nuria Morral, PhD 
 
June 27 2017                                                                                            
     Janaiah Kota, PhD 
 
                                 
     Hal E. Broxmeyer, PhD 
 
 
 
 
iii 
 
S. Louise Pay 
 
A Systemically-Delivered Stem Cell Therapy for Dry Age-Related Macular 
Degeneration  
 
Dry age-related macular degeneration (AMD) is a progressive neurodegenerative 
disorder characterized by geographical atrophy of the retinal pigment epithelium 
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term expression of RPE65 is not required for BMDC programming. Here, we 
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programming both murine and human BMDCs to RPE-like cells, reducing 
insertional mutagenesis risk and expanding the protocol to include human cells. 
We enhanced IDLV3-RPE65 infection of murine and human BMDCs by preloading 
concentrated vector on RetroNectin at MOI 50, and infecting with low-speed 
centrifugation, increasing RPE65 mRNA levels from ~12-fold to ~25-fold (p<0.05). 
IDLV3-RPE65 infection initiates expression of endogenous Rpe65 mRNA 
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human BMDCs, indicating programming to RPE-like cells. Inhibiting AC in RPE65-
infected BMDCs abrogated expression of the endogenous genes, confirming the 
role of AC activation in programming. Critically, IDLV3-RPE65-infected murine 
BMDCs are recruited to and incorporate into to the RPE layer, and preserve vision 
in murine models of retinal degeneration. We conclude that BMDCs programmed 
with IDLV3-RPE65 successfully prevent retinal degeneration progression and are 
appropriate for testing in human cells, with a view to move into human clinical trial 
for the treatment of dry AMD. This approach significantly increases the safety of 
the therapy and is, to the best of our knowledge, the first application of a single 
IDLV in the generation of therapeutic cells from adult stem cells. 
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CHAPTER I: INTRODUCTION 
 
Introduction 
 
The biological process of aging is associated with an increased risk for developing 
a number of diseases, including cancers, [1] cardiovascular diseases, [2] arthritis, 
[3] and neurodegenerative disorders such as Alzheimer’s disease and Parkinson’s 
disease. [4, 5] This increased risk is contributed to by a number of external factors. 
For example, genetic predisposition to disease, [2] environmental factors such as 
smoking and consumption of alcohol, [6] exposure to carcinogenic agents 
throughout life, [7] and pre-existing conditions such as diabetes. [8] 
 
The average life expectancy in the USA has increased significantly in the past 
~100 years, and we continue to develop life-lengthening treatments for infections, 
disorders, and diseases that have in the past resulted in a lower average life 
expectancy (Table 1.). Age-associated diseases are therefore increasingly 
becoming, and will continue to become, a significant concern.  
 
One of the most prevalent aging-associated diseases is Age-Related Macular 
Degeneration (AMD). Risk for developing AMD increased from age 50 onwards. 
[9] By 2020, an estimated 196 million people will be affected by AMD worldwide, 
increasing to 288 million by 2040. [10] AMD is a neurodegenerative disorder 
characterized by progressive, severe, and irreversible central vision loss resulting 
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from degeneration of critical retinal cells at the central region of the eye, known as 
the macula. [9] There are two forms of AMD: wet AMD, and dry AMD.  
 
Wet AMD is characterized by aberrant formation of blood vessels which invade the 
retinal pigment epithelial (RPE) layer and cause degeneration. Visual improvement 
has been observed in ~30% of wet AMD patients treated with anti-VEGF injections. 
[11] Dry AMD is characterized by geographical atrophy of the RPE at the macula 
and there are currently no effective treatments available. [12] Due to the nature of 
dry AMD and the lack of blood vessel invasion of the RPE/retina from the choroid, 
anti-VEGF therapies are not appropriate. The most viable and attractive option for 
targeting dry AMD in the early stages of disease is replacement of the damaged 
RPE. [12, 13] 
 
A number of studies have evaluated the potential for RPE cell transplant or RPE 
replacement with cells derived from adult RPE, embryonic stem cells (ESCs) and 
induced pluripotent stem cells (iPSC) in dry AMD. [14] While success has been 
observed in murine models this, has yet to carry over into human clinical trials. [12] 
Methods of harvesting RPE cells for transplant and delivering transplants of 
therapeutic cell sheets are highly invasive, [15] and cells transplanted by subretinal 
injection have been found to exhibit poor adhesion to the Bruch’s membrane. [16] 
Additionally, there are several safety concerns associated with the use of 
pluripotent cells. ESCs, and both autologous and non-patient-derived iPSCs, may 
be immunogenic, [17] and may form teratomas. [18] The first clinical trial using 
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iPSCs for AMD was interrupted by the discovery of genomic alterations in the 
iPSCs, which were not present in the patient cells from which the iPSCs were 
derived. [19] ESCs also have the added complication of well-documented ethical 
concerns, with their use restricted in several parts of the world due to the fact that 
their harvest requires the destruction of fertilized embryos.  
 
In this study, we present a minimally-invasive, systemically-delivered cell-based 
therapy for RPE replacement in dry AMD, using autologous adult bone marrow-
derived cells (BMDCs) modified with a single lentiviral (LV) vector.  
 
We assert that our approach will maximize recovery of vision, and delay the 
progression of the disease, as BMDC-derived RPE cells can be replaced before 
the neural retina, in particular the photoreceptor layer, has become damaged. 
Systemically injected cells, which are recruited to the RPE from the blood, integrate 
uniformly across the RPE layer as opposed to forming a ‘clump’ in one area, 
improving the potential for visual recovery. [13] The use of autologous BMDCs also 
reduces tumorigenic potential in comparison with iPSCs, due to the fact that the 
cells are not pluripotent. The use of autologous cells also reduces the potential for 
immunogenicity, and is less ethically problematic than the use of ESCs.  
 
In this chapter, we will review the structure and function of the RPE, the pathology 
of dry AMD, the application of stem cell-based therapies in AMD, and the use of 
4 
 
LV vectors. Finally, we will present an overview of the background, approach, and 
outcomes of our study.  
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Table 1. Life Expectancy and Leading Causes of Death from 1901 to 2014. 
The average life expectancy of males and females has increased from 47.6 and 
50.6 to 76.4 and 81.2 respectively between 1901 and 2014. The most prevalent 
causes of death have changed from predominantly infectious disease to lifestyle 
and age-related disease due to changes in the availability of treatments and 
changes in environmental factors which contribute to disease, along with the direct 
link between an increase in average life expectancy and the development with age-
related disease such as Alzheimer’s disease. 
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The Retinal Pigment Epithelium 
 
Overview of the Eye 
 
Almost every organism on Earth has evolved to use the light from the sun as a 
means of perceiving the world or as a source of energy, with over 95% of the 
world’s living organisms possessing a form of eye or a mechanism by which light 
can be processed, such as photosynthesis or carbon fixation. [20-22] The human 
eye is a complex structure consisting of several specialized components (Figure 
1.1) which are involved in the processing of light to generate signals which are 
then processed into images by the brain. At the front of the eye, the cornea, pupil, 
and iris function to control the entry and focusing of light into the eye. At the back 
of the eye, the retina, comprised of ten highly specialized layers, processes light 
into neural impulses, which are then transmitted to the brain via the optic nerve. 
[23]  
 
The retina, from the innermost to outermost layer, consists of: (1) the inner limiting 
membrane, (2) the nerve fiber layer, (3) the ganglion cell layer, (4) the inner 
plexiform layer, (5) the inner nuclear layer, (6) the outer plexiform layer, (7) the 
outer nuclear layer, (8) the outer limiting membrane, (9) the photoreceptor layer, 
and, finally (10,) the RPE. [23] (Figure 1.2). Layers 1-9 of the retina collectively 
comprise the neural retina, which is considered a part of the central nervous 
system (CNS). The neural retina and RPE layer develop separately, with the neural 
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retina formed from the inner wall of the optic cup, which is the evaginated optic 
vesicle that develops as an outgrowth of the diencephalon region of the brain, [24] 
and the RPE layer formed from the outer wall of the optic cup. [24]  
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Figure 1.1 
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Figure 1.1. The Structure of the Human Eye. Diagram of the human eye with 
major structures. (Image from: https://www.intechopen.com/books/autophagy-in-
current-trends-in-cellular-physiology-and-pathology/autophagy-in-ocular-
pathophysiology) 
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Figure 1.2 
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Figure 1.2. The Structure of the Retina. Diagrammatic cross-section of the 
retina, showing the neural retina layers, the underlying RPE, Bruch’s membrane, 
choroid and the specialized cell types at each layer. (Image from: 
https://www.intechopen.com/books/autophagy-in-current-trends-in-cellular-
physiology-and-pathology/autophagy-in-ocular-pathophysiology) 
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Structure and Function of the RPE 
 
Structure 
 
In humans, RPE cells are found at the highest density in the central macular region 
of the eye (Figure 1.1) and become less dense as the retina extends into the 
periphery, [25] with ~4220 cells/mm2 in the foveal region, decreasing to ~3002/mm2 
in the midperipheral regions, and ~1600/mm2 in the outer peripheral fundus.[26] 
Overall, the human RPE layer consists of ~3.5x106 (+/-4.9x105) cells.[26] Each 
RPE cell supports, on average, 30-40 photoreceptors. [27]  
 
The RPE is dysfunctional in most retinal degeneration disorders, and is the first 
cell type to degenerate in AMD. As RPE integrity and viability is critical for the 
maintenance of photoreceptor cells and, thus, the visual cycle and overall retinal 
function, we focused on regenerating the RPE layer in models similar to the 
pathology of dry AMD. The RPE is a highly specialized cell with a number of critical 
functions, the loss of which all contribute to retinal degeneration.  
 
The RPE consists of a monolayer of hexagonal cells which are held together by 
lateral tight junctions, adherens junctions, and gap junctions, forming the outer 
blood/retinal barrier. [28, 29] The RPE cells are polarized, with the apical microvilli 
extending into the interphotoreceptor matrix [30] of the subretinal space, and the 
infolded basal membrane tightly adhered to the underlying collagenous, acellular 
14 
 
Bruch’s membrane via integrin interaction (Figure 1.3). [29, 31] The apical microvilli 
of the RPE interact with the apical rod and cone photoreceptor outer segments in 
the outer nuclear layer of the neural retina. The choriocapillaris of the choroid lies 
directly beneath the Bruch’s membrane and consists of highly fenestrated 
endothelium and capillaries. [29, 32] Mature RPE cells are traditionally considered 
to be post-mitotic, meaning they are terminally differentiated and unable to divide; 
[33] however, it has recently been suggested that the lack of RPE division may be 
maintained by its close proximity with photoreceptor cells, resulting in contact 
inhibition as opposed to permanent inability to divide, which may contribute to 
disease in retinal detachment disorders. [34] While the normal RPE is non-
proliferative, the cells do retain the ability to proliferate as they can be stimulated 
to do so in culture, and become proliferative in some disease such as resulting 
from RPE injury or proliferative vitreoretinopathy. [35-37] 
 
The apical surface of the RPE is unusual in comparison with other epithelial cells 
as it is oriented toward the apical surface of the photoreceptors, as opposed to 
being oriented toward an inner vessel or other lumina. [38] The apical microvilli, 
approximately 5-7 μm long, [39] are intricately connected with, though not 
physically attached to, the apical membrane of the photoreceptor outer segments 
in the interphotoreceptor matrix of the subretinal space, which consists of proteins 
and other components required for the transport of nutrients to and from the retina 
and RPE. [30] This interaction is not only required for ‘communication’ between the 
photoreceptors and RPE, but also for maintaining retinal attachment to the RPE. 
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Disruptions in the interaction between RPE and photoreceptor cells in the 
interphotoreceptor matrix, such as during retinal detachment, results in 
degeneration of the photoreceptors due to their reliance on the RPE and 
subsequent loss of retinal integrity. Aquaporin-1 expressed on the RPE apical 
membrane contributes to maintaining the connection between the RPE and neural 
retina, aiding retinal attachment. [40] 
 
While specific localization of organelles and protein expression is typical in 
epithelial cells, some localization in RPE cells and protein expression differs 
significantly from other epithelial cell types – in contrast to the majority of epithelial 
cells, the sodium/potassium ATPase and associated ankyrin and fodrin proteins 
[41] are located at the apical membrane at the RPE. [38] The adhesion molecule 
N-CAM, [42] the extracellular matrix metalloproteinase inducer EMMPRIN/CD147 
[43, 44] and sodium/potassium/chlorine (Na+/K+/Cl-) transport proteins [38] are 
also located apically in the RPE. The difference in localization of channels and 
proteins is referred to as reverse polarity, [31, 44, 45] which is critical for the 
function of the RPE [38] as the sodium/potassium ATPase is necessary to maintain 
an ionic environment in the subretinal space that is conducive to 
phototransduction. [38] 
 
In contrast to the interaction between the apical membranes of the RPE and 
photoreceptor cells, the basal lamina of the RPE is directly attached to the Bruch’s 
membrane. The basal lamina of the RPE, as is typical for epithelia, is infolded, [46] 
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and considered to be the outermost layer of the Bruch’s membrane, [47] which is 
a permeable extracellular matrix of proteins that separates the RPE from the 
choriocapillaris. The basal lamina of the RPE is approximately 0.15 μm thick, [48, 
49] and contains an extracellular matrix of filamentous structures including 
fibronectin, heparan sulfate, proteoglycans, [47] type IV collagen isoforms alpha 1-
5. [50, 51] Laminins, for example laminins 1, 5, 10, and 11, are produced by the 
RPE cells and aid in the attachment of the RPE cell layer the Bruch’s membrane 
through interaction with integrins. [52] The attachments of the basement 
membrane and the actin cytoskeleton of the cell, adhering the RPE cell to the 
Bruch’s membrane, are observed as focal adhesions at the base of the RPE. [53] 
RPE cells are highly pigmented with melanin [54] and lipofuscin, with the former 
present during development, and the latter accumulating with age. [55] RPE cells 
contain several organelles including lysosomes, [56] phagosomes, [57] 
microperoxisomes, [58] and melanosomes. [31] Melanin is localized to elongated 
melanosomes, which are apically located and can extend into the apical microvilli. 
[59] Mitochondria and nuclei are basally localized, [31, 32] and the cytoplasm 
contains a large amount of smooth endoplasmic reticulum (ER) and minimal rough 
ER. [32]   
 
Finally, the lateral membranes of the RPE function as the outer blood/retinal barrier 
due to the presence of tight junctions near the apical membrane which control 
diffusion between cells, [28] adherens junctions, which are cell-cell adhesion 
molecules that bind cells together through interaction of cadherins with actin 
17 
 
filament,[60] and gap junctions, comprised of connexins, which facilitate the 
movement of small molecules and ions between the RPE cells. [61, 62] These cell-
cell adhesions are necessary for the regulation of transport of nutrients, ions, and 
water between the neural retina and the choriocapillaris [63] and to maintain the 
polarity of the RPE cells. [31]  
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Figure 1.3 
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Figure 1.3. The Retinal Pigment Epithelium. Diagrammatic representation of an 
RPE cell and underlying Bruch’s Membrane and choriocapillaris.  
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Function 
 
The specialized structure of the RPE cell contributes to its multiple functions, all of 
which are necessary to maintain the normal function of both the neural retina and 
the choroid, which the RPE cells support. As the RPE layer is situated between the 
photoreceptor layer and the choroid, and forms a tight barrier which is not 
permeable, the RPE functions to regulate the flow of nutrients, ions, and waste 
products to and from the choroid and the neural retina, maintain the 
photoreceptors, and to limit RPE cell damage resulting from its high metabolic 
activity and exposure to inducers of oxidative stress. [29, 64] While light absorption 
was one of the earliest elucidated functions of the RPE, and was thought for some 
time to be the only function of the RPE, it is now known that critical components of 
RPE functionality also include phagocytosis of the photoreceptor outer segments, 
the recycling of visual cycle substrates, spatial buffering of potassium, 
maintenance of the immune privileged status of the eye, and epithelial transport to 
and from the subretinal space and the choroid. [29, 64]  
 
Light Absorption and Pigments 
 
The pigmented melanin granules of the RPE primarily function to absorb scattered 
light. These pigmented granules, located in melanosomes, absorb light energy, 
protecting the photoreceptor cells and the RPE itself from extensive damage from 
excess light exposure. [65] This is important for maintaining RPE cells, as they are 
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constantly exposed to factors which contribute to oxidative stress and resulting 
oxidative damage and are not capable of regenerating in the event that they 
become damaged, due to their post-mitotic status.[66] RPE cells therefore require 
mechanisms to protect themselves against several sources of oxidative stress. [67] 
Melanin also functions as a metal ion scavenger.[68] Melanosomes in the RPE 
exhibit antioxidant properties against non-light-associated oxidative damage; for 
example, in cells expressing large numbers of melanosomes, oxidative damage 
from hydrogen peroxide was reduced in comparison with cells not expressing 
melanosomes. [67] 
 
In addition to melanosomes, RPE cells also contain lipofuscin and 
melanolipofuscin. Unlike melanosomes, which form during development and 
remain during the lifetime of the cell without the capacity to renew, lipofuscin and 
melanolipofuscin develop during the aging process. These pigments are implicated 
in age-related disorders of the RPE, and will be discussed in more detail in context 
with AMD pathology. Lipofuscinogenesis occurs as a result of autophagy [66] and 
incomplete phagocytosis of photoreceptor outer segments. [69] Melanolipofuscin, 
a combination of melanin and lipofuscin, has been associated with the cells’ post-
mitotic status. [70] 
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Phagocytosis of Photoreceptor Outer Segments 
 
Photoxidative damage to the photoreceptor outer segments results in daily 
shedding of damaged outer segment disc tips, which are constantly renewed at 
the base of the outer segment which is distal to the tip in order to maintain correct 
outer segment length. [71] The full outer segment is replaced in this manner 
approximately every ten days, with 10% of their length lost daily. [72, 73] Shedding 
follows a circadian pattern, with the initiation of disc shedding occurring once per 
day, coinciding with the onset of light. [74] The RPE phagocytoses the shed outer 
segment discs, and, as extensive photoreceptor degeneration is observed when 
the ability of RPE cells to phagocytose these discs is removed, this process is one 
of the most important roles of the RPE in supporting the neural retina. [75] Not only 
is it necessary for the RPE to remove these waste products to avoid pathological 
build-up of debris in the subretinal space, it is also necessary for the RPE cells to 
adequately break down the phagocytosed material to prevent damage to the RPE 
cells themselves – RPE cells must be capable of sustained, long-term processing 
of photoreceptor outer segments as they are non-dividing cells. [73] There are 
several regulated stages of photoreceptor outer segment phagocytosis by the 
RPE, which differs from traditional phagocytosis as RPE cells are not 
macrophages. [73, 75] 
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The first step is the recognition of the photoreceptor outer segment by the RPE, 
and subsequent binding, which is contributed to by phosphatidylserine, αvβ5 
integrin, CD36, and milk-fat-globule-EGF-factor-8 (MFG-E8).[73] 
Phosphatidylserine expression on the photoreceptor discs has been associated 
with recognition of these discs by the RPE as material to be phagocytosed, with 
segments expressing phosphatidylserine, a cell-surface marker indicating cell 
death, are recognized by the RPE.[73] It has been shown that αvβ5 integrin, which 
is apically localized in RPE cells, is required for the binding of shed outer segments 
to the RPE, with binding diminished in the presence of antibodies blocking its 
function in vitro and loss of in vivo phagocytosis observed in αvβ5-/- mice. [76, 77] 
Binding of αvβ5 integrin is facilitated by tetraspanin CD81, resulting in a decrease 
in binding when silenced. [78] MFG-E8, which is expressed early in the light cycle, 
around the same time that photoreceptor outer segment shedding occurs, 
contributes to the roles of αvβ5 integrin and phosphatidylserine, binding to αvβ5 
integrin and facilitating the interaction between the shed photoreceptor discs, αvβ5 
integrin, and the RPE. [73] In mice lacking MFG-E8, RPE phagocytosis of shed 
discs was reduced, and this could be restored by providing soluble MFG-E8, 
confirming its critical role in the phagocytosis process. [79] MFG-E8 and αvβ5 
integrin are not, however, required for the internalization of the segments.[76] This, 
instead, is mediated by expression of CD 36 receptors on the RPE, which has 
been reported to be both required and sufficient for the internalization of bound 
photoreceptor outer segments into the RPE, [76] required for the second step of 
phagocytosis.   
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This second step in RPE phagocytosis of photoreceptor outer segments is 
engulfment and phagosome formation, which is dependent on the expression MER 
proto-oncogene tyrosine kinase (Mertk), growth arrest-specific 6 (Gas6) or protein 
S, focal adhesion kinase (Fak), annexin A2, tubby, Tulp1, and myosin II. [73] The 
role of Fak in engulfment is related to the role of αvβ5 integrin in binding, as Fak 
forms a complex with, and is activated by, apical RPE αvβ5 integrin, and blocking 
this interaction in mice results in a lack of engulfment despite binding to the RPE. 
[80] Knocking out Annexin A2 delays Fak activation, leading to a buildup of 
phagosomes in the RPE. [81] Fak is also required for the phosphorylation of Mertk, 
which is also necessary for engulfment of photoreceptor outer segments by RPE 
cells. [80] In mice with the Mertk gene knocked down, photoreceptor outer segment 
debris builds up in the subretinal space, an absence of phagosomes, and exhibit 
retinal degeneration similar to that observed in the Royal College of Surgeons rat, 
which has an RPE with an inherent inability to phagocytose outer segments due 
to mutations in Mertk, demonstrating a critical role for Mertk in outer segment 
phagocytosis, and highlighting the critical importance of this phagocytosis in the 
support of the neural retina. [82, 83] Mertk binds to Gas6 and related protein, 
Protein S, the roles of which were first determined in the retina. [84] Both Gas6 
and Protein S are ligands of Mertk [85] and function independently to facilitate RPE 
phagocytosis of outer segments, as knocking out either gene does not affect the 
process; however, knocking out both results in a phenotype similar to that 
observed in the absence of Mertk. [84, 86] Additional Mertk ligands tubby and 
tubby-like protein 1 (Tulp) also activate Mertk, facilitate the organization of myosin 
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II in the RPE and colocalization with phagosomes, where tubby and Tulp1 were 
found to be colocalized with Lamp1, a marker of mature phagosomes. [85] 
 
The final step in RPE phagocytosis of photoreceptor outer segments is 
degradation, which requires myosin VIIa, caveolin-1, a decrease in lysosomal pH, 
and an increase in protease activity. [73] Myosin VIIa defects cause Usher 
syndrome, in which abnormal phagocytosis of photoreceptor outer segments leads 
to accumulation of disc segments in phagosomes within the RPE, resulting from 
an inhibition of fusion of the phagosome with the lysosome. [87] Phagosomes must 
be transported to the lysosome for degradation of the phagocytosed contents to 
occur. The protease Cathepsin D and Caveolin-1 are required for phagolysosomal 
degradation of engulfed outer segments,[88] and Caveolin-1 is recruited to the 
phagolysosome, where, in its absence, Cathepsin D levels decrease and 
lysosomal pH increases. [88] An acidic pH in the lysosome along with active 
protease activity is necessary for proper degradation to occur. Therefore, when 
this pH is increased, material will not be adequately cleared from the RPE. Severe, 
progressive vision loss occurs in Usher syndrome as a direct result of a build-up 
of unprocessed outer segment material in the RPE, highlighting the importance of 
clearing this material post-engulfment for maintaining the integrity and function of 
the RPE cell layer. Without the clearance of photoreceptor waste material, RPE 
cells are unable to adequately support the visual cycle.  
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Recycling of Visual Cycle Substrate 11-Cis-Retinal 
 
Another key mechanism by which RPE cells maintain the visual cycle is in the 
recycling of 11-cis-retinal for photoreceptor cells. During the visual cycle, the 
photoreceptor pigment rhodopsin component 11-cis-retinal, which is an isomer of 
retinaldehyde, is converted to all-trans-retinal, thus converting rhodopsin to its 
active form, metarhodopsin II. [89-91] This process is the ‘start signal’ of the visual 
cycle, which necessitates the rapid overturn of visual cycle substrates. 11-cis-
retinal must be available to convert metarhodopsin II back into rhodopsin for the 
next cycle, otherwise, the photoreceptor cells are no longer able to correctly 
polarize. Consequently, the ability of the cells to promote the visual cycle cascade 
is lost. [89-91] Photoreceptor cells, however, are unable to convert all-trans-retinal 
back to 11-cis-retinal, meaning that they are unable to independently generate the 
substrates required for the visual cycle to persist. [89-91] 
 
The RPE cells play a vital role in this process, converting all-trans-retinol into 11-
cis-retinal for the photoreceptors. All-trans-retinal is first converted to all-trans-
retinol in the photoreceptor cell, [92] then transported to the RPE cell, in which it is 
isomerized to form 11-cis-retinal. [89-91] This process involves six key proteins: 
the interphotoreceptor retinoid-binding protein (IRPB), the cellular retinol binding 
protein (CRBP), lecithin-retinol transferase (LRAT), the RPE protein 65kDa 
(RPE65), retinol dehydrogenases (RDH), and the cellular retinaldehyde-binding 
protein (CRALBP). [89-91] All-trans-retinol is chaperoned into RPE cell from the 
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photoreceptor by the interphotoreceptor retinoid-binding protein IRPB, [89-91] 
from which it is transferred to CRBP and is converted to all-trans-retinyl by LRAT. 
[89-91] RPE65 converts all-trans-retinyl to 11-cis-alchohol and, facilitated by 
CRALBP, retinol dehydrogenases convert this to 11-cis-retinal. [89-91] Finally, 
IRBP transports 11-cis-retinal back to the photoreceptor cells. [89-91] 
 
The photoreceptor pigment rhodopsin conversion to metarhodopsin as a result of 
the conversion of 11-cis-retinal to all-trans-retinal also necessitates the spatial 
buffering of potassium by RPE cells. Sodium and calcium decreases in the 
presence of light and photoreceptor polarization results in an increase in uptake of 
potassium from the subretinal space by the inner segments via Na+/K+-ATPase. 
[89] The apical membrane of the RPE first hyperpolarizes in response to the 
decrease in potassium. [64, 93-95] Following this, the basal membrane first 
hyperpolarizes, then depolarizes in response to the decrease in potassium, [94] 
resulting in a release of potassium into the subretinal space. [64] This potassium 
modulation is enabled by the expression of kir potassium channels on the surface 
of the apical plasma membrane of RPE cells, [96-98] and the electrical output of 
the hyperpolarization of the apical and basal membranes of the RPE during 
potassium channel response to photoreceptor polarization is a component of the 
c-wave of the electroretinogram. [99, 100] 
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Trans-Epithelial Transport between the Retina and Choroid 
 
In addition to the previously discussed mechanisms by which the RPE layer 
supports photoreceptor function, the RPE is also responsible for providing energy, 
in the form of glucose, and for transporting the fatty acid 22:6 omega 3 from the 
choriocapillaris to the photoreceptors. [101] Trans-epithelial transport is facilitated 
by sodium/potassium ATPase. [29] Glucose transport is critical to provide the 
energy required for phototransduction, and is transported into the subretinal space, 
for uptake by the neural retina, from the choroid. This is facilitated by the inducible 
glucose transporter GLUT1, and the constitutive glucose transporter GLUT3. [29] 
22:6 omega 3 is required for maintaining the structural integrity of the 
photoreceptor cells and synaptic membranes, [102] and is both transported to the 
subretinal space by the RPE and used by the RPE itself to generate neuroprotectin 
D1. [102, 103] Neuroprotectin D1 is both anti-inflammatory and anti-apoptotic, and 
has been shown to counteract RPE apoptosis following DNA hydrogen peroxide-
induced oxidative stress. [102, 103] 
 
The RPE cells also remove water from the subretinal space to the blood via the 
choriocapillaris, which is necessary to remove the water produced during 
phototransduction, and avoid a buildup of water in the retina. [38, 104-106] 
 
 
 
29 
 
Immune Modulation 
 
The microenvironment of the eye, including the subretinal space and the RPE, is 
protected by the prevention of the free movement of cells from the blood into and 
out of the eye, and therefore the eye is protected from inflammatory and immune 
responses through a combination of a physical barrier to entry of cells from the 
blood, comprised of the inner and outer blood/retinal barrier, inhibition through 
expression of immunosuppressive peptides, and active regulation of systemic 
immune cells. [107] The RPE plays several roles in maintaining the immune 
privileged status of the eye, [108] which is critical for preserving vision by protecting 
the eye from adverse inflammatory responses.  
 
Firstly, the outer blood/retinal barrier formed by the RPE prevents the entry of 
immune cells from the blood stream, effectively separating the eye from the 
systemic immune system. [64] Secondly, RPE cells are capable of directly 
influencing the adaptive immune response by releasing extracellular vesicles in 
response to inflammatory cytokines which are capable of inhibiting T-cells. [109] 
RPE cells express TGF-beta 1 and TGF-beta 2, [110] galectin-1, [111] interleukin 
1 receptor agonist (IL-1ra), [112] MHC molecule and adhesion molecules [29] 
resulting in a down regulation of immune responses. Human RPE cells also 
express the Fas ligand, which, when interacting with activated T-cells, induces 
programmed cell death in the T-cells, indicating that RPE cells are capable of 
directly killing activated T-cells to prevent immune cell invasion of the eye, as 
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blocking Fas ligand expression in the RPE inhibited FasL-associated T-cell death. 
[113] RPE cells also suppress the immune response through expression and 
secretion of complement factor H in response to inflammatory cytokine interferon 
gamma, [114] suggesting a potential mechanism for the involvement of 
complement factor H mutations in both promoting and protecting against the 
development of AMD.  
 
Regional Variations in the RPE 
 
The morphology, function, and size of RPE cells is not consistent across the whole 
human retina, with the number of RPE cells increasing, and size decreasing, 
according to location [115] and correlating with the number of photoreceptors 
requiring the RPE support. [26] Thus, the RPE cells at the macular region, where 
photoreceptors exist at their highest density, are present in larger numbers but are 
smaller (~14 μm) than those observed in the peripheral regions (~60 μm). [26, 116] 
The highest density of RPE cells exists in the fovea. In the peripheral retina, RPE 
cell density is at its highest in the nasal fundus.[26] Functionally, lysosomal 
enzymes acid phosphatase, B-glucoronidase, and N-acetyl-B-glucosaminidase 
have been found to be enriched in peripheral RPE cells in a canine model, [117] 
whereas in a bovine model, another lysosomal enzyme Cathepsin D was found to 
be enriched in the central region compared with the peripheral region, [118] 
indicating that lysosomal function varies across different locations in the eye. 
31 
 
Finally, sodium potassium pump expression varies regionally, with higher 
expression observed in the peripheral vs. macular region in humans. [119] 
 
Normal Aging Changes in the RPE 
 
Several changes occur in the RPE during aging which are not necessarily 
pathogenic, but may contribute to the development of retinal degeneration in some 
individuals. These changes include an overall density loss in RPE cells at a rate of 
approximately 0.3% per year with age, as determined by a study on 53 normal 
human eyes. [26] An increase in apoptotic RPE cells is observed in the macular 
region compared with the peripheral retina with aging; however, interestingly, the 
cell density in this region remains the same despite a high incidence of apoptotic 
cells, and it has been suggested that non-apoptotic peripheral RPE may be 
recruited to compensate for the loss of cells at the macula. [120]  
 
RPE cell pigmentation changes with normal aging, with a loss of melanin, an 
increase in complex melanin granules, and an increase in lipofuscin observed with 
age in a study of 50 eyes aged between 1-100, most pronounced in the macular 
region. [121] The presence of small sub-RPE deposits referred to as drusen is 
observed during normal aging. Numerous large drusen are considered a hallmark 
of AMD, but as small (<63 µm) drusen are also present in normal aging eyes, these 
are not considered indicative of disease in otherwise normal eyes. 
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Feher et al. described a decrease in mitochondrial number and function in normal 
aging eyes in conjunction with lipofuscin granule accumulation, [122] and it has 
also been reported that mitochondrial DNA damage accumulates with aging in 
rodents as a result of a change in the expression of enzymes necessary to repair 
mitochondrial DNA [123] which has become damaged as a result of exposure to 
reactive oxygen species, while the majority of the damage was observed in the 
photoreceptor cells, [124] mitochondrial DNA damage and lack of repair proteins 
was also observed in rodent RPE. [123] 
 
Collectively, while non-pathogenic in the context of vision loss, these aging-related 
changes may contribute to the development of RPE-related disorders such as dry 
AMD. 
 
Dry Age-Related Macular Degeneration 
 
Overview 
 
Senile macular degeneration was first identified by Otto Haab in 1885 as a 
pathological alteration of pigmentation and loss of retinal integrity around the 
macular region which correlated with progressive loss of vision in patients over 50 
years old. However, the disease was not fully characterized until the 1970s, when 
it was determined by Donald Gass that a build-up of sub-RPE deposits (referred 
to as drusen) prior to retinal degeneration at the macular region was a hallmark of 
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what is now referred to as AMD. AMD is a late-onset disorder, with symptoms 
typically appearing in adults age 50 and over. [125] In the 60-64-year-old age 
group, approximately 5% are affected by AMD in its early stages. [9] It is a 
multifactorial, heterogeneous neurodegenerative disorder characterized by the 
build-up of drusen, dysfunction and atrophy of the RPE prior to progressive loss of 
the photoreceptor cells. [125] Two forms of AMD are now known. Wet AMD is 
characterized by exudative choroidal neovascularization (CNV), whereas dry AMD 
is characterized by geographic atrophy in the absence of CNV, [125] though in the 
very late stages of disease, dry AMD can develop into wet AMD in some patients. 
As progression of dry AMD is considerably slower than progression of wet AMD, 
the ‘time window’ for treatment with a cell-based therapy is wider in dry AMD, and 
may allow for more effective early intervention if at-risk patients can be identified 
early in the development of RPE dysfunction. As there are no current effective 
therapeutic interventions available, we have focused on dry AMD in this project, 
hypothesizing that treatment early in the progression of the disease is more likely 
to preserve vision loss as it is easier to prevent further degeneration than to 
address severe vision loss after it has already occurred.  
 
In this section, we will review the normal aging process in the retina, the risk factors 
and pathology of dry AMD, and an overview of treatments which have been 
attempted in dry AMD.  
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Normal Aging Changes in the Retina 
 
The retina undergoes several ‘normal’ changes during aging in addition to the 
previously discussed changes in the RPE. In a study of 100 people aged 6-79 
(without retinal disease), Alamouti and Funk described an overall annual reduction 
in the thickness of the whole retina by 0.53 µM. [126] As much as 20% of retinal 
thinning is attributed to thinning of the retinal nerve fiber layer, [127] observed as 
a 0.44 µM annual reduction in thickness at this layer, [126] or 2.5 µM per decade 
of life. [128] This loss of thickness has been attributed to a loss of ganglion cells, 
with less thinning observed in the optic disc region. [128] The optic nerve itself is 
affected by aging, with the neuroretinal rim region decreasing by 0.28-0.39% 
annually. [129] An increase in both the vertical optic cup diameter and optic cup 
area is also observed during normal aging, resulting in an increase in the cup to 
disc ratio of 0.1 over a 40 year period in a study of 88 healthy individuals. [129] 
The density of cells in the photoreceptor layer also decreases annually with age, 
with a greater loss of rod photoreceptors in comparison with cone photoreceptors 
observed in a study of 55 normal eyes, with a mean yearly density loss of 0.37% 
and 0.18% respectively. [130] Photoreceptor loss occurs predominantly in the 
periphery of the retina and fovea, with the loss of rod cells preceding the loss of 
cone cells. [131] Retinal thinning also includes the macular region of the eye, with 
a loss in retinal thickness at the macular region observed as a loss of macular 
volume of 0.01mm3 per year. [127] 
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These age related changes, like those discussed in the RPE, are considered 
normal and are not typically associated with loss of visual function; however, 
changes in the thickness of the retina is observed in age-related disorders of the 
retina, indicating that the loss of retinal cells as part of the aging process may be 
a precursor to the development of retinal degeneration in people who are exposed 
to other risk factors.  
 
Risk Factors for Dry AMD 
 
The most significant risk factor for AMD is aging. Risk for developing wet or dry 
AMD increases from age 50 onwards, with Caucasian people over 75 years old 
having the greatest risk for developing the condition. [132] Other non-modifiable 
risk factors include gender, [133, 134] iris color, [135] and genetic susceptibility. 
[125, 136, 137] Several genetic loci are associated with either risk for, or protection 
against, developing AMD. [125, 136, 137] However, no single specific gene or 
mutation has been found to cause the disorder directly. Modifiable risk factors for 
AMD include smoking, [138] hypertension, [139] excessive alcohol use, [140] 
obesity, [141] and nutritional deficiencies in antioxidants and zinc. [142] 
 
The complexity of the risk factors, both genetic and environmental, and lack of a 
clear cause beyond aging itself as a common initiator in the development of either 
wet or dry AMD, therapeutic strategies are best aimed toward targeting the 
physiological damage to the retina and underlying RPE as opposed to correcting 
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the different factors which contribute to disease development. While genetic 
factors play a significant role in predisposing people to developing AMD, the 
complexity of the disorder makes it difficult to predict patient outcomes purely on 
the basis of genetics, or to design therapeutics for targeting a single gene, though 
identification and characterization of susceptibility alleles does provide insight into 
pathogenesis of the disease.   
 
Pathology of Dry AMD 
 
The fovea of the macula lutea (‘yellow spot’: Latin, macula = spot; lutea = yellow), 
located at the center of the retina in the human eye, [143] is the primary site of 
RPE degeneration in dry AMD. [144] It is clearly visible as a dark spot on fundus 
images of normal eyes (Figure 1.4). This region of the eye contains a dense 
concentration of cone photoreceptor cells and is responsible for central high acuity 
color vision. There are several clinical features which encompass dry AMD from 
the early to the late stages, including the accumulation of large soft drusen, RPE 
abnormalities, and geographic atrophy of the RPE.   
 
Early AMD 
 
Early dry AMD is largely asymptomatic in terms of altered vision, so it is important 
for early intervention that the disease is recognized before patients begin to 
experience vision loss, which typically presents as gradual diminished vision when 
performing activities such as driving or reading. [145] One or both eyes may be 
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affected, though in the early stages, unilateral vision loss is more common than 
bilateral vision loss. Patients with AMD in one eye have an increased risk for 
developing AMD in the other eye with increased severity where progression and 
severity in the affected eye can be a predictor for accelerated progression and 
severity in the unaffected eye in the future. [146] 
 
Early dry AMD features a thickening and breakdown of the Bruch’s membrane. 
[144, 147] Bruch’s membrane thickening is contributed to by the accumulation of 
primarily phospholipid deposits referred to as basal linear and basal laminar 
deposits within and around the membrane, [148] and also involves an increase in 
TIMP-3 expression in comparison with that observed with normal aging of the 
Bruch’s membrane [149] along with dysregulation of expression of other 
extracellular matrix proteins. [150] The earliest detectable signs of dry AMD are 
visualized as the accumulation of yellow-colored extracellular deposits known as 
drusen. [144] Drusen can be either ‘hard’ or ‘soft’, [151] with hard drusen typically 
<125 µm in diameter and soft drusen >125 µm in diameter. [152] While drusen are 
considered a ‘hallmark’ of AMD, it is important to note that the presence of drusen 
is not directly linked to AMD as some drusen are present at the macula of almost 
all eyes as a part of the normal aging process. [153] One subset of drusen, referred 
to as either pseudodrusen or reticular (‘net like’) drusen, are particularly associated 
with the development of late AMD. [154] 
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Drusen are located between the basement membrane of the RPE and the inner 
collagenous layer of the Bruch’s membrane (Figure 1.5). [155] While has been 
established for some time that the number and size of drusen can be predictive of 
the development of dry AMD, the composition of drusen and the process by which 
these deposits form is not fully understood. [155] It is generally accepted that 
drusen contain lipids, carbohydrates, and proteins [156] derived from both the RPE 
and Bruch’s membrane. [157] Interestingly, some drusen have been shown to 
contain amyloid beta, which is also found in plaques in Alzheimer’s disease. [158]  
Patients are classified as having early, intermediate, or late dry AMD depending 
on the appearance and features at the macular region. [159] Early dry AMD is 
characterized by the presence of drusen between 63 and 125µm in diameter 
(Figure 1.6a.). [159] These early presentations of drusen are not associated with 
vision loss. Changes in the pigmentation of the RPE are also indicative of the onset 
of dry AMD, [44] with hyperpigmentation observed in the presence of drusen which 
has been suggested to result from local RPE cell displacement (Figure 1.6a). [155] 
Intermediate dry AMD is characterized by the presence of medium drusen in 
combination with RPE abnormalities or large drusen (>125 µm) [159] (Figure 1.6b), 
and late-stage dry AMD is characterized by large confluent drusen, central vision 
loss and the presence of geographic atrophy, which is clearly visible as a large 
fluorescent spot in the macular region, with clearly visible choroidal vasculature 
due to regional RPE hypopigmentation. (Figure 1.6c).  
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Figure 1.4 
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Figure 1.4. Fundus photograph of a normal human eye showing the fovea of 
the macula and the optic nerve.  
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Figure 1.5 
 
 
Source: http://www.ophthotech.com 
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Figure 1.5. Diagrammatic Representation of the Location of Drusen in Dry AMD.  
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Figure 1.6 
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Figure 1.6. Fundus Photographs of Dry AMD Progression. (A) Fundus 
photograph of a human eye with early dry AMD. Arrow indicates RPE degeneration 
at the macular region of the eye. Circle indicates the presence of drusen. (B) 
Fundus photograph of a human eye with intermediate AMD. (C) Fundus 
photograph of a human eye with late dry AMD. 
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Late AMD 
 
As the disease progresses, geographic atrophy of the RPE results in loss of 
photoreceptor cells critical for high acuity vision at the macular region, 
autofluorescent lipofuscin granules accumulate in the RPE cells [160, 161] 
subretinal microgliosis develops, [162] and retinal morphology deteriorates. [125] 
The critical role of the RPE in maintaining the retina is first diminished, then lost, 
and the resulting loss of the photoreceptor cells results in irreversible loss of central 
high-acuity vision, as the greatest cell loss is observed at the macular region, 
though peripheral degeneration is also frequently observed. [160]  
 
The presence of geographic atrophy (GA) marks the progression of dry AMD from 
the early to the late stage of the disease, and is clearly visible by fluorescein 
angiography (Figure 1.6c). [163] The area of GA presents as a large 
autofluorescent patch on the fundus photograph, localized around the macular 
region of the eye.[163] The choroidal vessels are prominently visible around the 
area of GA as a result of a localized loss of RPE cell pigmentation, and the GA 
may be surrounded by areas of hyper- and hypo-pigmentation as a result of RPE 
dysfunction (Figure 1.6c). [163] While GA encompasses much of the macular 
region, in some cases identified earlier in the progression of the late stage of dry 
AMD, the area of GA will present in a ‘horseshoe’ figuration, with GA predominantly 
forming in the parafoveal area and not in the fovea itself, which is known as foveal 
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sparing (Figure 1.7), [163] as the involvement of the fovea may occur only in the 
later stages of late AMD, perhaps due to the migration of RPE cells from the 
periphery to the fovea as observed in normal aging. [164] Overall retinal thickness 
is significantly reduced in the region of GA in comparison with retinal thickness loss 
in normal aging, and RPE degeneration is often present in the periphery of the eye 
in addition to in the macular region. [163]  
 
At the very end stage of dry AMD, GA may progress to choroidal 
neovascularization, as observed in wet AMD. [163] This is observed in 
approximately 10-15% of patients with dry AMD, and involves the formation of 
abnormal blood vessels which invade the RPE layer and retina from the 
choriocapillaris, and will eventually lead to the formation of a disciform scar and 
severe vision loss. [163, 165] 
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Figure 1.7 
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Figure 1.7. Foveal Sparing in Human AMD. Asterisks mark the fovea surrounded 
by an area of foveal sparing located around the central region of the macula. This 
indicates areas of undamaged RPE/retina surrounded by areas of extensive 
damage, responsible for moderate preservation of vision at the very center of the 
visual field.  
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Therapies for Dry AMD 
 
As mentioned previously, there are no current effective therapies for dry AMD, 
though several approaches have been attempted in both animal studies and in 
human clinical trial. These include, but are not limited to, macular translocation 
surgery, [166] RPE transplantation, [163] retinal prosthesis implantation, [167] 
induced pluripotent and embryonic stem cell based therapies (iPSC and ESC), 
[168] all of which necessitate invasive surgery. Any procedure which involves 
transplantation into the subretinal space is associated with a significant risk for 
causing blindness due to intraocular hemorrhage, retinal detachment, or 
proliferative vitreoretinopathy as a result of retinal detachment. [169] The benefits 
of these treatments are therefore likely limited to patients in the later stages of 
disease, in order for the potential benefit to outweigh the potential risk, which limits 
the outcome in terms of visual recovery in comparison to what may be possible 
with a less invasive approach such as the one we describe in this study. One non-
invasive study by the Age-Related Eye Disease Study Research Group involving 
treatments with supplements containing a combination of antioxidants and zinc 
indicates that these may aid in preventing the progression of intermediate to late 
dry AMD, though little benefit was observed in patients with earlier stage AMD, 
[170] again making this an option which is unlikely to result in significant visual 
recovery due to the retinal damage already present.  
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The concept of macular translocation has predominantly been investigated in the 
context of wet AMD. Van Meurs et al. reported successful translocation of 
peripheral RPE, but observed deterioration of vision due to vitreoretinopathy in 3 
patients. [171] However, this surgery has been attempted in cases of geographic 
atrophy. The principle of the treatment is to detach and rotate the retina to 
relocalize the macular region in an attempt to preserve it. [163] This treatment is 
therefore highly invasive. Cahill et al. reported a study in which investigated the 
recurrence of RPE damage in dry AMD patients treated with macular translocation 
in 2005, finding that the translocation was insufficient to prevent the new 
development of pathology in the foveal region, indicating that this treatment is 
insufficient to preserve vision in dry AMD. [166] 
 
RPE transplantation was considered an attractive possibility in dry AMD due to the 
fact that it is widely accepted that loss of the RPE precedes damage to the neural 
retina. Therefore, replacing the damaged RPE with a new sheet of RPE cells was 
thought to be sufficient to preserve retinal function and, consequently, vision. The 
majority of human RPE transplantation studies have involved wet AMD with some, 
albeit limited, vision recovery in a small number of people. [172-175] While it was 
found that transplanting sections of a fetal RPE layer into the subretinal space of 
four dry AMD patients did not result in transplant rejection in comparison with 
results observed in wet AMD patients receiving the same treatment, and that visual 
function was not reduced as a result of the procedure in the dry AMD transplant 
recipients, [176] a patient treated with an RPE allograft developed leakage, 
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fibrosis, and anti-photoreceptor immune responses, indicating that while the eye is 
‘immune privileged’, immunosuppression is likely required for allografts and 
allogeneic transplants, which may be detrimental to the health of patients over the 
age of 65. [177] A subsequent trial in wet AMD demonstrated effective engraftment 
of an RPE allograft with immunosuppression, but no recovery of vision. [178] 
 
More recent advances in the development of organic retinal prostheses in a rat 
model [179] and the electrode-based Argus II Retinal Prosthesis System, which 
has been shown to be potentially beneficial in retinitis pigmentosa, [167] present 
an encouraging possibility for future use in humans, though retinal prosthesis 
insertion remains an invasive procedure.  
 
In recent years, researchers have been investigating the potential for stem cell 
treatment in RPE replacement through the subretinal transplant of RPE cells 
derived from ESC or iPSC, which have been successful in animal models. iPSC 
are advantageous as they can be derived from autologous cells and therefore do 
not require immunosuppressant therapy, though the transplant protocol for both of 
these cell types is, again, invasive as it necessitates invasion of the subretinal 
space. Unfortunately, while ESC have been shown to be relatively safe in terms of 
not generating teratomas or tumors, or tissue rejection, in one clinical trial, the 
visual recovery in the patients was limited, as was the patient number. [180] In 
terms of iPSC-derived RPE, the results of the first human clinical trial using these 
cells in AMD by Takahashi’s group in Japan revealed encouraging safety data, and 
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indicated that the treatment does not worsen vision, but again a lack of significant 
improvement in vision was observed. [181] This study was carried out on wet AMD 
patients as opposed to dry AMD, therefore it is not currently known if visual 
improvement can be obtained using these cells in dry AMD. [181] We propose that 
this lack of success in visual recovery is in part due to the fact that patients have 
been treated in the later stages of disease, and that subretinally-transplanted cells 
may not spread out enough to recover vision, as they have been shown to remain 
in a ‘clump’ at the site of injection. [180] The success and limitations of stem cell-
based therapy for dry AMD, along with our strategy for overcoming these 
limitations, will be discussed in more detail in the next section. 
  
Stem Cell-Based Therapy for Dry AMD 
 
Stem cell-based therapies for both wet and dry AMD have been under investigation 
for several years. Multiple sources of cells for cell-based therapy for diseases of 
the retina have been evaluated in murine models and human clinical trials, 
including mature cells such as RPE from the patient or a donor (of either fetal or 
adult origin), [169] iris pigment epithelial cells, [182] Schwann cell, [183] and a wide 
range of stem cells, including: mesenchymal stem cells, [184] adipose stem cells, 
[185] RPE cells derived from ESC, [180, 186] iPSC, [181] and bone marrow-
derived cells. [13, 187] The majority of recent studies have focused on stem cell-
based therapies as opposed to using developed RPE cells as stem cells have the 
capacity to proliferate, whereas using autologous or donor RPE is limited by the 
53 
 
limited proliferation potential of the cells. Stem cell-derived RPE cells are also 
easier to isolate and purify in larger numbers than RPE cells from the patient’s own 
eye or from donor eyes.  
 
Although these therapies have shown considerable promise in animal studies, the 
successful transfer into the clinic for treatment of humans has been limited to date. 
Several complications with the procedures for developing and delivering the cells 
contribute to this, including highly invasive cell delivery protocols, immune system 
rejection of cells where cells are not autologous, the inability of the cells to 
adequately differentiate and spread out across the RPE layer, inability of cells to 
adhere to the aged Bruch’s membrane, and the fact that most studies address late-
stage disease, at a point where replacing the RPE may be insufficient to recover 
vision as a result of involvement of the neural retina in disease development prior 
to treatment with cells.  
 
In order to develop a successful stem cell-based therapy for dry AMD, several 
factors must be considered: (1) the origin of the cells, (2) the cell delivery 
mechanism, and (3) the ability of the cells to integrate and function at the site of 
degeneration. The origin of the cell is closely linked to the available delivery 
mechanisms, of which there are three options: intravitreal, subretinal, and 
systemic. The majority of stem cells must be delivered subretinally for RPE repair, 
though improvement of vision has been observed in murine models with intravitreal 
injections.  
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Systemic delivery is the least invasive method, and is thought to only be 
appropriate for cells of bone marrow origin. In order for systemic delivery to result 
in adequate localization of cells to the RPE, the cells must be able to circulate in 
the blood stream, and it is not clear that any cell type besides the bone marrow 
progenitor-derived RPE and mesenchymal stem cells would have the capacity to 
do this. Bone marrow-derived cells are a particularly attractive cell source for RPE 
replacement therapy because they are easily obtained and can be delivered with 
the minimally invasive systemic injection approach, which provides the potential 
for treating in the early stages of disease. We have therefore focused on bone 
marrow-derived cells in our study. In this section, we will review the results of stem 
cell-based therapies in dry AMD to date, and introduce our approach for the use 
of bone marrow-derived cells, which will be discussed in greater detail in the 
subsequent section.  
 
Stem Cells in the Normal Retina/RPE 
 
Unlike the retinae of fish [188] and amphibians, [189] mammal retinae possess 
limited potential for regenerating damaged tissue. [190-192] There are, however, 
some cell types which contribute to low level neuronal regeneration following 
injury, which can also be induced by exposure to growth factors or drugs. [190-
192] Müller cells, which are neurogenic in fish, [190] have been found to express 
similarities to neural stem cells when activated following retinal injury [190, 193] or 
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exposure to an agonist of the alpha-7 nicotinic receptor. [192] Murine and human 
Müller cells have been found to have potent neurogenic potential when cultured ex 
vivo, indicating that the microenvironment of the mammalian retina actively 
suppresses its own regeneration potential. [193, 194] RPE cells have also been 
shown to be able to proliferate while outside of the retinal microenvironment, and 
a population of cells which have been described as adult RPE stem cells 
(RPESCs) have been isolated from the human retina. [195] Removing these cells 
and activating them ex vivo, or pharmacologically activating them in vivo may be 
a viable option for repair using endogenous mechanisms. [195]  
 
As RPESCs are a relatively recent discovery, few studies have evaluated their 
potential in RPE regeneration in retinal degeneration diseases; however, Stanzel 
et al. reported in 2014 that sheets of RPE generated from human RPE stem cells 
could be transplanted into rabbits and were capable of engrafting and persisting 
without immune system targeting, [196] suggesting that transplant of cells derived 
from RPE stem cells may be more capable of restoring visual function than 
transplant of mature RPE. This is likely to be due to the stem cell status of the 
cells, as immature RPE are more likely to mimic developing RPE than the 
transplant of fully differentiated RPE – if attachment of the cells to the Bruch’s 
membrane following transplant is dependent on the age of the cells, [16] it is 
possible that developing RPE stem cell-derived RPE layers may be able to engraft 
whereas adult RPE may not as a result of expression of early markers that the 
adult RPE would no longer express.  
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Stem Cells in Dry AMD 
 
Embryonic Stem Cell-Derived RPE 
 
ESCs self-renew and can give rise to any cell type. [197] They are associated with 
significant ethical concerns due to their embryonic origin, [198] and ESC-derived 
cells are highly immunogenic, [199] which limits their potential in regenerative 
medicine, especially in cases where giving immunosuppressants to address their 
immunogenicity would be contraindicated for the patient. Immunosuppressant 
therapy is associated with an increased risk for developing infection [200, 201] and 
malignancies. [202, 203] Nevertheless, ESCs have been applied in retinal 
degeneration disorders such as Stargardt’s macular dystrophy and dry AMD in 
three landmark clinical trials. The first two trials were carried out by Massachusetts 
company Ocata Therapeutics (formerly Advanced Cell Technology), [180, 186] 
and the third by a Korean group using cells obtained from Ocata Therapeutics. 
[204] 
 
In the first Ocata Therapeutics trial, reported by Schwartz et al., ESC-derived RPE 
cell transplants in one Stargardt’s muscular dystrophy patient, and one dry AMD 
patient, were not rejected and were not tumorigenic over the 4 month period in 
which patients were monitored. [180] While limited visual recovery was reported, 
the study was designed to evaluate safety, not therapeutic performance, and 
therefore the minimal recovery to 20/800 in the Stargardt’s muscular dystrophy 
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patient, and 7-letter improvement in the dry AMD patient, should not be interpreted 
to indicate that significant visual improvement could not be attained in future 
studies. [180, 205] In the second study, involving 18 patients (nine with Stargardt’s 
muscular dystrophy, and 9 with dry AMD), the ESC-derived RPE were again found 
not to be hyperproliferative. Again, minimal improvements in vision were reported, 
though only in 10 eyes. Additionally, a decrease in visual acuity was observed in 
one eye. [186] In the third trial, a lack of tumorigenicity and rejection was observed 
and visual acuity was improved by 9-19 letters in three out of four patients (two 
with dry AMD and two with Stargardt’s muscular dystrophy). [204] 
 
While these trials provide invaluable information on the tolerability and engraftment 
capacity of transplanted RPE, [180, 186, 204] they have received criticism for the 
statistical relevance of their findings due to the small sample size (24 patients 
total), [206] and the majority of observed improvement in visual acuity could be 
accounted for by the high variability of the mechanisms used to measure vision. 
[207-209] Larger trials are therefore necessary to determine the accuracy of the 
findings. Additionally, the patients were monitored from 4 months up to a year, 
which raises concerns regarding the validity of the authors’ claims that the ESC-
derived RPE are not tumorigenic, since this has not been investigated long-term.  
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IPSC-Derived RPE 
 
iPSC were developed by Takahashi and Yamanaka in Japan in 2007, who 
reported that retroviral vector-mediated expression of Klf4, Sox2, Oct4, and c-Myc 
in human fibroblasts resulted in the dedifferentiation of the cells to an ESC-like cell 
with pluripotent properties. Later modifications to this protocol eliminated c-myc, 
improving the cells’ safety as c-myc is a known oncogene. Expression of two 
additional genes, NANOG and LIN20 in combination with the previously mentioned 
factors enhances the production of iPSCs. [210] The advantages of iPSC as a 
source of RPE cells over ESC are clear: there are no ethical concerns associated 
with their development, and they can be derived from the patients’ autologous 
fibroblasts, reducing their immunogenicity. There are, however, some safety 
concerns with iPSC – Riggs et al. used transcriptome comparisons of iPSC and 
oncogenic foci to determine that the transcriptional alterations associated with 
dedifferentiation of fibroblasts to generate iPSCs are similar to the changes 
associated with the development of cancers. [211] While this in itself should not be 
taken to indicate that the iPSCs themselves are tumorigenic, it highlights that the 
potential for iPSCs to become tumorigenic may be higher than that of ESCs or 
other stem cell types. This may be overcome by screening of iPSCs prior to use in 
regenerative medicine approaches to filter out any tumorigenic cells prior to 
delivery. [212]  
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The most recent study involving iPSC-derived RPE cells was carried out in Japan 
by Yamanaka and Takahashi, the pioneers of iPSC development. While the study 
focused only on wet AMD, it provides valuable insight into the use of iPSC in retinal 
degeneration. First and foremost, the subretinal transplant of a sheet of iPSC-
derived RPE was tolerated and not degraded by the immune system. [181] 
Additionally, no significant adverse effects were observed in any of the patients 
treated. [181] These findings suggest that, while the procedure was invasive, it 
was also safe and did not result in any significant loss of vision, which is 
encouraging for the future potential of iPSC-derived RPE cells in humans. 
Unfortunately, however, as was the case in previously discussed clinical trials, 
none of the patients tested had any improvement in their visual function 1 year 
after the placement of the iPSC-derived sheets. [181] This suggests that lack of 
immunogenicity and retention of the graft over long periods of time may be 
insufficient for visual recovery in patients. While it is encouraging that vision was 
not found to worsen after treatment, the lack of improvement is a significant 
concern, as theoretically the replacement of the RPE layer should improve vision 
if no other complications are present. Some potential reasons for the lack of 
recovery of vision include inadequate ‘communication’ between the RPE and the 
photoreceptors or choroid, inadequate RPE function in terms of supporting 
photoreceptors and the choroid, or, as previously discussed, the photoreceptors, 
choroid, and/or neural retina may have already been too damaged for any recovery 
in vision to occur. It would be interesting to compare, in the long term, the use of 
this technique in patients with early AMD with late-stage AMD patients. Replacing 
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the RPE layer early in disease may preserve vision by delaying the progression 
from early to late AMD; however, obtaining approval to carry out iPSC-derived RPE 
cell sheet transplants on patients who do not yet have substantial vision loss may 
be difficult to obtain. At present it is not known whether or not the RPE sheets are 
capable of supporting vision at all, meaning that they could cause immediate and 
severe worsening blindness in early-stage patients. Further investigation is 
therefore required to determine whether or not the RPE sheets can be functional 
in terms of supporting high acuity vision prior to testing in these patients.  
 
Mesenchymal Stem Cells 
 
Mesenchymal stem cells (MSCs) have been shown to differentiate into an RPE-
like phenotype, expressing RPE65 and the RPE-associated CRALBP gene 
following exposure to RPE-conditioned media, or coculture with RPE cells, 
photoreceptor outer segments, or a combination of these techniques. [213] Rat 
bone marrow-derived MSCs differentiate into RPE, photoreceptor, and glial cells 
in a sodium iodate model [214] and retinal neural cells in a mechanical injury 
model. [215] MSCs have been evaluated in a clinical setting for the treatment of 
retinitis pigmentosa, which is an inherited disorder of the RPE, in which adipose 
tissue-derived MSCs which had not been differentiated to RPE-like cells prior to 
delivery were subretinally injected in 11 patients with advanced disease. [184] 
Complications included the development of choroidal neovascularization at the site 
of injection, and five developed epiretinal membranes requiring further treatment, 
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[184] highlighting the potential damaging effect of subretinal delivery. While none 
of the patients experienced loss of vision as a result of the treatment, only one 
reported an improvement in visual acuity. [184] 
 
Adipose Stem Cells 
 
Recently a study which lacked appropriate FDA approval tested the use of 
autologous adipose tissue-derived stem cells. The cells were injected intravitreally 
and bilaterally, and resulted in severe and irreversible blindness in both eyes of all 
3 patients treated with the procedure within 7 days of treatments. [185] This 
highlights several important issues: (1) that adequate safety studies must be 
carried out prior to use in humans, (2) that stem cell-based therapy must be 
regulated more stringently by the FDA, and, (3) that autologous stem cells are not 
necessarily safe. Autologous cells have long been touted as non-immunogenic. In 
principle, they are – these cells are ‘self’ and should therefore not be recognized 
as foreign when injected back into the patient. However, the treatment of 
autologous cells ex vivo has a significant potential to result in an immunogenic cell 
population when injected back into the patient. ‘Transformation’ of autologous cells 
to cells with an allogeneic phenotype may occur, for example, due exposure of 
cells to serum or growth factors that are either not human or not from the patient. 
Even if the cells themselves are not immunogenic, there is a potential for injecting 
components of reagents or media used to culture or expand cells along with the 
cells if the cell preparation protocol is not adequately monitored, as has been 
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suggested as the reason for the adverse response in the aforementioned clinical 
trial. While some changes to the cells may result in the cells being killed by the 
immune system, the presence of components of culture media have the potential 
to trigger, for example, a type I hypersensitivity reaction in the patient, if injected 
repeatedly. It is therefore vital that autologous cells are handled in such a way that 
they do not become immunogenic in order to protect patients treated with these 
cells. 
 
Bone Marrow Cells 
 
Bone marrow derived cells have traditionally been thought to be limited to 
differentiating along hematopoietic lineages. In recent years, however, it has been 
reported in several studies that these cells may be capable of differentiating along 
non-hematopoietic lineages. [216] Bone marrow-derived cells have an advantage 
over other cell types due to their ability to home to sites of injury; in particular, their 
expression of CXCR4 [217] aids migration to areas of cellular injury that involve 
the release of the cytokine CXCL12/SDF-1, the CXCR4 ligand. [217, 218] Both 
SDF-1 and CXCR4 have been localized to the photoreceptor layer and the retinal 
pigment epithelium in AMD, [219] indicating that the migration of bone marrow-
derived cells to the site of injury in AMD is a potential mechanism for reparative 
processes. The critical advantage of using a bone marrow-derived cell approach 
is that, due to the cells; natural ability to be recruited to sites of injury from the 
bloodstream, therapeutic bone marrow-derived cells can be delivered systemically. 
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This eliminates the need for invasive delivery mechanisms such as subretinal 
injection and subretinal transplant.  
 
It has been shown in two mouse models, one similar to wet AMD involving VEGF 
overexpression, and one similar to dry AMD, resulting from sodium iodate-induced 
RPE injury, that unmanipulated bone marrow-derived cells are recruited to the site 
of injury and regenerate damaged RPE in mice. [220] In this study, GFP LSK cells 
were transplanted into irradiated wild type mice with retinal injury. GFP+ cells were 
found in the RPE layer of these mice and were not found to be a result of cell fusion 
in XY FISH analysis, [220] indicating true incorporation of these cells at the site of 
injury.  
 
Because unmodified BMDCs are capable of genuine integration at the RPE layer, 
the potential for modifying these cells and ‘exploiting’ their regenerative capacity is 
an attractive prospect for treating dry AMD. BMDCs are advantageous because 
they are not pluripotent in the same way that ESCs and iPSCs are – these cells 
will not become any cell type or differentiate into multiple cell types without an 
external factor such as having been recruited to a site of cellular injury. They are 
also not able to form teratomas, as they will not form tumors originating from 
multiple germ layers. These cells are therefore significantly less likely to result in 
adverse side effects than ESC and iPSC. Additionally, they can be obtained from 
the patient, eliminating the need for immunosuppressants as autologous cells will 
not be rejected if handled appropriately ex vivo prior to reinjection. While iPSCs 
64 
 
are also autologous, BMDCs have the advantage that they only need to be 
differentiated from BMDC to RPE, as opposed to being dedifferentiated into iPSC 
prior to differentiation into RPE. As previously mentioned, this makes them 
considerably less likely to be tumorigenic as they are being directed to differentiate 
into a specific cell type from a starting point which is not designed to be able to be 
pluripotent.  
 
We have therefore focused on BMDCs in dry AMD. Prior to this study, our group 
published evidence that BMDCs programmed with the RPE65 gene are recruited 
to and integrate into the RPE layer of mice with either sodium iodate [216] RPE 
damage or SOD2 knockdown-mediated RPE damage.[13] In both of these models, 
expressing the human RPE65 gene resulted in enhanced migration to and 
integration into the RPE layer of BMDCs in comparison with mice treated with 
naïve BMDCs. This approach is thought to work for a number of reasons: (1) 
expressing the RPE65 gene provides a critical RPE function to the cells, (2) 
expressing the RPE65 gene activates expression of a second gene, Cralbp, and, 
(3) enhancing the BMDCs differentiation into RPE likely enhances their integration 
at the site of injury. Additionally, the minimally invasive systemic delivery allows for 
early intervention.  
 
Given that evidence in the literature suggests that mature RPE – either autologous, 
donor-derived, or stem cell-derived – does not integrate into and adequately 
adhere to Bruch’s membrane whereas immature RPE cells do, our approach offers 
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a significant advantage over other approaches. The reason for this is that our 
programming process for differentiating BMDCs results in an immature cell type 
which fully differentiates into mature RPE only in the microenvironment of the 
retina. This process mimics development, as the cells are incapable of fully 
differentiating ex vivo and likely rely on factors present in the retina itself to form 
fully functional RPE. These cells are therefore more likely to be functional than 
cells which have been transplanted after being fully differentiated ex vivo such as 
iPSC and ESC-derived RPE.  
 
Modifying BMDCs to express RPE associated genes prior to delivery likely 
enhances the therapeutic potential of the cells due to their ability to perform the 
function of normal RPE following recruitment for the bloodstream, and expression 
of RPE65 in the cells may also aid in recruiting the cells to the site of injury. While 
the lentiviral vector-mediated approach used in the aforementioned studies has 
proven successful, [13, 187] safety concerns still exist regarding the insertional 
mutagenesis and subsequent tumorigenic potential of lentiviral vectors. In this 
study, we therefore aimed to improve the safety of the RPE65 gene delivery 
approach.  
 
Lentiviral Vectors 
 
Stable integration of replication-incompetent LVs into the host genome allows for 
long-term expression of therapeutic transgenes in quiescent and rapidly dividing 
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cells. [221] However, not all LV transduction applications necessitate stable 
integration or long-term expression of a transgene. [222-224] Since the RPE65 
transgene activates expression of adenylate cyclase in BMDCs, and this in turn 
switches on expression of endogenous Rpe65, [216] we suggested that transient 
expression of the RPE65 transgene may result in sufficient programming in the 
absence of integration, further enhancing the safety of our approach for human 
clinical trials.  
 
In this study, we therefore carried out a systematic optimization of a 3rd generation 
non-integrating lentiviral vector (IDLV) expressing human RPE65 for programming 
both murine and human BMDCs.  
 
LV vectors are an attractive mechanism for gene therapy [225] for several reasons, 
including a high capacity for packaging large amounts of genomic material in 
comparison with retroviral vectors, [225, 226] low rate of replication-competent 
virion production capacity in self-inactivating LV vectors, [227] and the ability to 
generate LV vectors capable of infecting a wide range of cell types. [228, 229] Cell 
types which have been targeted with LV vectors include, but are not limited to, 
direct transduction into muscle cells, [230] neurons, [231] photoreceptors, [232] 
bone marrow-derived cells, [13, 216] hepatocytes, [230] and T-cells. [233] LV 
vector design has been extensively modified since the first use of the vectors, 
incorporating several safety features such as the development of self-inactivating 
vectors and the use of multiple plasmids to generate virions as a means of reducing 
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the probability of producing replication-competent lentivirus (RCL). [227, 234, 235] 
Avoiding RCL is critical to avoid off-target and deleterious effects arising from the 
infection of non-target cell types with the transduced vector, as typically vectors 
used in LV-based gene therapy have the capacity to infect a wide range of cell 
types. [236-238] RCL have not been observed in cells transduced with the most 
commonly used modified LV vectors, referred to as 3rd generation LV vectors. [239]  
 
Lentiviral Vector Structure 
 
The lentiviral vector genome is derived from the naturally occurring human 
immunodeficiency virus strain 1 (HIV-1).[234] Third generation LV vectors, in 
contrast with 1st generation LV vectors which utilized all of the HIV-1 genome with 
the exception of the env gene, are generated with only gag, pol, and rev. [234] This 
significantly improves vector biosafety. [234] Third generation vectors were 
developed by Dull et al., in 1998 and are generated by the transient transfection of 
HEK-293T cells with four plasmids: (a) an expression vector, containing the 
transgene under the control of an appropriate promoter along with the Rev 
responsive element (RRE) for nuclear export, the central polypurine tract (cPPT) 
to aid transduction into non-dividing cells, [240] the packaging signal (ψ), [234] the 
Woodchuck Post-Transcriptional Response Element (WPRE) for stabilizing the 
mRNA, [241, 242] and flanking 5’LTR with a self-inactivating 3’LTR (SIN-LTR) 
[227, 235], (b) a packaging plasmid expressing gag and pol for capsid formation 
and integration, [234] an RRE, and a polyA tail, (c) an envelope plasmid 
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expressing the desired envelope for pseudotyping the vector (typically vesicular 
stomatitis virus G protein, VSV-G), [234, 243] and, finally, (d) a rev-expressing 
plasmid. [234] Rev binds the RRE to nuclear export machinery and facilitates the 
nuclear transport of RRE-expressing transcripts. [234, 244] Together, these 
plasmids provide everything necessary to generate a LV vector expressing the 
desired expression vector which is capable of vector particle formation and stable 
integration into the host cell genome, but not replication. [234] 
                       
The stable integration of standard LV vectors into the host cell genome in both 
dividing and non-dividing cells [245] is a significant advantage of LV vector-based 
therapy for a wide range of diseases. [245] For example, in monogenic disorders 
such as β-thalassemia, caused by mutations in the HBB gene, and 
adrenoleukodystrophy, caused by mutations in the ABCD1 gene, the stable 
integration of LV vectors expressing the normal gene in hematopoietic stem cells 
(HSCs) used for transplant has yielded positive results in clinical trials. [246, 247] 
Success has also been achieved in LV vector-based clinical trials targeting 
Wiskott-Aldrich syndrome, caused by WASp mutations, [229, 248] metachromatic 
leukodystrophy, caused by a deficiency in arylsulfatase A, [249] and blood cancers 
arising from CD19+ cells such as chronic lymphocytic leukemia, acute 
lymphoblastic leukemia, and lymphomas. [233, 250-252] LV vectors have been 
established as considerably safer than other gene therapy approaches such 
oncogenic gamma retroviral vectors and adenoviral vectors, which have resulted 
in severe adverse effects such as the development of T-cell leukemia [253] and 
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fatal inflammatory responses [254] respectively. LV vectors are known to exhibit 
relatively low activation of immune responses against cells expressing the vector 
in comparison with other vectors such the adenoviral vector used in the 
aforementioned clinical trial, [255, 256] making them a safer alternative to these 
vectors.     
 
Integrase-Deficient Lentiviral Vectors 
 
Despite stable integration being advantageous in many LV vector-based therapies, 
integration is associated with the risk of insertional mutagenesis. [257] Insertional 
mutagenesis occurs when the vector inserts within a region of the genome which 
alters the expression of another gene, either through directly interrupting the 
coding sequence or through disruption of elements controlling gene expression 
such as promoter and enhancer regions. [257] Consequences of insertional 
mutagenesis include the development of cancer due to oncogene activation, loss 
of tumor suppressor genes, and other dysregulation of the cell cycle and cell death 
pathways. [258] Additionally, as more and more roles for non-coding regions of the 
genome are being identified, for example, long non-coding RNA and micro-RNAs, 
[259-261] it is becoming clear that LV vector integration may result in aberrant 
gene expression or gene expression control even when not inserted into coding 
regions of the genome. As a result, in applications where permanent expression 
of a transgene may not be required, the use of an integration defective LV (IDLV) 
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vector may significantly reduce the risk of LV vector-based pathologies following 
treatment.  
 
In order for vectors to integrate into the host genome, several enzymes are 
required to be present including the reverse transcriptase, polymerase, and 
protease enzymes generated by the HIV-1 pol gene, [262] the viral integrase 
enzyme, and integrase interactor 1(INI1/hSNF5). [262-266] A simple modification 
to one of these enzymes, the integrase enzyme, in the LV packaging plasmid 
results in the production of a LV vector which retains most of the function of a 
standard LV vector, but is incapable of integrating into the host genome. [267, 268] 
This vector remains episomal and is not retained as cells divide as a result of an 
Aspartic Acid to Asparagine substitution at position 116 in the integrase gene, 
referred to as D116N, which was first found to diminish integrase in a study in 
which the integrase gene was mutated in wild-type HIV-1. [267] When packaged 
with a packaging plasmid, such as the commonly used pMDL [269] or pCD-
NL/BH*DDD [270] packaging plasmids containing the D116N mutation, lentiviral 
particles are no longer capable of integrating into the host cell genome, and 
transgene expression reduces over time as cells divide. pMDL with the D116N 
mutation in its integrase enzyme demonstrates significantly reduced integration in 
comparison with its integrating counterpart, though its efficiency is markedly lower 
.[271]  
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Some residual integration does occur with IDLVs as a result of non-integrase-
mediated integration; however, the rate of residual integration is significantly lower 
than that observed with an integrating virus, and therefore the risk associated with 
insertional mutagenesis is significantly lower. [271] IDLVs have been successfully 
used in several studies in which transient expression of the transgene was 
sufficient, for example expression of zinc finger nucleases or gene editing. [222, 
224, 272-276] 
 
Project Summary 
 
In this study, we have addressed two major concerns in cell-based therapy for dry 
AMD. Firstly, we have established a non-integrating lentiviral vector-mediated 
approach for generating therapeutic cells, significantly reducing the potential for 
off-target effects resulting from insertional mutagenesis. Secondly, we have 
demonstrated that BMDCs treated with these non-integrating vectors are recruited 
to and regenerate damaged RPE in vivo. The use of autologous BMDCs is 
advantageous for four reasons: (1) the cells are not immunogenic as they are 
derived from the patients’ own bone marrow, (2) unlike ESCs, BMDCs are not 
associated with ethical concerns, (3) the cells are not pluripotent and are therefore 
less likely to result in tumorigenesis or teratomas formation in comparison with 
ESC and iPSC, and, (4) the cells can be given to the patient systemically, reducing 
the invasiveness of the treatment in comparison with strategies that involve 
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invasion of the subretinal space. Systemic delivery therefore allows for treatment 
early in the progression of the disease, and thus is more likely to preserve vision.  
In addition, we have expanded our approach to include human BMDCs in vitro, 
demonstrating that these cells can be induced to express RPE-associated markers 
in the same way as murine BMDCs, indicating that our approach is suitable for 
future analysis using human BMDCs in an immune-suppressed murine model of 
retinal degeneration. Furthermore, we have confirmed that adenylate cyclase 
activation plays a critical role in the programming of BMDCs to RPE-like cells in 
vitro.  
 
In Chapter III, we present the results of our first specific aim, which was to generate 
a 3rd generation IDLV expressing RPE65 (IDLV3-RPE65) for programming murine 
and human BMDCs to RPE-like cells. Our previous observation that expressing 
RPE65 induces expression of the endogenous Rpe65 gene; we therefore 
hypothesized that transient RPE65 expression from an IDLV may be sufficient. We 
demonstrate that IDLV3-RPE65 successfully infects both murine and human 
BMDCs and have optimized the infection protocol to address a significant 
difference in the normal infection efficiency of IDLVs vs. ILVs to include (1) high 
titer concentration with LentiX Concentration Reagent, (2) preloading of viral 
particles on RetroNectin, and, (3) spinoculation of cells. We show that BMDCs 
infected with IDLV3-RPE65 express the endogenous Rpe65 gene and RPE-
associated Cralbp gene at similar levels to that observed in cells infected with the 
integrating RPE65 viruses.  
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In Chapter IV, we present the results of our second specific aim, which was to 
evaluate the efficacy of systemically-delivered IDLV3-RPE65-programmed murine 
BMDCs in regenerating the RPE layer in models of retinal degeneration. We 
hypothesized that, as BMDCs infected with IDLV3-RPE65 expressed RPE-
associated genes at a similar level to BMDCs infected with the integrating 3rd 
generation RPE65 vector, ILV3-RPE65, these cells would be capable of 
regenerating the RPE and preserving vision in vivo. In this set of experiments, we 
also included a second set of IDLV and ILV vectors expressing both RPE65 and 
the development-associated gene micropthalmia-associate transcription factor 
(MITF), hypothesizing that this would enhance BMDC programming and 
consequently enhance preservation of vision. Unfortunately, we did not observe 
any advantage in using vectors expressing RPE65-MITF in comparison with 
RPE65 alone. However, we have shown that systemically-delivered murine 
BMDCs programmed ex vivo with IDLV3-RPE65 are recruited to and regenerate 
damaged RPE in both the acute and chronic models of retinal degeneration in 
mice, with improved visual function and evidence of RPE regeneration at the RPE 
layer in mice treated with the vector-modified cells.  
 
Finally, in Chapter V, we present the results of our third specific aim, which was to 
investigate the potential for pharmacological programming of BMDCs to RPE-like 
cells. As we have previously demonstrated that adenylate cyclase activation 
precedes the activation of the endogenous Rpe65 gene following RPE65 vector 
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infection, we hypothesized that activating adenylate cyclase may also promote the 
programming of BMDCs to RPE-like cells with the ability to travel to and regenerate 
the RPE when injected systemically. Using inhibitors of adenylate cyclase, we 
demonstrate that the activation of adenylate cyclase is critical for expression of 
both Rpe65 and Cralbp mRNA, with minimal expression observed in cells treated 
with the inhibitors after exposure to either adenylate cyclase activators or 
lentiviruses expressing RPE65. While BMDCs exposed to these drugs were not 
recruited to the eye in murine models of retinal degeneration, in this study, 
modifications to the protocol are likely to result in successful application of drug-
treated cells in future.  
 
Overall, we have expanded the knowledge of our field by contributing evidence 
that IDLVs may be sufficient to program BMDCs to RPE-like cells for systemic 
delivery, and demonstrated that human BMDCs can also be induced to express 
RPE-associated markers following infection with RPE65 vectors. This allows us to 
move the project another step closer to clinical trials in humans, with experiments 
currently underway to evaluate human BDMCs programmed with RPE65 in an 
immune-suppressed murine model of retinal degeneration.  
 
To the best of our knowledge, our study comprises first example of the use of a 
single IDLV in programming an adult BMDC to differentiate into a cell of non-
hematopoietic lineage.   
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CHAPTER II: MATERIALS AND METHODS 
 
In Vitro Methods 
 
Bacterial Growth 
 
All bacteria were grown in Luria-Bertani (LB) broth or on LB agar. LB broth was 
prepared with 10 g bacto-tryptone, 5 g yeast extract, and 10 g sodium chloride 
(NaCL) (Fisher Bioreagents, BP1427-500) in 800 mL dH2O, mixed using a 
magnetic stirrer and heat plate set at room temperature for 15 minutes. pH was 
adjusted to 7.5 with sodium hydroxide (NaOH; Fisher Bioreagents, BP1425-212) 
prior to adjusting the total volume to 1 L with dH2O. LB broth was then sterilized by 
autoclaving for 20 minutes on the Liquid cycle. For LB agar, 15 g of agar was 
added prior to adjusting the total volume to 1 L. Following sterilization, LB agar 
was allowed to cool to 50⁰C in a waterbath. The required antibiotics were then 
added: for Ampicillin (Fisher Scientific, BP1760-25), 100 µg/mL was used; for 
Kanamycin (Teknova, K2127), 50 µg/mL was used. Agar was mixed well by stirring 
and 12mL poured into petri dishes using aseptic technique. Where air bubbles 
formed, the Bunsen burner flame was briefly held over the plate. Plates were then 
cooled at room temperature for 1-3 hours and stored in plate sleeves at 4⁰C until 
use.  
 
 
76 
 
Transformation into JM110 Bacteria 
 
Prior to cloning, all plasmids were transformed into dam/dcm-negative Escheriscia 
coli strain JM110 obtained from Agilent (Catalog #200239) due to the presence of 
methylation-sensitive restriction sites in the cloning protocols. JM110 bacteria 
were stored on the bottom shelf of a -80⁰C freezer (Thermo Scientific) until use. 
For all transformations, JM110 bacteria were thawed on ice for 30 minutes prior to 
transferring 50 µL bacteria per transformation to 14 mL polypropylene round-
bottom tube (BD Falcon catalog #352059). Two extra tubes containing 25 µL 
JM110 bacteria were prepared each time a transformation was performed – one 
for the pUC18 positive control, and one for a negative control (i.e. untransformed). 
Prior to adding plasmid DNA, 0.85 µL beta-mercaptoethanol was added to each 
aliquot of cells and mixed gently by swirling. 1-5 µg plasmid DNA was then added 
to each tube; 0.5 µL pUC18 plasmid DNA was added to the positive control tube, 
and 0.5 µL dH2O was added to the negative control tube. Tubes were then 
incubated on ice for 30 minutes, heat-shocked for 45 seconds in a waterbath 
preheated to 42⁰C, and incubated on ice for a further two minutes. 250 mL plain 
LB broth was then added to each tube, and tubes were incubated for 1h at 37⁰C 
at 250 rpm. Transformations were then diluted 1:10 and 1:100 and plated on LB 
agar containing the required antibiotic (200 µL of the pUC18 control 
transformations were plated on LB agar containing ampicillin; negative control 
transformations were plated on plates containing all antibiotics used to propagate 
the plasmids being transformed). Plates were left to dry for one hour, inverted, and 
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incubated for 16-20h at 37⁰C. Transformations were considered successful where 
colonies were obtained on the pUC18 plate (~100 colonies) and no colonies were 
obtained on the negative control plate. 12-24 colonies were picked immediately 
after transformation and patched onto a numbered LB agar plate containing the 
required antibiotic. Patch plates were inverted and incubated overnight at 37⁰C 
before being transferred to the cold room. Bacteria was then picked off each colony 
and grown in preparation for miniprepping to screen for the plasmid of interest. 
Once identified, one colony containing the correct plasmid was maxiprepped and 
bacteria were stored long-term as a glycerol stock (80% glycerol in plain LB broth). 
 
Transformation into TOP10 Bacteria 
 
Following cloning, plasmids generated using the JM110 strain were transformed 
into the dam/dcm-positive E. coli ‘One-Shot TOP10’ strain obtained from Thermo 
Fisher (C404010). TOP10 cells were stored on the bottom shelf of a -80⁰C freezer 
prior to use. For transformations, cells were thawed on ice for 30 minutes and 
transferred into pre-chilled 14 mL BD Falcon tubes as previously described, at a 
volume of 25 µL cells per tube per transformation, plus a positive (pUC18) and 
negative (no plasmid) control as previously described. 1-5 µL plasmid was added 
to each tube and mixed by swirling gently. Transformations were incubated on ice 
for 30 minutes, heat-shocked at 42C for 60 seconds, and placed on ice for 1 
minute. 250 µL plain LB broth was added to each tube and tubes were incubated 
for 1 hour at 37⁰C, at 225 rpm. Transformations were then diluted 1:10 and 1:100 
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and plated on LB agar containing the required antibiotic (200 µL of the pUC18 
control transformations were plated on LB agar containing ampicillin; negative 
control transformations were plated on plates containing all antibiotics used to 
propagate the plasmids being transformed). Plates were left to dry for one hour, 
inverted, and incubated for 16-20 hours at 37⁰C. Transformations were considered 
successful where colonies were obtained on the pUC18 plate (~100 colonies) and 
no colonies were obtained on the negative control plate. 12-24 colonies were 
picked immediately after transformation and patched onto a numbered LB agar 
plate containing the required antibiotic. Patch plates were inverted and incubated 
overnight at 37⁰C before being transferred to the cold room. Bacteria was then 
picked off each colony and grown in preparation for miniprepping to screen for the 
plasmid of interest (see: Plasmid Preparation). Once identified, one colony 
containing the correct plasmid was maxiprepped and bacteria were stored long-
term as a glycerol stock (80% glycerol in plain LB broth). 
 
Plasmid Miniprep 
 
Plasmid minipreps were used to obtain plasmid for sequence verification and in 
the intermediate stages of vector cloning. The QIAGen Spin Miniprep Kit (QIAgen, 
27106) was used as per manufacturer’s instructions with the following 
specifications/modifications: single colonies were grown in 5 mL LB broth 
containing the required antibiotic (prepared as previously described) per miniprep 
for 16 hours at 37⁰C at 220 rpm in 14 mL BD Falcon polystyrene tubes (BD, 
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352051), and harvested by centrifugation at 5400 g for 10 minutes at 4⁰C. Where 
JM110 bacteria was used to propagate the plasmid, the extra wash step (step #7 
in the QIAPrep Miniprep Handbook, pg. 21) was carried out. 30 µL sterile nuclease-
free water was used to elute plasmid DNA.  
 
Plasmid Maxiprep  
 
Plasmids used for the production of lentiviruses were prepared by maxiprep to 
ensure that the DNA obtained was of high quality and high concentration (800 
ng/µL – 2 µg/µL). Initially, the PureLink HiPure Plasmid Filter Maxiprep Kit 
(Invitrogen, K210017) was used as per manufacturer’s directions; however, after 
several kits failed to produce good quality DNA, maxipreps were carried out using 
the QIAgen Plasmid Maxi Kit (QIAgen, 12165). As such, the pcz-VSVG lentiviral 
vector envelope plasmid, the pMDL 3rd generation lentiviral packaging plasmid, 
and the pMDL-D116N integrase-deficient lentiviral vector packaging plasmid were 
prepared using the Invitrogen kit, and all other plasmids were prepared using the 
QIAgen kit as per manufacturer’s directions with the following 
specifications/modifications: single colonies were grown in 200 µL LB broth 
containing the required antibiotic (prepared as previously described) at 37⁰C, 
220rpm for 1 hour to generate a starter culture which was then added to 250mL 
LB broth containing the required antibiotic, which was then incubated for 16h at 
37C, 220rpm. Bacterial cells were harvested by centrifugation at 5000 g for 15 
minutes at 4⁰C. Pellets were frozen overnight at 20⁰C as we have previously 
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determined that freezing pellets prior to harvesting plasmids results in a higher 
plasmid yield. The following day, pellets were thawed at room temperature for an 
hour. LyseBlue was added to Buffer P1 for all maxipreps. Buffer P3 was stored at 
4⁰C. Following air-drying of the pellet, the pellet was covered in 300-500 µL sterile 
nuclease-free water and incubated at 4⁰C overnight as we have previously 
determined that this increases the DNA concentration obtained. The following day, 
plasmid DNA was transferred to a sterile microfuge tube and stored at -20⁰C. 
Plasmid DNA concentration was measured as described below.  
 
Measurement of Plasmid Concentration 
 
Plasmid concentration was measured on a NanoDrop 2000 Spectrophotometer 
(Thermo Scientific, SO6497) in the Nucleic Acid>DNA category. Prior to each use, 
the arm of the NanoDrop was raised, and the upper and lower pedestals were 
cleaned with water to ensure no nucleic acids were present on the instrument 
before measurement. The instrument was then blanked using 1uL sterile nuclease-
free water. Water was cleaned from the upper and lower pedestals, and 1 µL 
plasmid was measured for each preparation. Where multiple plasmids were 
measured, the upper and lower pedestals were cleaned with water to avoid cross-
contamination. DNA was considered to be of suitable quality where the 260/280 
ratio of absorbance was between 1.8 and 2.0. Where ratios were considerably 
lower, plasmid preparation was repeated. 
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Plasmid Storage 
 
Bacteria containing plasmids plated on LB agar were kept in the cold room at 4⁰C 
for up to 1 month. Plasmid DNA was stored at -20⁰C in sterile nuclease-free dH2O 
for up to 6 months and at -80⁰C indefinitely. Glycerol stocks of bacteria containing 
plasmids were stored at -80⁰C. 200 µL of an overnight culture of bacteria was 
combined with 200 µL 80% glycerol (prepared in sterile dH2O) in a 2 mL cryovial 
and mixed by inverting. Cryovials were then flash-frozen in liquid nitrogen and 
stored at -80⁰C for up to 1 year. 
 
Plasmids 
 
The 3rd generation lentiviral vector expression plasmid pCDH-EF1-T2A-copGFP 
was obtained from Systems Biosciences (CD823A-1), and the packaging plasmids 
pMDL and pMDL-D116N along with helper plasmid Rev were obtained from the IU 
Vector Production Facility. The pcz-VSVG envelope plasmid was obtained from 
Dirk Lindemann (University of Dresden). The RPE65 gene and the MITF cDNA 
inserts were obtained from GeneArt Gene Synthesis Service. The pTYF-RPE65 
and pTYF-LacZ lentiviral vectors were provided by Lung-Ji Chang (University of 
Florida), packaged with pHP-VSVG.[13, 216]  
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Restriction Enzyme Digests 
 
Restriction enzymes were obtained from New England Biolabs. For cloning of the 
MITF gene into the GeneArt RPE65 plasmid, 1 µg of GeneArt RPE65 (Appendix 
1) and 1 µg of the GeneArt MITF (Appendix 1) plasmid were digested with 1 unit 
each of BamH1 (R3136) and EcoR1 (R3101) in 5 µL CutSmart Buffer and dH2O 
to 20 µL for 1 hour at 37⁰C. For cloning the RPE65 gene and the combined RPE65-
T2A-MITF construct into pCDH-EF1-T2A-GFP (Appendix 1), 1 µg GeneArt RPE65 
and 1 µg pCDH-EF1-T2A-GFP plasmids were digested with 1 unit each of Xba1 
(R0145S) and Sal1 (R3138) in 5 µL CutSmart Buffer and dH2O to 20 µL for 1 hour 
at 37⁰C. Following digest with restriction enzymes, all enzymes were inactivated 
as per manufacturer’s directions and bands separated on a gel.  
 
Agarose Gel Separation of Digested DNA Fragments 
 
To separate required bands from undesired bands, entire restriction digests were 
run on a 0.8% agarose gel containing 10 µL ethidium bromide/100 µL agarose for 
1 hour after enzymes were inactivated with an appropriate DNA ladder to 
determine the size of the correct band(s) to be excised. Bands were excised under 
UV light using a razor blade. 
 
 
 
83 
 
Gel Extraction of Digested DNA Fragments 
 
Digested bands separated by agarose gradient were extracted from agarose gel 
using a Gel Extraction Kit (QIAgen, 28704) as per manufacturer’s directions with 
no protocol modifications. Fragments were eluted in 30 µL dH2O.  
 
Ligation 
 
T4 DNA ligase was used for all ligations (New England Biolabs, M0202S) as per 
manufacturer’s directions with a 3:1 ratio of insert to vector as calculated using the 
New England Biolabs Online Ligation Calculator. Ligations were transformed into 
TOP10 bacteria as previously described, screened, and verified as previously 
described. The resulting plasmid pCDH-RPE65 was used to generate vectors 
ILV3-RPE65 and IDLV3-RPE65. The plasmid pCDH-RPE65-MITF was used to 
generate vectors ILV3-RPE65-MITF and IDLV3-RPE65-MITF. (Figure 2.1). 
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Figure 2.1 
A 
 
 
 
 
 
 
 
 
 
pCDH-RPE65-MITF 
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Figure 2.1.  Plasmid Maps for pCDH-RPE65 (A) and pCDH-RPE65-MITF (B). 
Generated in Serial Cloner.  
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Lentiviral Production and Titer 
 
All lentiviral vectors were produced by transfection of HEK-293T cells (ATCC, HEK 
293T/17 ATCC-CRL-11268) at IU School of Medicine with the exception of the 1st 
generation vector LV-RPE65, obtained from Lung-Ji Chang (University of Florida). 
HEK-293T cells were maintained in high glucose DMEM containing L-Glutamine, 
sodium pyruvate (ThermoFisher, 11995-081), 10% heat-inactivated fetal bovine 
serum (HI-FBS; ThermoFisher, 10437-010) and 1% penicillin/streptomycin (Gibco, 
15070-063), referred to as ‘complete DMEM’. Cells were split every 2-3 days and 
maintained under 80% confluence for no more than 45 passages.  
 
On Day One, HEK-293T cells were plated for infection. Seven 10 cm tissue culture 
dishes (Corning, CLS430167) per viral vector were coated with 6ml Attachment 
Factor (ThermoFisher, S006100) for 3 hours at 37⁰C. Attachment Factor was then 
aspirated and 8x106 HEK-293T cells were plated per plate in 10 mL complete 
DMEM. Plates were swirled to ensure even distribution of the cells across the 
plates. Plates were then incubated for 16-24 hours at 37⁰C. On Day Two, media 
was aspirated from all plates and replaced with 4 mL high glucose DMEM 
containing L-Glutamine, sodium pyruvate, 15% HI-FBS and 1% 
penicillin/streptomycin. For each plate, one 2 mL cryogenic vial containing 955 µL 
plain DMEM and 45 µL of 1 mg/mL polyethylenimine (PEI; Sigma Aldrich, 9002-
98-6 diluted in PBS, Sigma Aldrich 46-013-CM) was prepared. DNA mixture for 
each plate was then prepared in 2 mL cryogenic vials as follows: 1 mL plain DMEM 
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with 5 µg pcz-VSV-G envelope plasmid, 10 µg lentiviral vector (pCDH-RPE65 or 
pCDH-RPE65-MITF), 5 µg packaging plasmid (pMDL or pMDL-D116N), and 1 µg 
Rev. DNA mixture was added to one cryovial of PEI mixture per plate and mixed 
well by vortexing for 30 seconds. Tubes were then incubated at room temperature 
in the dark for 20 minutes. One tube (containing 2mL DNA/PEI mixture) was then 
added to each plate containing HEK-293T cells for a final volume of 6 mL per plate 
and a final HI-FBS concentration of 10%. Cells were incubated for 16 h at 37⁰C. 
On Day Three, media was aspirated and replaced with 5 mL fresh complete DMEM 
and plates were incubated for 20-24 hours. To titer the virus, 50,000 HT1080 cells 
obtained from Dr. David Gilley (IU School of Medicine) were plated per well in two 
6-well plates, coated with 1 mL Attachment Factor for 3 hours prior to plating of 
cells, in 3 mL complete DMEM. On Day Four, the viral supernatant (media on the 
plates containing the DNA/PEI mixture added on Day Two) was harvested and 
filtered through a polyethersulfone membrane with a mesh size of 0.45 µm 
(ThermoScientific Nalgene Filter Unit, 166-0045). Viral supernatant was then 
concentrated by centrifugation at 10,000 g for 2 hrs, or mixed with Lenti-X 
Concentrator (ClonTech, PT4421-2), 1 volume Lenti-X per 3 volumes viral 
supernatant. Lenti-X/viral supernatant mixture was then incubated for 1 hour at 
4⁰C, and centrifuged at 1500 g for 45 minutes. Supernatant was poured off and 
pellet was resuspended to yield a 10-20x concentration by resuspending in sterile 
PBS by carefully pipetting up and down 50x without generating air bubbles. Virus-
containing PBS was then aliquoted in 20-50 µL aliquots and snap-frozen in liquid 
nitrogen. Aliquots were stored at -80⁰C until use.  
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Immediately after freezing, one vial of virus was thawed and titered on HT1080 
cells plated on Day Three. 1.8 mL complete DMEM containing 8 µg/mL Polybrene 
was added to each of 11 sterile Eppendorf tubes. 200 µL viral supernatant was 
added to the first tube to bring the volume to 2 mL and vortexed to mix, to generate 
a 10x dilution. 200 mL was then taken from tube 1 and added to tube 2 and 
repeated until tube 11 to serially dilute the virus for titer measurement. 1 mL of 
each dilution was added to 1 well per tube of the 6-well plates of HT1080, with one 
well as a negative control. After incubating for 16-24 hours at 37⁰C, 3mL complete 
DMEM without Polybrene (Specialty Media, TR-10003-9) was added to each well. 
Plates were then incubated for 48 hours at 37⁰C. Viral titer was determined by 
qRT-PCR for the gene expressed (e.g. RPE65). Titer was confirmed by qRT-PCR 
in murine BMPCs by adding 2.5 µL or 10 µL viral supernatant to 50,000 cells as 
described below.  
 
Calculation of Viral Titer  
 
As the lentiviral vectors used in this study lack a reporter gene, viral titers cannot 
be obtained via FACS. Instead, a standard curve was generated by comparing 2-
∆∆CT values with flow cytometric data for GFP positive cells, to allow a comparison 
between 2-∆∆CT values and viral titer. The pCDH-EF1-GFP virus was serially diluted 
and titered as previously described. The viral titer was determined using the 
following equation:  
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The titer was considered accurate where linear with the dilution factor. The virus 
was then serially diluted and GFP expression was measured by qRT-PCR (as 
described below) to obtain 2-∆∆CT values corresponding with viral titer. A 2-∆∆CT 
value of 30 where 10 µL viral supernatant was added per well containing 50,000 
cells was considered to represent a viral titer of 108 at MOI 50; where a 2-∆∆CT value 
of 30 was obtained with 2.5 µL viral supernatant, viral titer was ~109 at MOI 50. 
 
Lineage Negative Cell Enrichment 
 
All lineage depletion was carried out using the EasySep Mouse Hematopoietic 
Progenitor Cell Enrichment Kit (StemCell Technologies, 19856), which removes 
non-hematopoietic and non-progenitor cells using an antibody cocktail of anti-CD5, 
anti-CD11b, anti-CD19, anti-CD45R/B220, anti-Ly6G/C, and anti-TER119. 
Manufacturer’s directions were followed without modification. The additional wash 
step was not carried out. Following isolation, cells were counted on a 1:10 dilution 
and prepared for Sca1+ cell isolation by FACS.  
 
Sca1 Positive Cell Selection 
 
Cells were resuspended at a concentration of 1x108 cells/mL in flushing buffer. 
20µL Sca1 PE Positive Labeling Reagent (StemCell Technologies, 18756) was 
added per mL of cells and cells were mixed well by pipetting and incubated for 20 
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minutes at room temperature in the dark. Cells were then washed 2x in flushing 
buffer by centrifugation at 350 g for 5 minutes, 1x in PBS by centrifugation at 350 
g for 5 minutes, and finally resuspended at a concentration of 10 million cells per 
mL for FACS sorting. Where GFP cells were used, cells were sorted for double 
positive GFP(cells)/PE(Sca1+) with a 7-12% recovery. Where wild-type cells were 
used, cells were sorted for PE (Sca1+) with a 7-12% recovery. Sorted cells were 
post-sorted to verify purity and were typically >95% pure. For the majority of 
experiments in which cells were not injected back into mice, the Sca1+ isolation 
was carried out using the StemCell Technologies Sca1+ Isolation Kit (18756).   
 
Isolation of BMDCs from Human Blood 
 
Cord blood CD34+ were isolated by the IU AngioBiocore with a purity of >99% by 
flow cytometry assisted cell sorting (FACS) or were obtained from cord blood 
isolations performed in other laboratories. Where CD34+ cells were obtained from 
blood bank samples or healthy donors, white blood cells were first isolated in the 
laboratory by Ficoll gradient followed by flow cytometry assisted cell sorting 
(FACS) for CD34+ cells stained with AlexaFluor488 anti-human CD34 antibody 
(BioLegend, 344518) or bead separation (StemCell Technologies EasySep 
Human CD34 Positive Selection Kit, 18056). For Ficoll separation, blood was 
aliquoted into 25 mL aliquots in 50mL conical tubes and diluted by topping off with 
25 mL PBS containing 2% FBS. A gradient for separation consisting of 1 part Ficoll 
to 2 parts diluted blood was prepared by adding 12.5mL Ficoll to empty 50mL tubes 
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and gently adding diluted blood to the Ficoll, ensuring that the blood sits on top of 
the Ficoll with no mixing. Samples were then centrifuged for 30 minutes at 2300 
rpm in an Eppendorf Centrifuge #5804 with the centrifuge brake off. The interphase 
layer was then transferred to new 50 mL tubes (10-20 mL per tube) and topped off 
with PBS containing 2% FBS and 1 mM EDTA. Samples were centrifuged for 10 
minutes at 350 g.  (Eppendorf Centrifuge 5804). Pellets were resuspended in 1 mL 
PBS containing 2% FBS and 1 mM EDTA. Red blood cells were then lysed by 
adding ammonium chloride (5-9 mL) to the sample and incubating on ice for 15 
minutes. Samples were then washed three times with PBS containing 2% FBS and 
1mM EDTA by centrifugation at 350 g (Eppendorf Centrifuge 5804). Cells were 
counted on a 1:100 dilution and prepared for isolation of CD34+ cells. Where the 
EasySep Kit was used, cells were isolated as per manufacturer’s directions with 
no modifications. Where FACS was used, cells were resuspended at 10 million 
cells/mL and incubated for 20 minutes at room temperature in the dark with 5 
µL/million cells of Alexa Fluor 488 anti-human RPE65 antibody. Cells were then 
washed 3x with PBS by centrifugation at 350 g and resuspended at a volume of 
10 million cells/mL for flow sorting.  
 
Lentiviral Vector Infection of Primary Cells for Injection 
 
Where cells were injected into mice, and unless otherwise specified in the text, all 
infections were done by 2 hour spinoculation at 150 g, 21⁰C on RetroNectin 
(ClonTech, T100B) as per manufacturer’s directions with the exception of the 
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concentration used: tubes and plates were coated with RetroNectin at a 
concentration of 2 µg/cm3. All cells were infected at a concentration of 1x105 cells 
per mL at an MOI of 50 in tubes with all integrating vectors, unless a higher or 
lower MOI is indicated. Following infection, cells were immediately washed 3x in 
PBS and resuspended in PBS at a concentration of 50,000 cells/100 µL for 
injection into mice.  
 
Lentiviral Infections for Optimization of Protocols 
 
Infections were carried out using a number of different methods to identify the 
optimum procedure. Briefly, BMDCs were infected overnight for 16 hour or by 2 
hour spinoculation at 150 g, 21oC, with no reagent, Polybrene, Protamine, 
RetroNectin at a concentration of 0-12 μg/mL added to media, or on RetroNectin 
at 0-12 μg/cm3.  RetroNectin was either pre-loaded with virus for 30 min at 37oC 
prior to infection, or cells and virus were added together at the same time as the 
infection. RetroNectin was used to coat up to 4 plates per preparation. 5000-
100,000 cells per well were infected at an MOI of 50 unless a higher or lower MOI 
is indicated in the text. Where Polybrene or Protamine Sulfate was used for in vitro 
experiments, Polybrene was used at a concentration of 8 µg/mL, and Protamine 
Sulfate was used at a concentration of 10 µg/mL. Where RetroNectin plates or 
tubes were pre-loaded with either cells or viral particles, pre-loading was carried 
out for 30 min at 37oC in the lowest volume of medium required to cover the surface 
of the plates. Where RetroNectin was added to the media instead of being used to 
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coat plates, the same volume that would have been used should the plates have 
been coated was added to the media.  
 
RNA Isolation from Cells 
 
The RNAEasy Mini Kit was used for all RNA isolations. Cells were harvested by 
centrifugation for 5 minutes at 350 g and resuspended in 350 µL buffer RLT. 1 
volume of freshly prepared 70% ethanol in RNAse-free water was added to each 
sample and mixed well by pipetting. Samples were then added to a RNAEasy Mini 
Spin Column in a 2 mL collection tube (contained in the kit) and centrifuged for 30 
seconds at >8000 g. Samples were then prepared as per the manufacturer’s 
directions and eluted in 20 µL RNAse-free dH20 in the final step. RNA 
concentration was measured on the Nano-Drop as described below.  
 
NanoDrop RNA Quantification 
 
All RNA was measured on the NanoDrop 2000 Spectrophotometer (Thermo 
Scientific, SO6497) in the Nucleic Acid>RNA setting. Prior to each use, the arm of 
the NanoDrop was raised, and the upper and lower pedestals were cleaned with 
water to ensure no nucleic acids were present on the instrument before 
measurement. The instrument was then blanked using 1 µL sterile RNAse-free 
water. Water was cleaned from the upper and lower pedestals, and 1 µL RNA was 
measured for each preparation. Where multiple RNAs were measured, the upper 
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and lower pedestals were cleaned with water to avoid cross-contamination. RNA 
was considered to be of suitable quality where the 260/280 ratio of absorbance 
was around 2.0. Where ratios were considerably lower (<1.6), the experiment was 
repeated. 
 
Synthesis of cDNA 
 
All RNA was converted to cDNA immediately after isolation as cDNA is more stable 
than RNA, allowing for storage at -20⁰C until use without the risk of degradation. 
RNA was prepared to yield 25 ng of cDNA per microliter to allow for adding 1uL 
cDNA per well of subsequent qRT-PCR experiments as the SsoFast Advanced 
qRT-PCR kit recommends use of a concentration of 0.00005-50 ng cDNA per 
reaction. cDNA at a concentration of 25 ng per microliter was generated using 500 
ng RNA in a 20 µL reaction of cDNA synthesis iScript kit (BioRad, 1708891). cDNA 
syntheses were set up in Hard-Shell 96-well PCR plates (BioRad, HSP9601) from 
a sealed bag. Mastermixes of iScript and reverse transcription mix were set up 
containing 4 µL reaction mix and 1 µL reverse transcriptase per reaction. 
Mastermixes were mixed well and 5 µL mastermix was added to one well of the 
plate per reaction. Wells were labeled directly on the plate. 500 ng RNA was then 
added to each well as required and mixed well by pipetting. The total volume of 
each well was then brought to 20 µL using RNAse-free dH2O. Plates were then 
sealed by rubbing a Kim wipe in a circular motion around the wells to ensure a tight 
seal with Microseal ‘A’ PCR Plate Sealing Film (BioRad, MSA5001). Plates were 
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briefly centrifuged to collect sample at the bottom of the wells with no air bubbles. 
The plates were then transferred to a PCR machine set to: 5 minutes at 25⁰C, 30 
minutes at 42⁰C, 5 minutes at 85⁰C, hold at 4⁰C. Samples were then stored at -
20⁰C until use. cDNA concentration was calculated from the amount of RNA added 
as opposed to using the NanoDrop to measure cDNA concentration directly as 
cDNA concentration cannot be accurately measured. Unless specified, all cDNA 
was prepared as 25 ng/µL from 500 ng RNA per 20 µL reaction.  
 
qRT-PCR Reaction   
 
A BioRad CFX96 or CFX384 Touch Real-Time PCR Detection System (BioRad 
catalog #1855195) was used for all qRT-PCR experiments. BioRad SSoFast 
Advanced Universal Probes Supermix (BioRad catalog, 1725284) was used for all 
qRT-PCR experiments. Where available, BioRad PrimePCR validated primers 
were used for all qRT-PCR experiments. Mastermixes were set up containing (per 
reaction) 5 µL SsoFast Supermix, 500 nM forward primer, 500 nM reverse primer, 
and nuclease-free water to a total volume of 9 uL mastermix per reaction. 9 uL 
mastermix was then added to each well of a Hard-Shell 96-well PCR plate as 
required – each sample was prepared in triplicate and each measurement was 
made in triplicate to allow for statistical analysis, so 9 wells per treatment were set 
up (3 samples, in triplicate). 25 ng cDNA was then added to each well of mastermix 
as required. Positive PCR controls for RPE65 experiments consisted of cDNA 
prepared from low-passage ARPE19 cells; for GFP experiments, positive controls 
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consisted of cDNA prepared from the bone marrow of GFP+ mice. Negative 
controls for qRT-PCRs consisted of a no-template control (1 µL d H2O instead of 
25 ng cDNA); negative controls for experiments consisted of uninfected or 
untreated cells. GAPDH or beta-Actin was used as internal controls for all qRT-
PCR experiments. Wells were mixed by pipetting and plates sealed using 
Microseal ‘A’ PCR Plate Sealing Film, and centrifuged briefly prior to running on 
the CFX96 machine set to cycle as follows: 98C for 2 minutes (1 cycle), 98⁰C 1-5 
seconds & 60-65⁰C 1-5 seconds (30-40 cycles), 65-95⁰C (in 0.5C inc) 2-5 
seconds/step, hold at 4⁰C. The CT values per well in the FAM setting (for SsoFast 
Advanced) were then recorded and analyzed using the comparative CT (2-∆∆CT) 
method to compare the CT value of the target gene with the internal control gene. 
Internal control values were considered to be good where CT values were <20, 
with 16-18 being optimum. Negative controls typically resulted in CT values 
between 36-39; positive controls typically resulted in CT values between 17 and 
20. Experiments were considered successful where no amplification was observed 
in the no-template control. If the no-template control produced a CT value, the PCR 
was repeated.  
 
Whole Eye Flat Mounts 
 
Eyes were enucleated, cleaned of fat and muscle, and the lens, vitreous, and 
cornea were carefully removed. Four shallow incisions were then made in the 
eyeball, allowing for separation of the retina from the RPE/choroid with minimal 
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cross-contamination. The RPE/choroid was then flattened on a glass slide with the 
RPE facing upward and gently covered with a glass coverslip. Flat mounts were 
imaged using a ZEISS confocal microscope. The relative number of cells per eye 
was calculated by counting the number of cells in set areas of each section of the 
flat mount, corresponding to approximately 10% of the whole flat mount surface, 
as shown below (Figure 2.2).  
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Figure 2.2 
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Figure 2.2 Areas of tissue quantified for GFP+ cells per flat mounted eye. 
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Tissue Sectioning 
 
Eyes were enucleated and fixed in 4% Paraformaldehyde overnight, then washed 
3x with PBS and transferred to 70% ethanol for sectioning. Whole eyes were 
paraffin-embedded, sectioned, and stained with H&E at the Histology Core of the 
Department of Anatomy and Cell Biology at IU School of Medicine. Sections were 
imaged with a ZEISS fluorescence microscope.  
 
Pharmacological In Vitro Differentiation of BMDCs and Inhibition 
 
Mouse and human BMDCs were isolated as previously described. 5000-50,000 
cells per well were added to flat bottomed 96-well plates in 100 µL complete 
DMEM. DMEM was supplemented with Forskolin (10 µmol/l; Tocris Biosciences 
1099), Rolipram (1 µmol/l; Sigma Aldrich, 61313-54-5), KH7 (50 µmol/l; Tocris 
Biosciences 3834), BPIPP (50 µmol/l; Tocris Biosciences 3635), or NKY80 (50 
µmol/l Tocris Biosciences 5071) as required. Cells were cultured for 1-7 days as 
required before being harvested and prepared for qRT-PCR as previously 
described.  
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In Vivo Methods 
 
Animals 
  
All animal studies were conducted under protocols approved by the Institutional 
Animal Care and Use Committee (IACUC) of IU School of Medicine and according 
to National Institutes of Health and the Association for Research in Vision and 
Ophthalmology guidelines. Adult (6–8 week old; or 12 month old) female C57BL/6J 
mice and homozygous GFP transgenic (C57BL/6-Tg (UBC-GFP)) mice were 
purchased from Jackson Laboratories, Bar Harbor, ME.  
 
Calculation of Number of Mice Required 
 
The number of mice needed for each isolation was calculated based on the 
average number of BMPCs (Lin-/Sca1+) obtained per mouse minus 50,000 to 
allow for isolation of fewer cells than expected. In general, 200,000 Lin-/Sca1+ 
cells were isolated from each mouse, therefore the cell number was calculated as 
#cells required/150,000.  
 
Sacrifice of Mice 
 
Mice were sacrificed by isoflurane (Aldrich, CDS019936) sedation followed by 
cervical dislocation. 
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Bone Marrow Cell Harvest 
 
Immediately after sacrifice, both hind legs were removed and dipped in 70% 
ethanol. Tissue was then cleaned off the tibiae and fibiae using Kimwipes. Bone 
marrow was then flushed out of each bone using a 15mL syringe with a 27g needle 
in room temperature flushing buffer (PBS containing 2% FBS and 1mM EDTA). 
Bone marrow was then filtered through a 100uM mesh cell strainer into 50mL 
conical tubes. Tubes were topped up with flushing buffer to 45mL and centrifuged 
at 350 g (Eppendorf Centrifuge 5804) for 5 minutes at room temperature. 
Supernatant was carefully poured off and 2 mL ammonium chloride red blood cell 
lysis buffer was added per mouse to each tube. Tubes were then incubated on ice 
for 15 minutes and centrifuged at 350 g (Eppendorf Centrifuge 5804) for 5 minutes 
at 4⁰C. Supernatant was removed and cells were resuspended in 4 mL flushing 
buffer and counted on a 1:100 dilution. Cells were then resuspended at a volume 
of 1x108 cells/mL as required for lineage depletion.  
 
Sodium Iodate Murine Model 
 
Sodium iodate (Fisher Scientific, S322100) in water at a concentration of 100 
mg/kg was injected intraperitoneally to acutely ablate the RPE layer. Cells were 
injected 8 hours after sodium iodate injection. Control mice received sodium iodate 
but no cells or 100 µL water by IP injection and no cells. 
Superoxide Dismutase 2 Knockdown Model 
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Wild-type C57BL/6J mice were injected subretinally with 1 μL of 2.5×1012 
particles/mL of recombinant AAV1 construct AAV1-Rz-SOD2 in the right eye. The 
left eye remained untreated. AAV1-Rz-SOD2, based on the pTR-UF2 vector, 
expresses the Rz432 SOD2-specific ribozyme Rz432 driven by the RPE-specific 
promoter VMD2, leading to chronic degradation of the RPE layer as described in 
Justilien et al., 200.[277] and was obtained from the University of Florida. 3-4 
SOD2-KD mice were used for each treatment group. Control injections consisted 
of rAAV-inactive ribozyme (AAV1-Rz-inactive), also obtained from the University 
of Florida in one group of mice per experiment. (Figure 2.3). 
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Figure 2.3 
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Figure 2.3. The Structure of the Mn-SOD and Inactive Hammerhead 
Ribozymes (A) and rAAV Vectors (B) for the SOD2-KD mouse model. The Mn-
SOD ribozyme degrades SOD2 messenger RNA. The control (inactive) ribozyme 
consists of the same structure with a GC mutation which blocks the ability of the 
ribozyme to target SOD2 mRNA. Source: Justilien et al. [277] 
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Systemic Delivery of Cells into Mice 
 
One month following SOD2-KD, mice received a systemic injection of 5x104 Lin-
/Sca1+/GFP+ BMDCs (either naïve BMDC, BMDC-ILV3-RPE65, BMDC-ILV3-
RPE65-MITF, BMDC-IDLV3-RPE65, BMDC-IDLV3-RPE65-MITF) in 100 μL of 
PBS, via the tail vein (n=3 or n=4 per group). Injections were performed by the IU 
In Vivo Therapeutics Core. Negative controls consisted of naïve BMDCs and mice 
injected with PBS (vehicle control), and the untreated left eye in the SOD2-KD 
model mice was the normal positive control. 
 
Measurement of Visual Function 
 
Two visual function tests, electroretinogram (ERG) and optokinetic nystagmus 
(OKN) were performed three months following injection of BMDCs as previously 
described. [13, 216] 
 
Statistical Analysis 
 
Experiments were carried out in triplicate. Results are expressed as mean ± SEM. 
ANOVA with Tukey post hoc tests were carried out to determine significance of 
results. Statistical analysis was performed using Prism 5 ver. 5.01 (GraphPad 
Software, Inc., La Jolla, CA) with p<0.05 considered statistically significant 
. 
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CHAPTER III: IMPROVING THE INFECTION OF BONE MARROW-DERIVED CELLS 
WITH AN INTEGRASE-DEFECTIVE LENTIVIRAL VECTOR. 
 
Introduction 
 
We have previously demonstrated that systemic delivery of immature bone 
marrow-derived cells (Lin-/Sca1+; BMDC), programmed ex vivo by inserting a 
stable RPE65 transgene using an integrating LV vector, can regenerate an efficient 
and functional retinal pigment epithelial (RPE) cell layer that restores visual 
function in mouse models of retinal degeneration. [13, 216] This has significant 
implications for the treatment of dry age-related macular degeneration (AMD), 
which is a major cause of vision loss in the elderly. [10] The primary defect in dry 
AMD is believed to be at the RPE, which shows cellular dysfunction, atrophy, and 
cell loss, particularly in the central retina. [221, 278] The most viable and attractive 
option for targeting dry AMD is in the early stages by replacement of damaged 
RPE using a minimally invasive approach, such as systemic delivery of 
programmed BMDC, as we have shown in animal models. [13, 216]  As success 
has been observed in murine models with murine cells, it is necessary to optimize 
and further develop our BMDC programming technique for safe and efficient 
application in human cells.  
 
Since we have previously found that the expression of RPE65 mRNA activates 
expression of adenylate cyclase in BMDCs within hours of infection, [216] and this 
in turn switches on expression of endogenous Rpe65 and RPE-associated marker 
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Cellular Retinaldehyde-Binding Protein-1 (Cralbp), [216] we hypothesized that 
transient expression of RPE65 from an IDLV may result in sufficient programming 
in the absence of integration. Limiting integration significantly reduces the risk of 
insertional mutagenesis, which can result in deleterious effects resulting from LV 
insertion in coding regions or regulatory elements). [224, 257, 258, 271, 279] This 
vector is ideal for programming BMDCs for use in human clinical trials.  
 
IDLVs are known to be less efficient than ILVs for a number of reasons, including 
low infection rates and episomal silencing. [224, 271, 280] Silencing post-
transduction is a significant concern for long-term expression of a transgene from 
IDLVs in non-dividing cells. [280] For our application, however, short term 
expression of RPE65 is thought to be sufficient for the programming of BMDCs, as 
we have shown that cells express the endogenous Rpe65 and Cralbp mRNAs 
within hours of infection with the integrating RPE65 vector. [13, 216]  This study, 
therefore, focused on improving the protocol for infecting BMDCs with IDLV-
RPE65 to maximize the number of cells infected with the virus.  
 
We demonstrate that IDLV3-RPE65 infection can be increased by: (a) increasing 
the concentration of the viral supernatant to reduce the volume required to obtain 
a high MOI, (b) pre-loading viral supernatant on RetroNectin prior to infection, and, 
(c) using a spinoculation method to infect the cells. In the process of optimizing the 
protocol IDLV3-RPE65 infection, we included measures to reduce the costs 
associated with RetroNectin use for LV transduction can be minimized by: (a) 
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confirming that using 2 μg/cm2 to coat plates is sufficient to achieve transduction 
with LV vectors, as has been reported in retroviral vectors, [281] and (b) re-using 
the 2 μg/cm2 preparation to coat up to three wells. IDLV3-RPE65 infected in this 
manner induces activation of the endogenous RPE-associated genes Rpe65 and 
Cralbp in murine BMDCs and CRALBP in human BMDCs at a similar level to ILV3-
RPE65 infection. This indicates that IDLV3-RPE65 is capable of initiating the 
differentiation of both mouse and human BMDCs to RPE-like cells in vitro, 
rendering them suitable for therapeutic transplantation in dry AMD.  
 
Results 
 
Infection of BMDCs with Third Generation ILV and IDLV Vectors. 
 
Infection of murine BMDCs with ILV3-RPE65 at a multiplicity of infection of 50 
(MOI; 50 viral particles per cell) resulted in a ~30-fold (p<0.05) increase in 
expression of human RPE65 mRNA compared with the null control (Figure 3.1A). 
Expression of murine Rpe65 mRNA was increased ~6-fold, and Cralbp ~5-fold 
(Figure 3.1A). As expression of these endogenous murine mRNAs is a critical step 
in BMDC programming, [216] we concluded that ILV3-RPE65 is appropriate for 
use in programming BMDCs, and for packaging as an IDLV. The average 
expression of human RPE65 mRNA from ILV3-RPE65 in murine BMDCs was ~28-
fold (p<0.05) higher than expression in the uninfected control, and expression of 
human RPE65 mRNA from IDLV3-RPE65 was ~3.6-fold (p<0.05) lower than 
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expression obtained with ILV3-RPE65 at the same MOI (Figure 3.1B). We 
therefore focused on improving IDLV3-RPE65 infection.  
 
To confirm that IDLV3 vectors have limited integration potential, we infected 
HT1080 cells with IDLV3-GFP and monitored the percentage of GFP+ cells for 12 
days. Expression of GFP from IDLV3-GFP-infected cells was significantly 
decreased (p<0.05) at day 6 in comparison with day 1, with a 2.1-fold decrease in 
expression of GFP at day 6 compared with day 1 (Figure 3.1C). Expression of GFP 
was almost absent by day 12 (Figure 3.1C), with a 14.9-fold decrease in 
expression compared with day 1 and a 7.2-fold decrease compared with day 6 
(p<0.05). Overall, between day 1 and day 12, the percentage of cells expressing 
GFP decreased from ~13% to ~1% (p<0.05). The residual expression of GFP 
retained at the end of the experiment is likely a result of a small number of viral 
integrations, as some residual integration does occur with IDLVs. [282] In contrast, 
ILV3-GFP stably integrates into the genome, with expression rising from ~65% to 
-~82% (p<0.05) from day 1 to day 4 before stabilizing at ~75% from day 5 through 
day 12 (Figure 3.1D). Together, Figure 3.1 shows that infection with IDLV3-
RPE65/GFP or ILV3-RPE65/GFP results in low integration and stable integration 
respectively – as expected, the starting percentage of GFP+ cells where the IDLV-
GFP vector was transduced into HT1080 cells was considerably lower than that of 
HT1080 cells infected with ILV-GFP (Figure 3.1C-D). HT1080 fibroblasts were 
used in this experiment as the BMDCs cannot be maintained in culture for long 
periods of time without the addition of growth factors, which would have altered the 
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cells in comparison with the cells kept in culture for a short period of time as used 
for future in vivo experiments. The HT1080 cell line was chosen as this cell line is 
traditionally used for titering lentiviral vectors.   
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Figure 3.1: IDLVs Infect Murine BMDC and Induce Expression of 
Endogenous mRNA, and Infect HT1080 Cells with Minimal Integration.  
Murine Lin-/Sca1+ cells were isolated from whole bone marrow of C57BL6/J mice, 
and infected at an MOI of 50 with ILV3-RPE65 (A) or IDLV3-RPE65 (B) on 
RetroNectin-coated plates (2 µg/cm2 RetroNectin in PBS, incubated at 4ºC 
overnight) by centrifugation for 2h at 150 g prior to harvest for qRT-PCR analysis. 
50,000 HT1080 cells per well were infected with IDLV3-GFP (C) or ILV3-GFP (D) 
at an MOI of 50 with Polybrene for 16h and cultured for 1-12 days with GFP 
expression measured each day by counting the number of positive and negative 
cells and calculating the percentage of cells expressing GFP. Uninfected cells 
were used as a negative control. For the GFP assays, cells stably expressing GFP 
were used as a positive control. In order to achieve the MOI of 50 for integrating 
vectors, 10 µL of viral supernatant was added as the vector titer was 109. For non-
integrating vectors, 250 µL of viral supernatant was added as the vector titer was 
~107. (A) Expression of RPE65 mRNA from ILV3-RPE65 was ~30-fold higher than 
in untreated cells respectively. Cells also expressed the endogenous Rpe65, and 
Cralbp mRNA ~6 and ~4-fold higher than uninfected cells respectively (p<0.05). 
(*=p<0.05; n(per experiment)=3, n(experiments)=9). (B) Expression of RPE65 
mRNA from ILV3-RPE65 was ~28-fold higher than expression in the negative 
control (p<0.05). Expression of RPE65 mRNA from IDLV3-RPE65 was ~8-fold 
higher than in the negative control (p<0.05). Expression of RPE65 was significantly 
lower from IDLV3-RPE65 than ILV3-RPE65 (p>0.05). (*=p<0.05; n(per 
experiment)=3; n(experiments)=3). (C) The percentage of cells expressing GFP 
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was measured each day. Between Day 1 and Day 6, expression of GFP reduced 
from ~13% to ~6% (p<0.05). Expression further reduced between Day 6 and Day 
12 from ~6% to ~1% (p<0.05). (*=p<0.05; n(per experiment)=3; 
n(experiments)=3). (D) The percentage of cells expressing GFP was measured 
each day. Between Day 1 and Day 4, GFP expression increased from ~64% to 
82% (p<0.05) before stabilizing at ~75% through Day 12.  
(*=p<0.05; n(per experiment)=3; n(experiments)=3) 
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Optimization of the Use of RetroNectin in BMDCs 
 
The colocalization of cells and LV particles is critical for efficient infection, and the 
goal of infection-promoting reagents such as polycations and the recombinant 
human fibronectin fragment RetroNectin is to enhance the nonspecific adhesion of 
the virions to the target cell surface. [281, 283] Previously published experiments 
were carried out using Polybrene; [13, 216] however, as Polybrene is known to be 
toxic to some cell lines and primary cells, we first compared infection efficiencies 
with Polybrene, the less toxic polycation Protamine Sulfate, and RetroNectin.  
ILV3-RPE65 and IDLV3-RPE65 infection with Protamine Sulfate was significantly 
less efficient than infection in the presence of Polybrene or RetroNectin (p<0.05; 
Figure 3.2A, B). Protamine Sulfate yielded an ~8-fold and ~11-fold increase in 
RPE65 mRNA from ILV3-RPE65 in murine and human BMDCs respectively, 
whereas Polybrene or RetroNectin yielded a ~25-fold and ~24-fold increase in 
ILV3-RPE65-infected cells (p<0.05; Figure 3.2A). In IDLV3-RPE65 infected cells, 
a ~5 and ~4-fold increase in RPE65 mRNA was observed with Protamine Sulfate 
in murine and human BMDCs respectively, compared with a ~14 and 13-fold 
increase in the presence of RetroNectin, and ~12-fold and ~13-fold increase in the 
presence of Polybrene (p<0.05; Figure 3.2B). Interestingly, combining RetroNectin 
and Polybrene together resulted in a lower infection efficiency than when each 
reagent was used individually, with an average fold increase of ~28 (p<0.05) in 
RPE65 mRNA from ILV3-RPE65 when used individually compared with an 
average fold increase of ~21.5 (p<0.05) when used together (Figure 3.2C). A 
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similar effect was observed with IDLV3-RPE65, with a ~16-fold (p<0.05) increase 
in RPE65 mRNA with both Polybrene and RetroNectin individually compared with 
a ~13-fold (p<0.05) increase in expression when used in combination (Figure 
3.2D).  
 
The infection efficiency of ILV3-RPE65 and IDLV3-RPE65 vectors on increasing 
concentrations of RetroNectin was compared to determine the lowest 
concentration required to yield high levels of infection. The instruction manual 
suggests a concentration of 4-20 µg/cm2, but it has been reported that cells can 
be infected with retroviral vectors on 2 µg/cm2 RetroNectin. [281] A >25-fold 
(p<0.05) increase in RPE65 mRNA from ILV3-RPE65 in both murine and human 
BMDCs was observed when infected on 2 µg/cm2 RetroNectin (Figure 3.2E). 
Infection was not significantly enhanced by transducing the cells on 4 µg/cm2 or 
12 µg/cm2 RetroNectin (Figure 3.2E). Similarly, infection with the IDLV results in a 
~12-fold (p<0.05) increase in mRNA in murine and human BMDCs infected on 2 
µg/cm2 RetroNectin, which is not significantly enhanced when the concentration of 
RetroNectin is increased, with a similar fold increase observed when cells are 
infected on 4 µg/cm2 or 12 µg/cm2 RetroNectin (Figure 3.2F). We have therefore 
confirmed that the use of 2 µg/cm2 RetroNectin is appropriate for infecting murine 
and human BMDCs with ILV3-RPE65 and IDLV3-RPE65.   
 
Next, we investigated the binding capacity of RetroNectin when used to coat 
multiple plates. Instead of discarding the RetroNectin after coating the first plate, 
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we transferred it to a new plate and repeated the coating procedure up to three 
times. As shown in Figure 2G, RPE65 mRNA in both human and murine BMDCs 
was found to be ~27-fold (p<0.05) higher than in the control in cells infected on 
RetroNectin used 1, 2, and 3 times. In contrast, on the 4th use of RetroNectin, 
RPE65 mRNA levels dropped to ~8-fold over the control, indicating that 
RetroNectin cannot be used more than three times.  
 
Finally, we investigated whether or not adding RetroNectin to the media could also 
facilitate infection. RetroNectin was added to the media at a concentration of 0-12 
µg/µL, and human RPE65 mRNA levels were compared to those achieved on 
plates coated with 2 µg/cm2 RetroNectin following infection with ILV3-RPE65. 
Adding RetroNectin to the culture media does not facilitate ILV3-RPE65 infection 
murine or human BMDCs, with no significant RPE65 mRNA increase observed 
(Figure 3.2H). In comparison with cells infected on a RetroNectin-coated plate, 
cells infected with 2, 4, or 12 µg/mL RetroNectin in the media were found to 
express RPE65 mRNA ~16, ~10, and ~8-fold (p<0.05) less respectively (Figure 
3.2H).  
 
 
 
 
 
118 
 
 
 
119 
 
Figure 3.2. Optimization of the Use of RetroNectin in BMDCs 
 
Murine (Lin-/Sca1+) or human (CD34+) BMDCs were infected at an MOI of 50with 
ILV3-RPE65 or IDLV3-RPE65 with Polybrene (8 μg/μL), Protamine Sulfate (10 
μg/μL), or RetroNectin (2, 4, or 12 μg/μL; or 2, 4, or 12 μg/cm3), or a combination 
of Polybrene and RetroNectin (2 μg/cm3). Cells were infected for 12 h and 
harvested for qRT-PCR analysis at 16 h. (A) Human RPE65 mRNA levels were 
increased ~25-fold over control in murine BMDCs and ~23-fold in human BMDCs 
infected with ILV3-RPE65 using RetroNectin. Similar levels were observed in 
BMDCs infected with ILV3-RPE65 using Polybrene, with a 24-fold (p<0.05) 
increase in murine BMDCs and a 23-fold (p<0.05) increase in human BMDCs. 
Expression in cells infected with ILV3-RPE65 with Protamine Sulfate was lower 
than that observed with RetroNectin or Polybrene, with an ~8-fold (p<0.05) 
increase in murine BMDC and a ~10-fold (p<0.05) increase in human BMDCs.  (B) 
Human RPE65 mRNA levels were increased ~15-fold (p<0.05) over control in 
murine BMDCs and ~14-fold (p<0.05) in human BMDCs infected with IDLV3-
RPE65 using RetroNectin. Similar levels were observed in BMDCs infected with 
IDLV3-RPE65 using Polybrene, with a 13-fold (p<0.05) increase in murine BMDCs 
and a 14-fold (p<0.05) increase in human BMDCs. Expression in cells infected with 
IDLV3-RPE65 with Protamine Sulfate was lower than that observed with 
RetroNectin or Polybrene, with a ~6-fold (p<0.05) increase in murine BMDC and a 
~5-fold increase in human BMDCs (p<0.05). (C) Human RPE65 mRNA levels were 
increased ~29-fold over control in murine BMDCs and ~28-fold in human BMDCs 
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infected with ILV3-RPE65 using RetroNectin. Similar levels were observed in 
BMDCs infected with ILV3-RPE65 using Polybrene, with a 27-fold (p<0.05) 
increase in murine BMDCs and a 28-fold (p<0.05) increase in human BMDCs. 
Expression in cells infected with ILV3-RPE65 with Polybrene and RetroNectin in 
combination was lower than that observed with RetroNectin or Polybrene, with a 
~21-fold (p<0.05) increase in murine BMDC and a ~20-fold (p<0.05) increase in 
human BMDCs. (D) Human RPE65 mRNA levels were increased ~16-fold over 
control in human BMDCs infected with ILDV3-RPE65 using RetroNectin. Similar 
levels were observed in BMDCs infected with ILVD3-RPE65 using Polybrene, with 
a 16-fold (p<0.05) increase vs. control. Expression in cells infected with IDLV3-
RPE65 with Polybrene and RetroNectin in combination was lower than that 
observed with RetroNectin or Polybrene, with a ~13-fold (p<0.05) increase vs. 
control.  (E) Murine and human BMDCs infected with ILV3-RPE65 in the presence 
of 2µg/cm2 RetroNectin expressed human RPE65 mRNA 27- and 28-fold over 
control (p<0.05) respectively. Expression was not increased in either cell type with 
an increase in RetroNectin concentration to 4 µg/cm2 or 12 µg/cm2. (F) Murine and 
human BMDCs infected with IDLV3-RPE65 in the presence of 2µg/cm2 
RetroNectin expressed human RPE65 mRNA 13-fold over control (p<0.05) in both 
cell types. Expression was not increased in either cell type with an increase in 
RetroNectin concentration to 4µg/cm2 or 12µg/cm2. (G) Murine and human BMDCs 
infected with ILV3-RPE65 in the presence of 2µg/cm2 RetroNectin used to coat 1 
plate expressed human RPE65 mRNA 23- and 24-fold over control (p<0.05) 
respectively. Levels did not increase or decrease in cells infected with ILV3-RPE65 
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in the presence of 2µg/cm2 RetroNectin used to coat 2 or 3 plates. In contrast, 
where 2µg/cm2 RetroNectin was used to coat a 4th plate, RPE65 mRNA levels 
were only 7- and 8-fold over control (p<0.05) in murine and human cells 
respectively. (H) Murine and human BMDCs infected with ILV3-RPE65 on 2µg/cm2 
RetroNectin-coated plates expressed human RPE65 mRNA 24- and 25-fold over 
control respectively (p<0.05). Cells infected with media containing 2, 4, or 12 µg/µL 
RetroNectin did not significantly express RPE65 mRNA.  
(*=p<0.05; n(per experiment)=3; n(experiments)=3). 
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Enhancing the Infection of BMDCs with IDLV3-RPE65 
 
IDLV3-RPE65 transduces murine and human cells at a lower efficiency than ILV3-
RPE65 (Figure 3.1, 3.2). RPE65 mRNA levels IDLV3-RPE65 are approximately 8-
15-fold higher than control in IDLV3-RPE65-infected cells, whereas in ILV3-
RPE65-infected cells, mRNA levels are 27-30-fold higher than control. This is 
consistent with previously reported findings that IDLVs do not infect as efficiently 
as ILVs.[271] As maximizing the number of infected cells is, we investigated 
methods by which IDLV3-RPE65 infection of BMDCs could be enhanced. 
 
Increasing the MOI does not significantly enhance expression in HT1080 cells 
infected with IDLV3-GFP, with GFP mRNA remaining at ~8-fold over control in 
IDLV3-GFP-infected cells, despite an increase of the MOI from 50 to 500 (Figure 
3.3A). In contrast, increasing the MOI of ILV3-GFP from 50 to 500 significantly 
enhances GFP mRNA levels, with a ~27-fold (p<0.05) increase over the control 
with MOI 50, and a ~150-fold increase at MOI 500 (p<0.05). As increasing the MOI 
did not enhance infection, we next modified the procedure by which the viral 
particles were concentrated. Increasing the centrifugation time from 1 hour to 2 
hours increased the virion recovery of IDLV3-RPE65, with an increase in human 
RPE65 mRNA in cells infected with 20 µL supernatant from ~8-fold over control at 
1h to ~12-fold over control at 2h (Figure 3.3B). Further increasing the concentration 
time to 3 hours did not enhance virion recovery. Additionally, centrifuging the viral 
123 
 
particles for 4 hours significantly reduced recovery, with RPE65 mRNA observed 
at less than 5-fold over the control in BMDCs infected with 20 µL IDLV3-RPE65 
supernatant.  
 
To further investigate whether the concentration protocol could be modified to 
enhance IDLV3-RPE65 infection, we concentrated the viral supernatant with 
LentiX Lentiviral Vector Concentrating Reagent (Catalog #PT4421-2, ClonTech). 
Concentrating the viral supernatant 10x with LentiX resulted in a ~12-fold (p<0.05) 
increase in expression over the control when infected at an MOI of 50. IDLV3-
RPE65 concentrated at 20x resulted in a significant increase in RPE65 mRNA, 
with a ~20-fold (p<0.05) increase at the same MOI (Figure 3.3C).  
 
While Lenti-X concentration of IDLV3-RPE65 enhanced infection efficiency in 
comparison with the centrifugation-concentrated vector, the efficiency was still 
lower than that of ILV3-RPE65, with a ~20-fold increase with IDLV3-RPE65 
compared with an average 27-fold increase with ILV3-RPE65. It has been reported 
that preloading retroviral vectors onto RetroNectin, either once or up to five times, 
significantly enhances gene transfer.[281] We therefore evaluated the use of 
preloading in ILV3-RPE65 and IDLV3-RPE65 infections. RPE65 mRNA levels 
after ILV3-RPE65 infection remained at ~27-fold (p<0.05) over control when 
murine BMDCs were infected with or without preloading (Figure 3.3D). In contrast, 
RPE65 mRNA increased from ~13-fold (p<0.05) over control on RetroNectin alone 
to ~23-fold (p<0.05) in murine BMDCs infected with IDLV3-RPE65 preloaded on 
124 
 
the RetroNectin (Figure 3.3D). Preloading the plate twice enhances IDLV3-RPE65 
infection (p<0.05) (Figure 3.3E). No significant improvement is observed between 
2 and 3 preloads. (Figure 3.3E).  
 
As RetroNectin binds to both the virus and the cells, we also looked at infection on 
plates that had been preloaded with cells prior to the addition of the virus. No 
advantage in preloading cells in comparison with preloading viral supernatant was 
observed (Figure 3.3F).  
 
Despite the increase in IDLV3-RPE65 infection with preloading, RPE65 mRNA 
levels were still lower (~23-fold over control) than those obtained with ILV3-RPE65 
~27-fold over control). As a final modification to the protocol, we combined 
RetroNectin preloading with infection by centrifugation, referred to as 
spinoculation. Spinoculating murine BMDCs with preloaded IDLV3-RPE65 results 
in a ~27-fold increase in expression of the vector when combined with preloading 
on RetroNectin without spinoculation (p<0.05) (Figure 3.3G).  
 
We have therefore demonstrated that concentrating IDLV3-RPE65 20x with LentiX 
followed by infection of cells on 2µg/cm2 RetroNectin, pre-loaded with the virus at 
an MOI of 50, with spinoculation, increases RPE65 mRNA at a similar level to 
ILV3-RPE65.   
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Figure 3.3. Enhancing the Infection of BMDCs with IDLV3-RPE65 
 
HT1080, murine (Lin-/Sca1+), or human (CD34+) BMDCs were infected with ILV3-
GFP (A), ILDV-GFP (A), ILV3-RPE65 or IDLV-RPE65 (B-G) at an MOI of 50 (A, 
C-G), 100 (A), or 500 (A), or with 20 μL concentrated viral supernatant (B). 
RetroNectin at 2 μg/cm3 was used for all infections, and was either used by itself 
(A-C) or with preloading of vectors (D-G) or cells (F). Cells were infected for 12 h 
and harvested for analysis at 16 h unless spinoculated (G), where cells were 
infected for 2h at 150 g and harvested for analysis at 4h. (A) Increasing the MOI 
of ILV3-RPE65 increased RPE65 mRNA levels from ~27-fold over control (p<0.05) 
at MOI 50 to ~68-fold over control (p<0.05) at MOI 100 and ~150-fold over control 
(p<0.05) with MOI 500. Increasing the MOI of IDLV3-RPE65 did had no significant 
effect on expression, with RPE65 levels remaining at ~7-fold over control (p<0.05). 
(B) Centrifugation of IDLV3-RPE65 supernatant for 2 hours increased recovery of 
virions, with a ~10-fold increase in infection of murine BMDCs with concentrated 
supernatant at the same volume in comparison with 8-fold observed at 1 hour. 
Centrifugation for 3 hours did not enhance infection efficiency, and centrifuging for 
4 hours reduced the viability of virions, with RPE65 expression only 3-fold over 
control (p<0.05). (C) Concentrating viral supernatant 20x enhanced the infection 
of IDLV3-RPE65 in comparison with concentrating 10x and infecting at the same 
MOI, with a 19-fold (p<0.05) increase in RPE65 mRNA observed at MOI 50 with 
the 10X concentrated vector and 10-fold (p<0.05) with the 20X concentrated vector 
at the same MOI. (D) Preloading ILV3-RPE65 on RetroNectin for 30 minutes prior 
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to adding murine BMDCs did not enhance infection, with a 28-fold increase 
(p<0.05) observed with or without preloading. In contrast, with IDLV3-RPE65, 
preloading increased RPE65 expression from 15-fold over control (p<0.05) to 23-
fold over control (p<0.05). (E) Preloading ILV3-RPE65 on RetroNectin up to three 
times did not result in an increase in human RPE65expression. Preloading IDLV3-
RPE65 twice increased infection, with RPE65 mRNA levels increasing from 21-
fold to 24-fold over control (p<0.05). No increase was observed with three 
preloads. (F) Murine BMDCs infected with IDLV-RPE65 expressed RPE65 the 
highest level when viral particles were preloaded onto RetroNectin, with a 24-fold 
increase (p<0.05) in expression vs 10-fold with no preload (p<0.05). Preloading 
the cells instead of the virus yielded an increase in RPE65 expression, with a 17-
fold increase vs. control (p<0.05); however, this was lower than observed when 
viral particles were preloaded, indicating no advantage in preloading cells (G) 
IDLV-RPE65 infects murine BMDCs at the highest efficiency when the virus is 
preloaded onto RetroNectin followed by infection by spinoculation, with an 26-fold 
increase (p<0.05) in expression over control in comparison with 20-fold with 
preload alone (p<0.05), and 22-fold with spinoculation alone (p<0.05).  
(*=p<0.05; n(per experiment)=3; n(experiments)=3). 
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In Vitro Differentiation of Human and Murine BMDCs with IDLV3-RPE65  
 
We have previously reported that pTYF-RPE65 infection of murine BMDCs 
initiates expression of the endogenous murine Rpe65 and Cralbp mRNAs.[216] 
Murine BMDCs infected with either ILV3-RPE65 or IDLV3-RPE65 vectors express 
endogenous Rpe65, and Cralbp mRNAs 5-10-fold (p<0.05) over control (Figure 
3.4A). This indicates that IDLV3-RPE65 is likely to be sufficient for promoting the 
expression of the RPE-associated genes that contribute to the programming of the 
BMDCs to RPE-like cells.  
 
In human BMDCs, a ~5-fold increase in expression of CRALBP mRNA is observed 
in cells infected with either ILV3-RPE65 or IDLV3-RPE65 (Figure 3.4B). This 
indicates that IDLV3-RPE65 may also be capable of promoting differentiation of 
human BMDCs to RPE-like cells.  
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Figure 3.4. In Vitro Differentiation of Human and Murine BMDCs with IDLV3-
RPE65. 
 
 Murine Lin-/Sca1+ BMDCs (A) or human CD34+ cells (B) were infected at MOI 50 
with ILV3-RPE65 on RetroNectin (2 µg/cm2) by spinoculation for 2h at 150g, or 
with IDLV3-RPE65 pre-loaded on RetroNectin (2 µg/cm2) prior to spinoculation. 
Cells were then harvested and lysed for qRT-PCR analysis. RPE65 expression 
was ~32-fold over control and ~28-fold over null control in murine (A) and human 
(B) BMDCs infected with ILV3-RPE65 respectively (p<0.05). RPE65 mRNA levels 
were ~13,4-fold over control in both murine (A) and human (B) BMDCs infected 
with the IDLV vector respectively (p<0.05). In murine BMDCs, endogenous Rpe65 
mRNA levels were increased ~6- and ~7-fold vs control in cells infected with ILV3-
RPE65 and IDLV3-RPE65 respectively, and Cralbp mRNA levels were increased 
7- and 8-fold vs control in cells infected with ILV3-RPE65 and IDLV3-RPE65 
respectively (A). In human BMDCs, CRALBP mRNA levels were 5-fold over control 
in cells infected with either vector. 
 
 (*=p<0.05; n(per experiment)=3; n(experiments)=12 [murine BMDC, ILV3-
RPE65]; n(per experiment)=3; n(experiments)=3 [human BMDC, ILV3-RPE65; 
murine and human BMDC, IDLV3-RPE65]).  
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Discussion 
 
We have previously shown in two murine models of RPE damage that adult 
BMDCs modified ex vivo with an ILV expressing RPE65 are recruited to and 
preserve the RPE and retina following systemic delivery. [13, 216]  Compounding 
factors facilitating the lack of visual recovery in humans after cell-based therapy 
for dry AMD to date [180, 181, 186] include treatment in the late stages of disease, 
limited motility of cells across the RPE layer post-injection, and side effects of 
invasive cell delivery.[13, 216] [219, 220]  
 
Transient expression of RPE65 is likely to be sufficient, as we previously reported 
that the endogenous Rpe65 and Cralbp genes are activated within hours of RPE65 
vector infection. [13, 216]  IDLVs lack the integrase gene, and integrate at a 500-
1250-fold lower rate than integrating vectors, [282] with residual integration likely 
occurring through integrase-independent mechanisms, such as DNA break-
induced non-LTR-mediated integration. [284] In a clinical setting, inclusion of a 
suicide gene in the transducing vector would allow for rapid elimination of cells 
containing integrated virus if off-target effects resulting from insertional 
mutagenesis were to occur. Suicide gene-mediated inducible apoptosis has been 
demonstrated to be safe and effective in human clinical trials.[285, 286] Our 
findings are consistent with observations that low-level transgene expression is 
maintained 10-14 days post-infection. [287-289] 
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It has been well established in the literature that IDLVs are less efficient than ILVs. 
[224, 271] Critical difficulties in the application of IDLVs have arisen for a number 
of reasons, primarily a low number of virions entering cells, [224] and 
downregulation of transgene expression due to episome inhibition, [280] which has 
been shown to be counteracted by a deletion in the U3 region of the virus. [280] 
Several groups have published modifications to the transducing vector which 
improve the stability of expression from episomal IDLV particles. These 
modifications include codon-optimization of the transgene, [290, 291] the use of a 
strong promoter such as SV40 [292] instead of the CMV promoter which is 
susceptible to silencing, [293] and inhibiting viral life cycle proteins. [294, 295] We 
have utilized some of these modifications here through the use of the EF-1α 
promoter, which is constitutively expressed at a similar level in all cell types, and 
codon-optimization of the RPE65 cDNA for use in human cells.  
 
Overall, we focused on increasing the number of virions entering cells as opposed 
to further modifying the transducing vector, as retention of transgene expression 
was not thought to be required for our application. The critical difference between 
our use of IDLV3-RPE65 and the majority of IDLV3-based studies published to 
date is that we only require expression of RPE65 at a high level for a few hours 
post-infection for the vector to activate the endogenous genes, and are therefore 
using it as a molecular ‘switch’ as opposed to a long-term modification. 
Consequently, we measure expression at 4 hours post-infection, in contrast with 
typical lentiviral vector expression studies which measure transgene expression 
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after several days in culture. [222, 224, 231, 262, 265, 267, 268, 271-273, 275, 
280, 282, 289, 291, 292, 295] This time point was chosen as we have previously 
demonstrated that RPE65 induces Rpe65 and Cralbp expression within the first 
few hours of infection. [216] 
 
We propose that the method outlined here is optimal for the application of IDLVs 
in studies in which short-term (1-12 hrs) expression is sufficient, as the increase in 
expression in the early stages post-infection may not be sustained – our success 
in improving expression through increasing viral number per cell is likely to precede 
silencing of the episome. [280] For studies in which longer-term expression of the 
transgene is required, vector modifications such as U3 deletions may be necessary 
to maintain transgene expression after increasing the infection efficiency. [280] 
To improve IDLV3-RPE65 infection efficiency, the infection protocol was 
systematically modified. Infection is dependent on direct virion-cell interaction. 
Viral particles have a half-life of around 4-8hrs, [296, 297] during which they are 
capable traveling 580-610 microns, [298] and are negatively charged. It is 
therefore necessary to enhance the localization of cells and virions using reagents 
which either bind both, or eliminate the negative charge of both the cells and the 
virions. RetroNectin enhances infection efficiency via co-localization of virions and 
cells [299, 300] through binding by a heparin binding domain and VLA5/VLA4 
binding domains respectively, [281, 283] and is frequently used to maintain 
retroviral gene transfer in hematopoietic stem cells (HSCs) derived from primates, 
canines, and humans. [301-303] It has advantages over the commonly used 
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polycation Polybrene, which facilitates gene transfer by counteracting the negative 
charge of the cells and virions, in that it is less toxic to cells, yet produces similarly 
efficient infections. Protamine Sulfate has been shown to be as effective as 
Polybrene with the mouse SAX retroviral vector; [304] however, we found it to be 
significantly less effective than Polybrene or RetroNectin in BMDCs. Therefore, we 
focused on using RetroNectin to enhance infection with IDLV3-RPE65.  
 
Efficient infection of the HEL cell line and human CD34+ cells with retroviral vectors 
has been reported on plates coated with 2 µg/cm2 RetroNectin, [281] despite the 
instruction manual indicating a requirement for 4-20 µg/cm2. Our findings support 
this data, indicating that lentiviral vectors also transduce both human and mouse 
BMDCs on 2 µg/cm2 RetroNectin. Additionally, we show that a single preparation 
of 2 µg/cm2 RetroNectin can be removed and used to coat up to three wells before 
any reduction in efficiency. Both of these findings minimize the cost of LV 
approaches using RetroNectin. Also consistent with the literature, in which it has 
been reported that preloading of retroviral vectors on RetroNectin enhances gene 
transfer, [281] preloading of IDLV on RetroNectin prior to infection of cells resulted 
in a higher infection efficiency, [281] indicating that preloading is effective for 
infection with lentiviral as well as retroviral vectors.  
 
Expression of the endogenous Rpe65 and Cralbp genes in murine BMDCs 
infected with IDLV3-RPE65 confirm that the IDLV is functioning in a similar way to 
the ILV. Expression of CRALBP in human BMDCs infected with ILV3-RPE65 or 
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IDLV3-RPE65 indicates that expression of RPE65 in these cells is functioning in a 
similar way as expression in murine BMDCs, and suggests that expression of this 
is likely to result in human BMDC differentiation into RPE-like cells. This is of 
significant importance for the therapeutic potential of this technique in humans, 
which will be the focus of our future studies. 
 
To summarize, use of IDLV3-RPE65 significantly reduces the risk of our LV-based 
approach, as the number of viral integrations per cell and the subsequent risk of 
insertional mutagenesis is markedly reduced. IDLV3-RPE65 successfully initiates 
the expression of endogenous genes, which we believe to be responsible for the 
ability of RPE65-infected BMDCs to integrate into and regenerate damaged RPE 
in mouse models of RPE degeneration, in both murine and human BMDCs. 
Efficacy is significantly enhanced by modifying the infection protocol with 
RetroNectin. Our approach is quick and ideal for applications in which short term 
transient expression may be sufficient, avoiding time-consuming and costly 
modifications of the transducing vector.  
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CHAPTER IV: MURINE BONE MARROW-DERIVED CELLS PROGRAMMED 
WITH 3RD GENERATION INTEGRATING AND INTEGRASE-DEFICIENT 
LENTIVIRAL VECTORS PREVENT RETINAL DEGENERATION. 
 
Introduction 
 
In order to verify that murine BMDCs programmed with ILV3-RPE65 or IDLV3-
RPE65 are functional in terms of regenerating damaged RPE, it was necessary to 
evaluate the ability of these cells to repair RPE in murine models of retinal 
degeneration. We have previously demonstrated that pTYF-RPE65-infected 
BMDCs prevent retinal degeneration and preserves visual function in an acute 
[216] and a chronic [13] model of RPE damage. Critically, in these studies, the cells 
were administered systemically, either via the retro-orbital sinus vein [216] or the 
tail vein, [13] eliminating the need for invasive subretinal transplant of the cells and 
making the treatment considerably more desirable and feasible for use in human 
patients with early-stage retinal degeneration. [216]. It was demonstrated that the 
RPE65-expressing lentiviral vector was critical for the process of programming 
regeneration-capable BMDCs as the cells which were infected with the same 
lentiviral vector expressing a control LacZ gene did not result in significant recovery 
of vision or preservation of retinal morphology. This indicates that it is the 
expression of RPE65 from the vector that results in cellular differentiation, as 
opposed to the process of infecting the cells with the lentiviral vector and/or the 
integration of viral particles into the host cell genome. [13, 216] 
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In this current study, we evaluated BMDCs infected with ILV3-RPE65 and IDLV3-
RPE65 in the two previously published models, the acute injury sodium iodate 
model, [216] and the chronic injury superoxide dismustase 2 knock-down (SOD2-
KD) model of retinal degeneration. [13] We also evaluated BMDCs infected with 
two additional vectors, ILV3-RPE65-MITF and IDLV3-RPE65-MITF. The rationale 
for this is that micropthalmia-associated transcription factor MITF isoforms are both 
involved in the development of the retina and RPE cells, [305] and expressed in 
terminally differentiated RPE cells. [306] MITF-M is expressed in differentiated 
RPE. [306] MITF-A and J are present during the development of the retina and 
RPE, and MITF-H and MITF-D are present in the RPE, with MITF-D expressed 
only in the RPE [305]. Defects in MITF isoforms have been found to result in 
micropthalmia [307] and hyperproliferation of hypopigmented RPE cell and lack of 
RPE layer formation, [308] along with other non-ocular phenotypes resulting from 
deficiency in melanin production such as white fur in mice with MITF aberrations. 
[307] In addition to being expressed in terminally differentiated RPE cells, the M 
isoform of MITF has been found to be activated following exposure to an inhibitor 
of cAMP degradation, which in turn stimulates the production of melanin. [309] As 
we have consistently been unable to observe the development of pigmented RPE 
in vitro following infection with pTYF-RPE65 or ILV3/IDLV3-RPE65, [13] and as we 
have previously demonstrated the involvement of the cAMP/adenylate cyclase 
pathway in the differentiation of BMDCs with pTYF-RPE65, [216] we hypothesized 
that including MITF-M in the infecting vector may enhance the differentiation 
process.  
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The sodium iodate model consists of an intraperitoneal injection of 100mg/kg 
sodium iodate per mouse, which selectively and immediately results in necrosis of 
the RPE, photoreceptor cell death, and activation of the immune response in the 
retina. [310] As this model results in rapid, severe retinal degeneration, it is not the 
most accurate representation of the process of pathogenesis in human AMD. It is, 
however, valuable in initial studies into the efficacy of the 3rd generation vector-
treated cells, as results are available within 7-28 days [216] as opposed to 3-6 
months in the chronic SOD2-KD model. [13] The sodium iodate damage resembles 
the pathology of human AMD in the late stages, though cell death is necrotic 
whereas in human AMD death occurs mainly through apoptosis. [277, 310] The 
SOD2-KD model closely resembles human AMD in the early stages, with the 
exception that retinal degeneration is widespread across the retina in mice as 
opposed to being central as it is in humans, as mice do not have a macula. [277] 
Therefore, it is advantageous to evaluate the cells in both models in order to 
determine their suitability for treatment in both late and early-stage disease, though 
our ultimate goal is to treat early in disease to maximize retinal protection. When 
other cell types such as photoreceptors have already begun to degenerate, visual 
recovery via RPE replacement will be limited.  
 
The SOD2-KD model involves subretinally injecting an adeno-associated viral 
vector (AAV) containing a hammerhead ribozyme to SOD2 mRNA, expressed 
under the control of a chicken beta-actin (CBA) promoter and the cytomegalovirus 
(CMV) enhancer. (Figure 2.4). [277] This vector results in progressive oxidative 
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damage, due to a lack of the manganese superoxide dismutase required for the 
conversion of superoxide in the mitochondria to hydrogen peroxide and oxygen. 
This in turn leads to an increase in reactive oxygen species in the mitochondria, 
which initiates apoptotic cell death. [277] SOD2-KD-induced retinal degeneration 
progresses slowly over a period of 4 months. [277] This model is a close 
representation to early dry AMD, as it results in progressive loss of retinal function, 
the vacuolation and depigmentation and degeneration of the RPE cells, thickening 
of Bruch’s membrane, and a progressive shortening of the photoreceptor outer and 
inner segments which eventually leads to the death of photoreceptor cells by 
apoptosis. [277] As we have previously determined that recovery of vision is 
optimal in SOD2-KD mice when BMDCs infected with pTYF-RPE65 were given at 
the 1 month time point, [13] we selected this time point for treatment in the current 
study.  
 
Here, we investigated the ILV3-RPE65 and IDLV3-RPE65 treated cells in the 
sodium iodate model prior to the SOD2-KD model and determined that cells 
treated with either vector (a) are recruited to the eye, (b) integrate into the RPE 
layer, and, (c) preserve visual function as measured by electroretinography, which 
determines the electrical response of the retina to light, and by optokinetic 
nystagmus analysis (OKN), which measures the visual acuity of the mouse. In the 
SOD2-KD model, we observed similar results and further expanded the analysis 
to include a 6-month measurement of visual acuity in these mice. We determined 
that RPE recovery following injection with BMDCs programmed with either the 
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ILV3-RPE65 or IDLV3-RPE65 is maintained for at least 6 months. The timing of 
injection of BMDC post-infection with ILV3-RPE65 is of particular importance for 
cellular recruitment to the RPE, with cells injected 16h post-infection failing to be 
recruited to the RPE. We hypothesize that the BMDCs need to be in an early stage 
of programming when injected, retaining characteristics of bone marrow-derived 
cells, in order to effectively circulate in the blood to travel to the intended area of 
the eye.  
 
Results 
 
ILVs and IDLVs Expressing Both RPE65 and MITF Activate Expression of 
Endogenous Murine Rpe65 and Cralbp mRNA.  
 
ILV3-RPE65 and IDLV3-RPE65 were compared with the new vectors, ILV3-
RPE65-MITF and IDLV3-RPE65-MITF, to confirm that the inclusion of the MITF 
gene in these vectors did not have a detrimental effect on the expression of the 
endogenous Rpe65 and Cralbp mRNAs. Expression of RPE65 and MITF via 
infection of the same cells with two vectors each expressing one gene, as opposed 
to one vector expressing two genes, results in an approximately 50% reduction in 
expression of both genes in comparison to expression when cells are transduced 
with either vector alone. BMDCs infected with RPE65 or MITF independently 
expressed the genes 40-fold and 20-fold over control respectively, which reduced 
to 22-fold and 13-fold over control when BMDCs were infected with both viruses 
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together (Figure 4.1A). We therefore expressed MITF from the same vector as 
RPE65, linked by a T2A site, resulting in similar expression of RPE65 and MITF at 
~33-fold and ~35-fold over control from the ILV3 vectors and ~5-fold and ~6-fold 
from the IDLV3 vectors respectively (p<0.05) (Figure 4.1A). Additionally, 
expression of RPE65 was similar in BMDCs infected with both ILV3 vectors, with 
an approximately 33-fold increase in expression over control, and ~5-fold and ~7-
fold over control in BMDCs infected with IDLV3 vectors (p<0.05) (Figure 4.1A). 
 
Inclusion of MITF in the vector did not reduce expression of Rpe65 in infected 
BMDCs. Expression of Rpe65 was 3-fold over control in ILV3-RPE65-infected 
cells, ~7-fold over control in ILV3-RPE65-MITF-infected cells, and ~5-fold over 
control in BMDCs infected with either of the IDLV3 vectors (p<0.05) (Figure 4.1B). 
Expression of Cralbp was 8-fold over control in BMDCs infected with either ILV3 
vector, and ~4-fold  and ~3-fold over control in BMDCs infected with IDLV3-RPE65 
and IDLV3-RPE65-MITF respectively (p<0.05) (Figure 4.1B). It is important to note 
for continuity that this experiment was performed prior to the experiments outlined 
in Chapter 1, which accounts for the low infection efficiency observed with the 
IDLVs in Figure 4.1B.  
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Figure 4.1 
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Figure 4.1. ILV3-RPE65-MITF and IDLV3-RPE65-MITF Initiate Expression of 
human Rpe65 and Mitf mRNA in Murine BMDCs. 
 
(A) Murine Lin-/Sca1+ BMDCs were isolated from whole bone marrow of C57BL6/J 
mice infected at an MOI of 50 on RetroNectin (2 µg/cm2) with ILV3-RPE65, ILV3-
MITF, either alone or in combination, or with ILV3-RPE65-MITF by spinoculation 
for 2h at 150 g, 21ºC, prior to harvest for mRNA analysis. Expression of RPE65 
was ~40-fold over control when infected alone, dropping to ~22-fold when infected 
with ILV3-MITF (p<0.04). ILV3-MITF infected alone resulted in a ~20-fold increase 
in expression, dropping to ~13-fold when infected with ILV3-RPE65 (p<0.05). ILV3-
RPE65-MITF infection resulted in a ~33-fold increase in expression of both 
mRNAs. (*=p<0.05, n(per experiment)=3; n(experiments)=3) (B) Murine Lin-
/Sca1+ BMDCs were isolated from whole bone marrow of C57BL6/J mice infected 
at an MOI of 50 on RetroNectin (2 µg/cm2) with ILV3-RPE65, IDLV3-RPE65, ILV3-
RPE65-MITF, or IDLV3-RPE65-MITF for 2 hrs at 150 g, 21ºC, and harvested for 
qRT-PCR analysis after 4 hrs. Human RPE65 mRNA was expressed ~33-fold over 
control in ILV3-RPE65 and ILV3-RPE65-MITF-infected cells (p<0.05), and human 
MITF mRNA was expressed ~35-fold over control in ILV3-RPE65-MITF-infected 
cells (p<0.05). Human RPE65 mRNA was 7- and 4-fold over control in IDLV3-
RPE65 and IDLV3-RPE65-MITF-infected cells respectively, and human MITF 
mRNA was ~7-fold over control in IDLV3-RPE65-MITF-infected cells. Cells 
infected with all viruses expressed the endogenous Rpe65 and Cralbp mRNAs, 
with expression in ILV3-RPE65 and ILV3-RPE65-MITF-infected cells 3-fold and 6-
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fold, and ~8-fold respectively. In IDLV3-RPE65 and IDLV3-RPE65-MITF-infected 
cells, Rpe65 expression was ~5-fold over control and Cralbp expression was ~4-
fold and ~3-fold over control respectively. (n(per experiment)=3, 
n(experiments)=12; *=p<0.05).  
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Timing of Injection of RPE65-Programmed BMDCs is Critical for Preserving 
Retinal Morphology and Visual Function 
 
 
In the previously published studies, RPE65-BMDCs were injected into sodium 
iodate or SOD2-KD mice immediately after infection with pTYF-RPE65. [216] 
However, as expression of lentiviral vectors increases as the vectors integrate into 
the genome, it was thought that injecting the cells up to 24 hours after transducing 
may increase retinal preservation and visual function. Surprisingly, we found that 
culturing murine BMDCs for 16-20 hours after infection with ILV3-RPE65 
significantly diminished the ability of the cells to regenerate damaged RPE or 
preserve retinal function.  
 
As shown in Figure 4.2A, sodium iodate treated mice injected with 50,000 BMDCs 
infected with ILV3-RPE65 via the tail vein had almost ‘flat’ ERG traces in 
comparison with the untreated mice, which had normal A-wave and B-wave 
patterns. The B-wave was almost absent in all sodium iodate treated mice treated 
with BMDC-ILV3-RPE65. These results were observed consistently in all three 
treated mice (Figure 4.2A). The average A-wave in normal mice was ~275 (+/- 25), 
decreasing significantly to ~12 (+/- 3) in sodium iodate treated mice injected with 
BMDC-ILV3-RPE65 (p<0.05) (Figure 4.2B). Similarly, while the average B-wave in 
normal mice was ~650 (+/- 50), the average B-wave in treated mice was ~5 (+/- 2) 
(p<0.05), demonstrating a significant decrease in retinal function (Figure 4.2B).  
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ERG data was backed up by OCT, with significant areas of damage visible in the 
retinas of treated mice in comparison with the wild type normal control. Finally, we 
found that no GFP+ cells were present in the RPE layer of these mice (Figure 
4.2D). Overall, we found that injecting cells that have been cultured overnight after 
infection with ILV3-RPE65 do not rescue RPE damage in vivo and likely are not 
recruited to the RPE layer, as no cells were found in the RPE of these mice.  
Consequently, for the remainder of these studies, we injected the BMDCs 
immediately after transducing them with lentiviral vectors.  
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Figure 4.2 
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Figure 4.2. BMDC-ILV3-RPE65 Incubated Overnight Following Infection Do 
Not Preserve Vision or Are Recruited to the RPE Layer. Lin-/Sca1+ cells were 
isolated from the femurs and tibiae of ~8-week-old GFP+ mice and infected at MOI 
50 with ILV3-RPE65 by spinoculation with Polybrene and incubated for 16 hrs 
post-infection. 50,000 cells were injected via the tail vein per mouse in C57BL6/J 
mice which had been given a 100mg/kg IP injection 1 day prior to injection of 
BMDC-ILV3-RPE65. OCT and ERG was carried out approximately 7 days after 
treatment with cells. Mice were then sacrificed and eyes enucleated, fixed in 
paraformaldehyde, and flat mounted for analysis. (A) Scotopic ERG traces in the 
OS and OD of the normal control mice show typical pattern for normal mice, with 
a well-defined A-wave and B-wave. In contrast, the A-wave and B-wave is almost 
absent in Sodium Iodate treated mice treated with BMDC-ILV3-RPE65. (B) Normal 
mice had an average A-wave of 275 µV and an average B-wave of 650 µV. Sodium 
Iodate-treated mice treated with BMDC-ILV3-RPE65 had an average A-wave of 
12 µV and an average B-wave of 5 µV. (C) Retinae of Sodium Iodate treated mice 
treated with BMDC-ILV3-RPE65 is clearly visible with OCT. Arrows show areas of 
pathology. (D) No GFP+ cells are visible in flat mounted eyes of Sodium Iodate-
treated mice treated with BMDC-ILV3-RPE65. (n=3, *=p<0.05) 
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BMDCs Infected ILV3-RPE65 Immediately After Infection Are Recruited to 
the RPE and Preserve Retinal Function in Sodium Iodate-Treated Mice.  
 
To confirm that the lack of recruitment observed in Figure 4.2 was in fact a direct 
result of the 16 hr time point used, and not a deficiency in the programming of 
BMDCs with ILV3-RPE65, we conducted a short term experiment with the acute 
sodium iodate model of retinal degeneration. This was necessary to confirm the 
ability of ILV3-RPE65-infected cells to be recruited to and restore vision in our 
mouse models as BMDCs used in all of the previous studies were infected with 
pTYF-RPE65 as opposed to ILV3-RPE65. Mice injected with ILV3-RPE65-infected 
GFP+ BMDCs immediately after spinoculation of the BMDCs as opposed to 16 hr 
later demonstrated significant recovery of vision in comparison with mice injected 
with null (uninfected Lin-/Sca1+) cells. Electroretinography demonstrated near-
normal pattern in mice injected with ILV3-RPE65-infected BMDCs in comparison 
with an almost flat ERG trace observed in mice injected with null BMDCs. The A-
wave was improved from ~44 µV in the null BMDC-treated mice to ~104 µV in 
BMDC-ILV3-RPE65-treated mice, in comparison with ~146 µV in the normal 
control (Figure 4.3A). The B-wave showed similar recovery, with an improvement 
from ~88 µV n the null BMDC-treated mice to ~236 µV in BMDC-ILV3-RPE65-
treated mice, in comparison with ~330 µV in the normal control (Figure 4.3B). 
 
We also injected a group of mice with 200k ILV3-RPE65-infected cells as opposed 
to the usual 50k, hypothesizing that an increase in cell number may enhance 
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migration and recovery of vision. While it was found that mice injected with 200k 
cells had greater coverage of GFP+ cells at the RPE layer, with ~40% coverage in 
eyes from mice injected with 200k cells compared with ~20% in mice injected with 
50k cells (Figure 4.3C), injecting with 200k cells did not significantly improve visual 
function over mice injected with 50k cells, with optokinetic nystagmus analysis 
demonstrating a spatial frequency of 0.482 c/d in the former and 0.505 c/d in the 
latter, in comparison with normal and vehicle control mice, which had spatial 
frequencies of 0.643 c/d and 0.593 c/d respectively (Figure 4.3D). We therefore 
carried out the remainder of the in vivo studies with 50k cells.  
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Figure 4.3 
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Figure 4.3. BMDC-ILV3-RPE65 Cells Are Recruited to and Preserve Vision in 
Sodium Iodate Treated Mice.  
 
Wild-type C57BL6/J mice were injected with 100 mg/kg sodium iodate in water 1 
day prior to systemic delivery of GFP+ cells isolated from C57BL6/J GFP+ mice. 
Cells injected were either null (uninfected) GFP+ BMDCs, 50k GFP+ BMDCs 
infected at an MOI of 50 with ILV3-RPE65, or 200k GFP+ BMDCs infected at an 
MOI of 50 with ILV3-RPE65. All infections were done on RetroNectin (2 µg/cm2) 
by spinoculation at 150 g for 2h at 21C. Cells were injected into mice immediately 
after infection. For the sodium iodate control, mice were injected with water instead 
of sodium iodate. For the vehicle control for the cell injections, mice were injected 
with PBS instead of cells. 7 days after injection with cells, mice were evaluate by 
electroretinography and OKN. Eyes were then enucleated and the RPE/Choroid 
layers whole-mounted onto slides to determine the presence of GFP cells in the 
RPE layer.; (A) Electroretinography (ERG) demonstrates improvement of the A-
wave in BMDC-ILV3-RPE65-treated mice in comparison with null BMDC treated 
mice. The average A-wave of normal mice was ~146 µV, ~44 µV in null BMDC-
treated mice, and ~103 µV in BMDC-ILV3-RPE65-treated mice. (n=4) (B) ERG 
also demonstrates an improved B-wave in BMDC-ILV3-RPE65-treated mice in 
comparison with null BMDC treated mice. The average A-wave of normal mice 
was ~330 µV, ~87 µV in null BMDC-treated mice, and ~236 µV in BMDC-ILV3-
RPE65-treated mice. (n=4) (C) GFP+ cells were observed in the flat-mounted RPE 
layer of mice injected with BMDC-ILV3-RPE65, with a fluorescence intensity of 
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approximately 20% in one eye from a mouse injected with 50k cells, and 40% in 
an eye from a mouse injected with 200k cells. Images show two different areas of 
the same eye. (n=1) (D) Optokinetic nystagmus analysis (OKN) revealed improved 
spatial frequency in sodium iodate treated mice treated with either 50k or 200k 
cells in comparison with BMDC-null or vehicle control treated mice. Normal and 
sodium iodate control (water-injected) mice had an average spatial frequency of 
0.648 c/d and 0.652 c/d respectively. Vehicle control and null mice had an average 
spatial frequency of 0.126 c/d and 0.192 c/d respectively. Mice treated with 50k or 
200k BMDC-ILV3-RPE65 had an average spatial frequency of 0.496 c/d and 0.503 
c/d respectively, with no significant difference between these two groups (n=3, 
*=p<0.05). 
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BMDCs Infected with Non-Integrating IDLV Are Recruited to and Preserve 
Retinal Function in Sodium Iodate-Treated Mice. 
 
Having confirmed that BMDC-ILV3-RPE65 recover vision in sodium iodate treated 
mice when injected at the correct time point, we injected sodium iodate-treated 
mice with BMDCs infected with ILV3-RPE65-MITF and the two IDLV3 vectors as 
a preliminary study. ERG results show clear improvement in both the A-wave and 
B-wave of mice treated with the IDLV3 vectors. The normal A-wave was measured 
at ~140 µV, dropping to ~40 µV in mice treated with null BMDCs (Figure 4.4A). In 
contrast, the A-wave was ~100 µV and 80 µV in mice treated with BMDC-ILV3-
RPE65 or BMDC-IDLV3-RPE65, and ~120 µV and ~70 µV in mice treated with 
BMDC-ILV3-RPE65-MITF and BMDC-IDLV3-RPE65-MITF respectively (Figure 
4.4B). Similarly, improvement in the B-wave was also observed, with normal mice 
having an average B-wave of ~320 µV, mice treated with null cells ~20 µV,  BMDC-
ILV3-RPE65 ~230 µV, BMDC-IDLV3-RPE65 220 µV, BMDC-ILV3-RPE65-MITF 
170 µV, and BMDC-IDLV3-RPE65-MITF 190 µV. Optokinetic nystagmus analysis 
confirmed that the presence of GFP+ cells in the RPE layer of these mice 
contributed to a recovery in vision, with a spatial frequency average of 0.192 c/d in 
null-BMDC-treated mice increasing to 0.496 c/d, 0.415 c/d, 0.315 c/d, and 0.453 
c/d in BMDC-ILV3-RPE65, BMDC-ILV3-RPE65-MITF, BMDC-IDLV3-RPE65, and 
BMDC-IDLV3-RPE65-MITF-treated mice respectively (Figure 4.4C). 
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Figure 4.4 
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Figure 4.4. BMDCs Programmed with IDLV3 Vectors Preserve Vision in 
Sodium Iodate-Treated Mice.  
 
Wild type C57BL6/J mice were treated with 100 mg/kg sodium iodate in water or 
water (control) 1 day prior to tail vein delivery of BMDC-null, BMDC-ILV3-RPE65, 
BMDC-ILV3-RPE65-MITF, BMDC-IDLV3-RPE65, or BMDC-IDLV3-RPE65-MITF. 
All infections were done on RetroNectin (2 µg/cm2) by spinoculation at 150 g for 
2h at 21C. Cells were injected into mice immediately after infection. (A) The A-
wave was improved in BMDC-ILV3-RPE65, BMDC-ILV3-RPE65-MITF, BMDC-
IDLV3-RPE65, or BMDC-IDLV3-RPE65-MITF-treated mice in comparison with 
BMDC-null-treated mice, with an average of 100 µV, 120 µV, 80 µV, and 70 µV 
respectively, compared to 40 µV in the null-treated mice. (B) The B-wave was 
improved in BMDC-ILV3-RPE65, BMDC-ILV3-RPE65-MITF, BMDC-IDLV3-
RPE65, or BMDC-IDLV3-RPE65-MITF-treated mice in comparison with BMDC-
null-treated mice, with an average of 230 µV, 220 µV, 170 µV, and 190 µV 
respectively, compared to 20 µV in the null-treated mice. (C) The visual acuity of 
BMDC-ILV3-RPE65, BMDC-ILV3-RPE65-MITF, BMDC-IDLV3-RPE65, or BMDC-
IDLV3-RPE65-MITF-treated mice in comparison with BMDC-null-treated mice, 
with an average of 0.496 c/d, 0.415 c/d, 0.315 c/d, and 0.453 c/d respectively, 
compared to x in the null-treated mice. (n=2-3) 
 
 
157 
 
BMDCs Infected with Non-Integrating IDLV Are Recruited to and Preserve 
Retinal Function in SOD2-KD Mice. 
 
The primary goal of our study was to evaluate IDLV3-based vectors in the chronic 
SOD2-KD model of retinal degeneration, as this model is as similar to human AMD 
as is possible in a mouse. After confirming that the IDLV3-based vectors are 
capable of generating BMDCs which are recruited to and recover vision in the 
sodium iodate model, we next tested these cells in the SOD2-KD model. As we 
are primarily interested in applying this treatment in early AMD, and as our 
previously published studies indicate that early treatment yields the best results, 
we injected all mice with 50k BMDCs 1 month after subretinal injection of the right 
eye (OD) with an adeno-associated virus containing a ribozyme to SOD2 (rAAV-
SOD2). The untreated left eye (OS) acted as an internal normal control. OCT was 
performed at the 3 month time point after BMDC injection. Electroretinography and 
OKN were performed 3 and 6 months after treatment with BMDCs. After visual 
function testing, eyes were enucleated and either flat mounted to quantify 
integrated BMDCs at the RPE layer, or sectioned to observe RPE and retinal 
morphology.  
 
In all mice injected with BMDCs infected with ILV3 or IDLV3-based vectors, GFP+ 
cells were found at the RPE layer of the rAAV-SOD2-injected eye (Figure 4.5A). 
Mice injected with BMDC-ILV3-RPE65 had the greatest number of cells in the RPE 
layer, with an average of 976 cells across 10% of each flat mounted eye (Figure 
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4.5B). Mice injected with BMDC-ILV3-RPE65-MITF had an average of 637 cells 
across 10% of each flat mounted RPE, BMDC-IDLV3-RPE65 645 cells, and 
BMDC-IDLV3-RPE65-MITF 557 cells, and null-BMDCs 20 cells (Figure 4.5B). In 
addition, GFP+ cells observed at the RPE layer in BMDC-ILV3-RPE65-treated 
mice were found to co-express ZO-1 (experiment performed by Dr. Xiaoping 
Qi)[13] a marker of tight junctions that are characteristic of RPE cells (Figure 4.5C), 
and rhodopsin (experiment performed by Dr. Xiaoping Qi),[13] which indicates that 
the cells are capable of phagocytosing photoreceptor outer segments (Figure 
4.5D), further confirming that these BMDCs take on an RPE-like phenotype in vivo. 
These markers will also be stained for in BMDC-IDLV3-treated cells in future 
experiments.  
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Figure 4.5 
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Figure 4.5. BMDCs Programmed with ILV3 or IDLV3 Vectors Are Recruited to 
and Integrate at the RPE Layer in SOD2-KD Mice.  
 
Vector-Infected BMDCs are Recruited to the RPE Layer in SOD2-KD Mice, where 
they Integrate and Adopt and RPE-Like Phenotype. Wild-type C57BL6/J mice were 
injected subretinally with AAV-SOD2 or AAV-inactive 1 month prior to tail vein 
injection with 50k GFP+ lin-/Sca1+ BMDCs infected at an MOI of 50 with ILV3-
RPE65, IDLV3-RPE65, ILV3-RPE65-MITF, or IDLV3-RPE65-MITF. All infections 
were carried out on 2 µg/cm2 RetroNectin by spinoculation at 150g for 2h at 21ºC. 
Eyes were enucleated, fixed in 4% PFA overnight, and the RPE/Choroid layer was 
flat mounted on slides 3 months after injection with cells. Eyes were also fixed and 
paraffin embedded followed by cross sectioning and staining for the presence of 
rhodopsin. Recruitment of injected cells to the RPE layer was visualized as GFP+ 
cells at the RPE/Choroid layer using confocal microscopy and quantified as the 
number of cells present in ~10% of the total flat mount. To observe expression of 
tight junctions, flat mounts were stained with an antibody to ZO-1. Experiments for 
figure 6 C and D were performed by Dr. Xiaoping Qi. (A) GFP cells were observed 
in the RPE layers of mice treated with BMDC-ILV3-RPE65, BMDC-IDLV3-RPE65, 
BMDC-ILV3-RPE65-MITF, or BMDC-IDLV3-RPE65-MITF. Each panel shows 
areas of the RPE/Choroid from the eyes of two mice per group (B) Quantification 
of cell number was carried out using a confocal microscope. Approximately 10% 
of the surface of each eye was quantified by counting the number of cells present 
in a visual field through the microscope using the 10x objective. Mice injected with 
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BMDC-ILV3-RPE65, BMDC-IDLV3-RPE65, BMDC-ILV3-RPE65-MITF, or BMDC-
IDLV3-RPE65-MITF had an average of 976, 637, 645, and 557 GFP+ cells in the 
RPE layer respectively. The average number of GFP+ cells in the RPE layer of 
BMDC-null-treated mice was 20. (n=3) (C) Integrated GFP+ BMDCs infected with 
ILV3-RPE65 co-expressed ZO-1, a marker of tight junctions characteristic to RPE 
cells (data: Dr. Xiaoping Qi). (D) Integrated GFP+ BMDCs infected with ILV3-
RPE65 co-expressed Rhodopsin, present in photoreceptor outer segments, 
indicating that the cells are functioning as RPE cells in phagocytosing 
photoreceptor outer segments (data: Dr. Xiaoping Qi).  
(*p<0.05; n=3).  
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Histology demonstrated significant regeneration of the RPE layer in comparison 
with mice treated with null-BMDCs in mice treated with BMDCs infected with all 4 
vectors (Figure 4.6, A-G). While pathology in some of the eyes and in parts of the 
RPE were present in mice treated with vector-infected BMDCs, RPE morphology 
was consistently improved, with a clear monolayer of pigmented cells present in 
comparison with the vacuolated degenerating RPE cell layer observed in mice 
treated with null BMDCs (Figure 4.6 A-G). In these mice, significant pathology was 
observed along with areas of normal retina, though the RPE was degenerated 
throughout, which is consistent with the progressive nature of the SOD2-KD model 
(Figure 4.6C).  
 
Electroretinography at the 3-month time point revealed significant preservation of 
visual function in mice treated with ILV3 or IDLV3-based vectors in comparison 
with mice treated with null BMDCs (control), with near-normal ERG traces in the 
vector-infected BMDC-treated mice compared with an almost flat ERG trace in 
null-BMDC-treated mice (Figure 4.7A). The A-wave in the normal eyes averaged 
at 132 µV, 46 µV in null-BMDC-treated mice, and 116 µV, 140 µV, 93 µV, 86 µV in 
BMDC-ILV3-RPE65, BMDC-LV3-RPE65-MITF, BMDC-IDLV3-RPE65, and 
BMDC-IDLV3-RPE65-MITF-treated SOD2-KD eyes respectively (Figure 4.7B). 
The B-wave demonstrates a similar pattern, with an average of 286 µV in normal 
mice, 80 µV in null-BMDC-treated mice, and 240 µV, 315 µV, 266 µV, 243 µV in 
BMDC-ILV3-RPE65, BMDC-ILV3-RPE65-MITF, BMDC-IDLV3-RPE65, and 
BMDC-IDLV3-RPE65-MITF-treated SOD2-KD eyes respectively (Figure 4.7C). 
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The inactive ribozyme (positive control for the SOD2 ribozyme) did reduce both 
the A-wave and the B-wave (73 µV and 173 µV respectively), indicating that some 
of the injury to the RPE observed may be due to the injection procedure itself in 
addition to the SOD2-KD.  
 
As ERG does not necessarily correspond with visual acuity in mice, OKN was 
carried out to back up the ERG results. The spatial frequency of the normal eye 
consistently averaged at around 0.6 c/d. rAAV-inactive-injected eyes had a 
reduction in spatial frequency to ~0.5, thought to result from lack of recovery at of 
the injection site, due to the invasive nature of subretinal delivery (Figure 4.7D). In 
SOD2-KD eyes of mice injected with null BMDCs, the spatial frequency averaged 
at 0.06 cd, considerably lower than that observed in SOD2-KD eyes which 
received vector-infected BMDCs (Figure 4.7D). In BMDC-ILV3-RPE65-treated 
mice, the average spatial frequency was 0.524 c/d (Figure 4.7D). In BMDC-ILV3-
RPE65-MITF-treated mice, the average spatial frequency was 0.498 c/d (Figure 
4.7D), in BMDC-IDLV3-RPE65-treated mice 0.538 c/d, and finally in BMDC-IDLV3-
RPE65-MITF-treated mice, 0.489 c/d (Figure 4.7D). While all spatial frequencies 
remained significantly lower than normal (p<0.05), they were also significantly 
higher than that observed in null-BMDC-treated mice, demonstrating that this 
improvement is a result of the infection of the BMDCs with the vectors.  
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Figure 4.6  
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Figure 4.6. BMDCs Programmed with ILV3 or IDLV3 Vectors Preserve Retinal 
Integrity in SOD2-KD Mice.  
 
Wild-type C57BL6/J mice were injected subretinally with AAV-SOD2 or AAV-
inactive 1 month prior to tail vein injection with 50k GFP+ lin-/Sca1+ BMDCs 
infected at an MOI of 50 with ILV3-RPE65, IDLV3-RPE65, ILV3-RPE65-MITF, or 
IDLV3-RPE65-MITF. All infections were carried out on 2 µg/cm2 RetroNectin by 
spinoculation at 150g for 2h at 21ºC. Eyes were enucleated, fixed in 4% PFA 
overnight, and sectioned 3 months after injection with cells. Haemotoxylin and 
Eosin-Stained Cross Sections of Retinae Show Improved Morphology in SOD2-
KD Mice Treated with Vector-Infected BMDCS. Eyes were enucleated and 
immediately transferred to 4% paraformaldehyde for fixing for approximately 72 
hrs, paraffin-embedded, and sectioned by the IU Histology Core. Sections were 
imaged on a Zeiss upright microscope with a color camera and images captured 
using Zeiss Zen software. All main images were taken with the 20x objective; 
insets were taken with the 40x objective. (A) RPE layer of a normal retina (oculus 
sinister [OS]; left eye, untreated), with normal pigmentation and morphology. (B) 
RPE of a retina of a mouse injected with the control AAV containing an inactive 
ribozyme (oculus dexter [OD]; right eye), which has normal pigmentation and 
morphology. (C) RPE of retina from a mouse injected with the AAV containing a 
ribozyme to SOD2 followed by systemic injection of null BMDCs, which appears 
highly depigmented, vacuolated, and degenerated. (OD) (D-G) RPE from the 
retina of mice injected with AAV-Rz-SOD2 followed by systemic treatment with 
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BMDCs infected with (D) ILV3-RPE65, (E) IDLV3-RPE65, (F) ILV3-RPE65-MITF, 
or (G) IDLV3-RPE65-MITF. RPE cells demonstrating significant pigmentation in 
comparison with the null control are shown in K-N. RPE recovery is most 
pronounced in mice treated with BMDC-ILV3-RPE65 or BMDC-IDLV3-RPE65, 
with highly pigmented cells in particular observed in the BMDC-IDLV3-RPE65-
treated eye.  
(*p<0.05; n=3) 
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Figure 4.7 
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Figure 4.7. BMDCs Programmed with ILV3 or IDLV3 Vectors Preserve Visual 
Function in SOD2-KD Mice. Wild-type C57BL6/J mice were injected subretinally 
with AAV-SOD2 or AAV-inactive 1 month prior to tail vein injection with 50k GFP+ 
lin-/Sca1+ BMDCs infected at an MOI of 50 with ILV3-RPE65, IDLV3-RPE65, 
ILV3-RPE65-MITF, or IDLV3-RPE65-MITF. All infections were carried out on 2 
µg/cm2 RetroNectin by spinoculation at 150g for 2h at 21ºC. Electroretinography 
and Optical Nystagmus testing was carried out 3 months after injection of the cells. 
Mice demonstrated improved visual function in mice treated with AAV-Rz-SOD2 
following injection with vector-infected BMDCs but not in mice treated with null 
BMDCs. (A) ERG trace patterns in mice treated with vector-infected BMDCs show 
a normal pattern with reduced amplitude. In null mice, the ERG trace was flattened. 
Mice injected with the inactive ribozyme also had reduced amplitude. (B) The A-
wave amplitude in normal mice was 132 µV. In SOD2-KD mice treated with BMDC-
null, it was reduced to 46 µV. In mice treated with BMDC-ILV3-RPE65, BMDC-
ILV3-RPE65-MITF, BMDC-IDLV3-RPE65, or BMDC-IDLV3-RPE65-MITF, the A-
wave was 116 µV, 140 µV, 93 µV, and 86 µV respectively. (B) The B-wave 
amplitude in normal mice was 286 µV. In SOD2-KD mice treated with BMDC-null, 
it was reduced to 80 µV. In mice treated with BMDC-ILV3-RPE65, BMDC-ILV3-
RPE65-MITF, BMDC-IDLV3-RPE65, or BMDC-IDLV3-RPE65-MITF, the A-wave 
was 240 µV, 315 µV, 266 µV, and 243 µV respectively. (C) The spatial frequency 
in BMDC-null treated mice was reduced to 0.06 c/d compared with an overall 
average of 0.6 in the normal eye across all groups. In mice treated with BMDC-
ILV3-RPE65, BMDC-ILV3-RPE65-MITF, BMDC-IDLV3-RPE65, or BMDC-IDLV3-
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RPE65-MITF, spatial frequencies averaged at 0.524 c/d, 0.498 c/d, 0.538 c/d, and 
0.489 c/d respectively. (*p>0.05, n=3) 
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At 6-months post-injection of BMDCs, visual recovery was largely retained, though 
significant variation was observed between mice in each group at this time point in 
the ERG measurements, including in the normal mice (Figure 4.8A). In normal 
eyes, the A-wave was ~124 µV and the B-wave was ~289 µV, and in null control 
SOD2-KD mice, the A-wave was ~27.5 µV and the B-wave was ~70 µV. In BMDC-
ILV3-RPE65-treated mice, the A-wave was ~150 µV and the B-wave was ~353 
µV. In BMDC-ILV3-RPE65-MITF-treated mice, the A-wave was ~90 µV and the B-
wave was ~205 µV. In BMDC-IDLV3-RPE65-treated mice, the A-wave was ~100 
µV and the B-wave was ~220 µV. In BMDC-IDLV3-RPE65-MITF-treated mice, the 
A-wave was ~52.5 µV and the B-wave was ~137.5 µV.  (Figure 4.8A). 
 
OKN results were less variable and in the normal eyes, the average spatial 
frequency was ~0.650 c/d, in null-BMDC-treated SOD2-KD eyes it was ~0.15 c/d, 
in ILV3 and IDLV3-BMDC treated mice, the average was around 0.600 c/d (Figure 
4.8B).  
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Figure 4.8. 
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Figure 4.8. Improvement in Visual Function in SOD2-KD Mice Treated with 
ILV3 or IDLV3 Vectors Persists for At Least Six Months. A group of mice 
treated with SOD2-KD followed by vector-infected BMDC tail vein injection (50k 
cells) were retained for 6 months for a later ERG and OKN time point. (A, B) In 
normal eyes, the A-wave was ~124 µV and the B-wave was ~289 µV, and in null 
control SOD2-KD mice, the A-wave was ~27.5 µV and the B-wave was ~70 µV. In 
BMDC-ILV3-RPE65-treated mice, the A-wave was ~150 µV and the B-wave was 
~353 µV. In BMDC-ILV3-RPE65-MITF-treated mice, the A-wave was ~90 µV and 
the B-wave was ~205 µV. In BMDC-IDLV3-RPE65-treated mice, the A-wave was 
~100 µV and the B-wave was ~220 µV. In BMDC-IDLV3-RPE65-MITF-treated 
mice, the A-wave was ~52.5 µV and the B-wave was ~137.5 µV.  (C) In normal 
mice, the spatial frequency was ~0.7 c/d in all normal eyes. In BMDC-ILV3-RPE65, 
BMDC-ILV3-RPE65-MITF, BMDC-IDLV3-RPE65, and BMDC-IDLV3-RPE65-
MITF-treated mice, the spatial frequency was 0.621 c/d, 0.622 c/d, 0.602 c/d, and 
0.586 c/d respectively. In BMDC-null treated mice, the spatial frequency was 0.140 
c/d. (*p>0.05, n=3) 
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Discussion  
 
Insertion of a lentiviral vector in the HMGA2 gene in a lentiviral vector-based 
therapy for beta-thalassemia [247] highlights the importance for considering the 
safety of lentiviral vectors when using them to manipulate therapeutic cells. Due to 
the risk of insertional mutagenesis, it is advantageous to use a vector which does 
not integrate where possible. [311] Here, we have focused on an approach which 
exploits the transient nature of IDLV expression, as programming BMDCs in this 
context does not require permanent expression of the transgene. Other 
applications in which this is advantageous include the use of CRISPR/Cas9, where 
IDLVs can be used to deliver gene-editing sequences (Chang et al., personal 
correspondence) and also as a tool for detecting off-target cleavage in both 
CRISPR/Cas9 and TALENs-based approaches. [312] IDLVs are also 
advantageous for in vivo gene therapy in non-dividing cells, where the transgene 
can be stably and persistently expressed. [282] 
 
We have shown that IDLV3-RPE65 is sufficient to program BMDCs to RPE-like 
cells, which are then capable of migrating to the retina, integrating into the RPE 
layer, and preserving vision in mice with retinal degeneration. The SOD2-KD mice 
were injected with BMDC-derived RPE-like cells programmed using IDLV3s 
infected with the modified protocol. Despite this difference in the programming of 
the BMDCs with the IDLV3s between these two models, visual preservation was 
not markedly lower in mice treated with cells that had been infected at a 
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significantly lower efficiency. This suggests that either (a) additional mechanisms, 
on top of infection itself, promote the programming of the cells, for example cell-
cell communication in vitro during or after infection, or (b) visual recovery is 
attainable with a smaller number of cells than injected. It is more likely that our 
finding is due to the latter, as the cells are not kept in vitro for more than 30 minutes 
prior to injection following infection, on top of the fact that in the initial study by 
Sengupta et al., [216] mice only received 5K cells, whereas in our later [13] and 
current studies, mice were given 50K cells. This indicates that as little as 10% of 
the injected cells may be necessary for visual recovery – which is, coincidentally, 
the approximate number of cells expressing the viral construct when IDLV3-based 
vectors are used to infect without the modifications made to the infection protocol 
outlined in Chapter 3.  
 
There is, however, a potential for infected cells to influence the programming of 
neighboring un-infected cells. Conditioned medium has been shown in several 
studies to enhance cellular differentiation or regeneration. [313-318] Experiments 
to determine whether or not conditioned medium from ILV3 or IDLV3-based vector-
infected BMDCs is capable of inducing differentiation of naïve BMDCs to an RPE-
like cell would provide further insights into this as a potential mechanism in the 
programming of our cells. Indeed, should exposure to conditioned media be 
sufficient to promote BMDC programming, future applications could avoid injection 
of infected cells altogether, using the vectors only as a means to generate the 
medium required to program the cells for therapeutic application. [316]  
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Our finding that visual preservation with IDLV3-programmed BMDCs is not 
significantly lower in mice treated with the IDLV3-programmed cells in comparison 
with ILV3-programmed cells strongly supports the use of IDLV3-RPE65 for 
reprogramming BMDCs for application in human cells. Although adding MITF-M to 
the infecting vector in the current study did not provide any measurable advantage 
over using vectors containing RPE65 alone, this does not necessarily suggest that 
inclusion of MITF overall cannot improve BMDC programming, as we have only 
tested one isoform of MITF. Instead of using MITF-M, expressed in differentiated 
RPE, isoforms H and D, which are present in developing retina and/or RPE cells, 
may function to enhance BMDC programming at a greater level than MITF-M. For 
future studies, the inclusion of MITF-D in the infecting vector as opposed to MITF-
M may yield better results – preferential over MITF-H, as MITF-D is only expressed 
in the RPE, whereas MITF-H is present in both the RPE and neural retina, and A 
and J are mainly localized in the neural retina. [305-308] It would be interesting to 
determine whether or not expression of the MITF isoform involved in development, 
MITF-D, is capable of activating expression of the differentiated RPE isoform, 
MITF-M in vitro, as we did not observe significant or consistent expression of Mitf 
in murine or human BMDCs infected with vectors expressing human RPE65 or 
RPE65-MITF (data not shown).  
 
The relatively lower number of cells found in the RPE layer in mice injected with 
BMDCs programmed with IDLV3-based vectors in comparison with mice injected 
with the ILV3-RPE65 programmed BMDCs raises an interesting question about 
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the mechanism of action of the BMDC-derived RPE-like cells in vivo. If the cells 
themselves were solely responsible for preserving vision, we would have expected 
to have observed a proportionately lower recovery of vision in mice with fewer cells 
at the RPE layer. Instead, however, we observed very similar ERG and OKN data 
in mice treated with cells programmed with either ILV3-RPE65 or IDLV3-based 
vectors. As a result, it is likely that the BMDC-derived RPE-like cells not only 
function to support the retina/choroid independently of the existing RPE, but also 
act in a neuroprotective manner, preserving the existing RPE in addition to 
regenerating it. Paracrine activity by stem cells has been widely reported .[319] In 
the eye, it has been shown in a study on glaucoma, in which mesenchymal stem 
cells were injected intravitreally, that the presence of these cells is neuroprotective, 
enhancing the protection of the retinal ganglion cell layer in rats. [320] Another 
study used a lentiviral vector approach to generate neuroprotective neural stem 
cells for intravitreal delivery in retinal degeneration disorders, showing rescue of 
degenerating photoreceptor cells in murine models. [321] 
 
The consistency between this study and our previously published studies, [13, 216] 
along with our findings that human BMDCs infected with the RPE65 viruses also 
express the endogenous markers believed to be necessary for cellular 
programming, indicates that this approach is ready to be applied with human 
BMDCs in vivo. Sustained visual improvement at the 6-month time point is 
encouraging, as our previously published models only measured vision up to the 
3-month time point. Although multiple injections with autologous BMDC-derived 
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RPE-like cells are technically feasible and safe, should visual recovery be 
temporary, the ability to address the problem with a single delivery of cells is 
advantageous for a number of reasons. Firstly, obtaining large numbers of cells 
for multiple treatments increases the invasiveness of the therapy, which is ideally 
avoided. Secondly, while autologous cells are generally thought to be non-
immunogenic, any ex vivo modification of cells has the potential to increase the 
immunogenicity in terms of ‘priming’ the immune system to respond in the event 
of a second exposure. This type of reaction would be rare, but potentially fatal in 
the case of an allergic response to repeated injections of the cells. A ‘one shot’ 
therapy is therefore desirable, and sustained vision to the 6-month time point in 
mice indicates that long-term recovery from one treatment may be viable.  
 
While beyond the scope of the focus of this study, since the completion of testing 
murine BMDC-derived RPE-like cells in murine models, our laboratory has 
demonstrated improvement of vision, as measured by ERG, in a preliminary study 
with NOD-SCID-gamma-null SOD2-KD mice injected with human CD34+ cells 
infected with ILV3-RPE65 (Godoy  et al., personal communication), further backing 
up our claim that the techniques outlined in the current study are appropriate for 
further development for use in human clinical trials for dry AMD. 
 
As a final note on the safety of this application in humans, is generally accepted 
that stem cell-based therapies that are delivered to the eye via intravitreal or 
subretinal injection should be applied in one eye at a time, to ensure that, should 
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patients have an adverse reaction to the treatment resulting in worsening of vision 
or blindness, one eye remains unaffected. A recent treatment given by a US “stem 
cell” company involving intravitreal injection of adipose-derived stem cells resulted 
in blindness in three women who received simultaneous bilateral injections.[185] 
Systemic delivery of cells does not allow for the treatment of one eye at a time. 
However, the risk associated with a systemically-delivered therapy is significantly 
smaller than the risk associated with injections into the eye itself. Firstly, any 
components of cell culture medium – which is likely to have contributed to the 
severe damage observed in the aforementioned patients[185] – will not be directly 
delivered to the eye and therefore are unlikely to cause damage to the eye. 
Secondly, our model relies on injury-based recruitment of cells from the 
bloodstream, meaning that large numbers of cells that are not required are not 
likely to be recruited to the retina, unlike in intravitreal and subretinal injection 
where the cells are directly delivered to the eye. We have also consistently 
demonstrated throughout our studies that the normal eyes of mice which have 
received systemic injections with our cells retain normal vision and normal retinal 
morphology, and that the injected cells are recruited primarily to the injured eye in 
the same mice, suggesting that this recruitment is largely tissue-specific and that 
the cells are very unlikely to be recruited to the eye in numbers large enough to 
cause pathology in areas in which significant damage is not present. We therefore 
believe that systemic delivery of this cell type is not a safety concern, and does not 
constitute ‘bilateral treatment’ in the same way as giving injections of cell 
preparations directly into the eye. 
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CHAPTER V: PHARMACOLOGICAL TREATMENT OF MURINE AND HUMAN 
BONE MARROW-DERIVED CELLS INDUCES DIFFERENTIATION TO RPE-
LIKE CELLS IN VITRO AND PROVIDES INSIGHTS INTO THE MECHANISM 
OF PROGRAMMING. 
 
Introduction 
 
We have previously demonstrated using Ingenuity Pathway Analyses that 
adenylate cyclases 1, 3, and 5 are upregulated in murine BMDCs following 
expression of the human RPE65 gene from the 1st generation ILV-RPE65. [216] In 
this study, it was also found that exposure of murine BMDCs to adenylate cyclase 
activator Forskolin, and cAMP degeneration inhibitor Rolipram, resulted in 
expression of the RPE-associated protein CRALBP, [216] indicating a potential 
critical role for adenylate cyclase activation in the differentiation of these cells to 
an RPE-like phenotype.  
 
In the current study, we have further analyzed the role of adenylate cyclase in 
murine and human BMDC differentiation to an RPE-like phenotype. As adenylate 
cyclase activation appeared to be directly involved in the differentiation of BMDCs 
to RPE-like cells, we postulated that inhibiting adenylate cyclase expression would 
prevent the expression of RPE-associated markers in both murine and human 
BMDCs treated with either Forskolin/Rolipram or the RPE65-expressing LV vector. 
To test this hypothesis, we compared expression of Rpe65/RPE65, 
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Cralbp/CRALBP, and Mitf/MITF in murine and human BMDCs exposed to either 
Forskolin/Rolipram or the 3rd generation ILV-RPE65, with or without inhibitors of 
adenylate cyclase. The inhibitors used included BPIPP, a non-competitive inhibitor 
of both adenylate cyclase and guanylate cyclase which inhibits Forskolin-induced 
adenylate cyclase activation,[322] NKY 80 which primarily inhibits adenylate 
cyclase 5 but also inhibits adenylate cyclases 2 and 3,[323, 324] and KH 7, an 
inhibitor of the soluble adenylate cyclase 10 which was intended as a control 
inhibitor due to its inert activity against the transmembrane adenylate cyclases 
observed as upregulated in the previously published study. [216] 
 
We observed that the presence of all the inhibitors tested reduced the expression 
of RPE-associated genes in Forskolin/Rolipram-treated BMDCs of both mouse 
and human origin, with BPIPP and NKY 80 resulting in the most efficient inhibition 
of these genes. KH 7 resulted in some downregulation of expression, suggesting 
that soluble adenylate cyclase may also be involved in BMDC to RPE-like cell 
differentiation. We also observed almost 100% inhibition of RPE-associated gene 
expression in mouse and human BMDCs treated with the inhibitors following ILV3-
RPE65 infection. Collectively, these data confirm that activation of adenylate 
cyclase plays a critical role in the programming of BMDCs to RPE-like cells.  
 
Finally, we attempted to evaluate the regenerative potential of Forskolin/Rolipram-
derived RPE-like cells from murine BMDCs in both the sodium iodate and SOD2-
KD models of retinal degeneration. Unfortunately, little success was observed with 
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no cells found in the retina or RPE of mice treated with these cells. We hypothesize 
that modifications to the timing of our cell treatment and injection protocol for the 
delivery of these cells will be critical to obtain sufficient cell migration and in the 
RPE. 
 
Results 
 
Exposure of Murine and Human BMDCs to Adenylate Cyclase Activators 
Initiates Expression of Endogenous RPE-Associated Genes 
 
Exposure of murine BMDCs treated once with 10 µmol/l Forskolin and maintained 
in culture for 3 days resulted in a ~5-fold increase (p<0.05) in expression of the 
Rpe65 gene and a ~3.5-fold (p<0.05) increase in expression of Cralbp in 
comparison with the control untreated cells (Figure 5.1A). No significant difference 
in expression of either Rpe65 or Cralbp was observed in cells treated twice with 
10 µmol/l Forskolin and maintained in culture for a total of 6 days. Fold increase in 
expression of Rpe65 and Cralbp in these cells was also ~5-fold and ~3.5-fold 
higher respectively.  
 
In contrast with the result observed with Forskolin, treating murine BMDCs with 
1µmol/l Rolipram twice did increase expression of both Rpe65 and Cralbp in 
comparison with BMDCs treated only once. Murine BMDCs treated twice with 1 
µmol/l Rolipram and cultured for a total of 6 days expressed Rpe65 and Cralbp 
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~4.8 and ~3.8-fold higher than the untreated control respectively (p<0.05), 
whereas BMDCs treated once with 1µmol/l Rolipram and cultured for 3 days 
expressed ~3.8-fold and ~2.5-fold more Rpe65 and Cralbp in comparison with the 
negative control (Figure 5.1B). However, the overall fold change in expression of 
both genes in BMDCs treated with Rolipram, whether the cells received one 
treatment or two, was lower than overall fold change in expression of both genes 
when the cells were exposed to one or two treatments of Forskolin.  
 
When Forskolin (10 µmol/l) and Rolipram (1µmol/l) were combined and added to 
murine BMDCs together, again either as a single treatment for 3 days our as two 
treatments for a total of 6 days, expression of both Rpe65 and Cralbp increased 
~5-fold and ~3.8-fold over the untreated control respectively with no significant 
difference between expression of either gene in the cells treated once compared 
with the cells treated twice (Figure 5.1C).  
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Figure 5.1 
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Figure 5.1. Forskolin and Rolipram Induce Expression of Rpe65 and Cralbp 
mRNA in Murine BMDCs. Murine (lin-/Sca1+) BMDCs were exposed to 10 µmol/l 
Forskolin, 1 µmol/l Rolipram, or a combination of 10 µmol/l Forskolin and 1 µmol/l 
Rolipram. Cells were either treated once, with drug-containing media left on the 
cells for 1 day prior to replacement with complete DMEM, or twice, with media 
replaced with a second treatment after 1 day and replaced with complete DMEM 
on the 3rd day. All cells were cultured for a total of 3 days. (A) Cells treated with 
Forskolin once expressed Rpe65 mRNA ~5-fold over control and Cralbp mRNA 
~3-fold over control (p<0.05) with no increase or decrease in expression when 
treated twice. (B) Cells treated with Rolipram once expressed Rpe65 mRNA ~3.5-
fold over control and Cralbp mRNA ~2.5-fold over control (p<0.05). Cells treated 
twice expressed Rpe65 mRNA ~4.5-fold over control and Cralbp mRNA ~4-fold 
over control (p<0.05). (C) Cells treated with Forskolin and Rolipram once 
expressed Rpe65 mRNA ~5-fold over control and Cralbp mRNA ~3.5-fold over 
control (p<0.05) with no significant increase or decrease in expression when 
treated twice. 
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Experiments carried out in murine BMDCs were repeated with human BMDCs. 
Significant variation in expression of RPE65 was observed in cells treated twice 
with 10 µmol/l Forskolin, and in expression of CRALBP in cells treated once with 
10 µmol/l Forskolin (Figure 5.2A), though expression of RPE65 and CRALBP was 
significantly higher in all cells treated with Forskolin despite individual variation 
within the samples. RPE65 was upregulated ~4-fold in human BMDCs treated 
once with 10 µmol/l Forskolin and ~6-fold in cells treated twice (p<0.05); CRALBP 
expression was increased ~4.5-fold (+/- 3) in cells treated once, and ~3-fold in cells 
treated twice with 10 µmol/l Forskolin (Figure 5.2A). Rolipram significantly 
increased expression of both genes in human BMDCs ~6.8-fold and 3.8-fold in 
cells treated once, and ~7.4 and 3.9-fold in cells treated twice (Figure 5.2B). No 
significant advantage was observed in treating the cells with Rolipram twice 
(Figure 5.2B).  
 
In contrast with data observed in murine BMDCs, human BMDCs express 
significantly more RPE65 when treated with Rolipram than when treated with 
Forskolin (Figure 5.2A and B), though CRALBP expression remains similar. 
Combining Forskolin and Rolipram treatments, either treating once or twice, results 
in RPE65 and CRALBP expression with significantly less variation than when 
Forskolin is used alone (Figure 5.2A and C), with an average fold increase in 
RPE65 of ~5.3-fold and ~5.9-fold in Forskolin/Rolipram treated cells treated once 
or twice respectively, and a correlating increase in CRALBP of ~3-fold and ~4-fold 
(Figure 5.2C). 
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Our findings that expression of the murine Rpe65 gene is upregulated following 
exposure of murine BMDCs to Forskolin and/or Rolipram confirms the role of the 
endogenous Rpe65 gene in the programming of murine BMDCs with the lentiviral 
vector approach. The consistency in expression of both Rpe65 and Cralbp in 
murine BMDCs whether treated with the adenylate cyclase activator Forskolin or 
the cAMP degradation inhibitor Rolipram, either independently or in combination, 
is consistent with our previously published data[216] and our belief that adenylate 
cyclase activation plays a critical role in BMDC differentiation to RPE-like cells. Our 
observations that Forskolin/Rolipram treatment also result in expression of the 
RPE65 and CRALBP genes in human BMDCs further solidify this hypothesis, and 
indicate that the programming process of human BMDCs may be very closely 
related to the programming process of murine BMDCs.  
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Figure 5.2 
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Figure 5.2. Forskolin and Rolipram Induce Expression of RPE65 and 
CRALBP mRNA in Human BMDCs.  
 
Human (CD34+) BMDCs were exposed to 10 µmol/l Forskolin, 1 µmol/l Rolipram, 
or a combination of 10 µmol/l Forskolin and 1 µmol/l Rolipram. Cells were either 
treated once, with drug-containing media left on the cells for 1 day prior to 
replacement with complete DMEM, or twice, with media replaced with a second 
treatment after 1 day and replaced with complete DMEM on the 3rd day. All cells 
were cultured for a total of 3 days. (A) Cells treated with Forskolin once expressed 
RPE65 mRNA ~4-fold over control and CRALBP mRNA ~4.5-fold over control 
(p<0.05). Cells treated twice expressed Rpe65 mRNA ~6-fold over control and 
Cralbp mRNA ~3-fold over control (p<0.05).  (B) Cells treated with Rolipram once 
expressed RPE65 mRNA ~7-fold over control and CRALBP mRNA ~4-fold over 
control (p<0.05). Cells treated twice expressed RPE65 mRNA ~7.5-fold over 
control and CRALBP mRNA ~4-fold over control (p<0.05). (C) Cells treated with 
Forskolin and Rolipram once expressed RPE65 mRNA ~5-fold over control and 
CRALBP mRNA ~3-fold over control (p<0.05). Cells treated twice expressed 
RPE65 mRNA ~6-fold over control and CRALBP mRNA ~4-fold over control 
(p<0.05). 
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Inhibiting the Expression of Adenylate Cyclase Inhibits Murine and Human 
BMDC Differentiation In Vitro 
 
To confirm the role of adenylate cyclase activation in the differentiation of murine 
and human BMDCs in vitro, we inhibited adenylate cyclase immediately prior to 
the treatment of cells with Forskolin, Rolipram, or ILV-RPE65. We first 
demonstrated that the inhibitors used – the transmembrane adenylate cyclase 
inhibitors BPIPP and NKY 80, and the soluble adenylate cyclase inhibitor KH7, did 
not influence expression of the Rpe65 or Cralbp genes in murine BMDCs which 
had not been exposed to either adenylate cyclase activating drug Forskolin, or 
cAMP degradation inhibitor Rolipram (Figure 5.3A). No significant difference in 
expression was observed in murine BMDCs exposed to the vehicle used to deliver 
the drug, DMSO, or in response to any of the inhibitors (Figure 5.3A). 
 
Next, we compared the efficacy of each inhibitor in downregulating the activation 
of Rpe65 and Cralbp following exposure to Forskolin in murine BMDCs. When 
NKY 80 or BPIPP was added to cells treated with Forskolin individually, expression 
of Rpe65 was ~2.5-fold (p<0.05) over expression in control untreated cells, which 
is significantly lower than the ~6-fold (p<0.05) increase in Rpe65 expression in 
cells treated with Forskolin alone (Figure 5.3B). Combining inhibitors NKY 80 and 
BPIPP together further reduced Rpe65 expression to a level similar to that 
observed in cells which had not been treated with Forskolin. While the KH7 
inhibitor decreased Rpe65 expression to approximately half that observed in cells 
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treated with Forskolin only, the level of inhibition is significantly different, indicating 
a role for non-transmembrane adenylate cyclase in the redifferentiation process 
(Figure 5.3B). Expression of Cralbp was significantly inhibited by treating 
Forskolin-exposed cells with NKY 80 or BPIPP alone (~0.1-fold and ~2.5-fold 
higher than the untreated control respectively, compared with a ~4-fold increase 
with Forskolin alone), and combining NKY 80 with BPIPP again resulted in a 
significantly lower expression of Cralbp than when BPIPP was used alone. Again, 
KH7 unexpectedly reduced Cralbp expression, further implicating soluble 
adenylate cyclase in the programming process (Figure 5.3B).  
 
Inhibition of adenylate cyclase via these inhibitors resulted in a similar pattern of 
inhibition when combined with cellular treatment with Rolipram by itself, or where 
cells were treated with both Forskolin and Rolipram together (Figure 5.3C, D). NKY 
80 and BPIPP consistently and significantly reduce expression of both Rpe65 and 
Cralbp, with the strongest inhibition consistently observed when used in 
combination. KH7 also consistently results in reduced expression of both the 
Rpe65 and Cralbp genes (Figure 5.3 C, D). 
 
Since inhibiting adenylate cyclase significantly reduces expression of Rpe65 and 
Cralbp in murine BMDCs, we next compared expression of RPE65 and CRALBP 
in human donor BMDCs exposed to Forskolin or Rolipram with or without a 
combination of NKY 80 and BPIPP, or KH7. Interestingly, in human BMDCs, KH7 
did not inhibit expression of RPE65 or CRALBP to the same degree as this inhibitor 
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inhibited Rpe65 and Cralbp in murine BMDCs (Figure 5.4). NKY 80 and BPIPP 
did, however, significantly reduce expression of both genes in human  
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Figure 5.3 
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Figure 5.3. Adenylate Cyclase Inhibitors Block Expression of Rpe65 and 
Cralbp in Forskolin and Rolipram-Treated Murine BMDCs.  
 
BMDCs were exposed to 10 µmol/l Forskolin, 1 µmol/l Rolipram, or a combination 
of 10 µmol/l Forskolin and 1 µmol/l Rolipram in the presence or absence of 50 
µmol/l BPIPP, NKY 80, or KH7. (A) Cells treated with inhibitor vehicle DMSO, 
BPIPP, NKY 80, KH7, or a combination of BPIPP and NKY 80 did not significantly 
express Rpe65 or Cralbp mRNA (B) Cells treated with Forskolin in the absence of 
any inhibitor expressed Rpe65 mRNA ~6-fold over control and Cralbp mRNA ~4-
fold over control (p<0.05). Rpe65 mRNA expression reduced to ~2-fold over 
control in cells treated with NKY 80 or BPIPP, approximately equal to control in 
cells treated with both NKY 80 and BPIPP, and ~3-fold over control in KH7-treated 
cells (p<0.05). Cralbp mRNA expression was approximately equal to control in 
cells treated with NKY 80, KH7, or NKY 80 with BPIPP, and ~2-fold over control in 
cells treated with BPIPP. (C) Cells treated with Rolipram in the absence of any 
inhibitor expressed Rpe65 mRNA ~6-fold over control and Cralbp mRNA ~4-fold 
over control (p<0.05). Rpe65 mRNA expression reduced to ~2-fold over control in 
NKY 80-treated cells, ~3-fold over control in BPIPP-treated cells, ~1.6-fold over 
control in NKY80 and BPIPP-treated cells, and ~3-fold over control in KH7-treated 
cells. Cralbp expression was reduced to approximately the same level as the 
untreated control in cells treated with all inhibitors. (D) Cells treated with Forskolin 
and Rolipram expressed Rpe65 mRNA ~8-fold and ~4.5-fold over control (p<0.05). 
In the presence of NKY 80 or a combination of BPIPP and NKY 80 reduced 
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expression of Rpe65 to approximately that observed in the untreated control. 
BPIPP reduced Rpe65 mRNA to ~3-fold over control, and KH7 ~2-fold over control 
(p<0.05). Cralbp expression was reduced to approximately that of the untreated 
control in all conditions apart from KH7, in which expression was ~2-fold over the 
control. (*=p<0.05; n(per experiment)=3, n(experiments)=3). 
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Figure 5.4 
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Figure 5.4. Adenylate Cyclase Inhibitors Block Expression of RPE65 and 
CRALBP mRNA in Forskolin and Rolipram-Treated Human BMDCs.  
 
BMDCs were exposed to 10 µmol/l Forskolin, 1 µmol/l Rolipram, or a combination 
of 10 µmol/l Forskolin and 1 µmol/l Rolipram in the presence or absence of 50 
µmol/l NKY 80/BPIPP, or KH7. In the presence of Forskolin, RPE65 mRNA was 
~4.5-fold over control (p<0.05), reduced to approximately that of the control in the 
presence of NKY 80/BPIPP and ~1.5-fold over control in the presence of KH7. 
CRALBP mRNA levels were ~4-fold over control (p<0.05), reduced to 
approximately that of the control in the presence of NKY 80/BPIPP and ~3-fold 
over control in the presence of KH7 (p<0.05). In the presence of Rolipram, RPE65 
mRNA was ~6-fold over control (p<0.05), reduced to approximately that of the 
control in the presence of NKY 80/BPIPP and ~3-fold over control in the presence 
of KH7 (p<0.05). CRALBP mRNA levels were ~4-fold over control (p<0.05), 
reduced to approximately that of the control in the presence of NKY 80/BPIPP and 
~4-fold over control in the presence of KH7 (p<0.05). In the presence of Forskolin 
and Rolipram, RPE65 mRNA was ~4.5-fold over control (p<0.05), reduced to 
approximately that of the control in the presence of NKY 80/BPIPP and ~4-fold 
over control in the presence of KH7. CRALBP mRNA levels were ~5-fold over 
control (p<0.05) reduced to approximately that of the control in the presence of 
NKY 80/BPIPP and ~4-fold over control in the presence of KH7. 
(*=p<0.05; n(per experiment)=3, n(experiments)=3).  
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BMDCs treated with Forskolin, Rolipram, or a combination of Forskolin and 
Rolipram (Figure 5.4).  
 
We next measured the effect of inhibiting adenylate cyclase on expression of 
Rpe65, Cralbp, and CRALBP in murine and human BMDCs infected with ILV3-
RPE65. Exposure to NKY 80 and BPIPP, and to KH7, does not reduce expression 
of the lentiviral transgene RPE65 (Figure 5.5). KH7 also does not inhibit expression 
of Rpe65 or Cralbp in mouse cells treated with ILV-RPE65 to the same level as it 
inhibits these genes in cells treated with Forskolin and Rolipram (Figure 5.5). KH7 
also does not inhibit expression of CRALBP in human BMDCs. Consistent with our 
observations with inhibiting adenylate cyclase in Forskolin/Rolipram-treated cells, 
the combination of NKY 80 and BPIPP consistently reduced the expression of the 
murine Rpe65 and Cralbp genes in murine ILV-RPE65 infected BMDCs, and also 
inhibited expression of the human CRALBP gene in human ILV-RPE65 infected 
cells (Figure 5.5).  
 
These data support our hypothesis that expression of RPE65/Rpe65 and 
CRALBP/Cralbp is almost completely inhibited by the inhibition of adenylate 
cyclase in both Forskolin/Rolipram treated cells and ILV-RPE65-treated cells. This 
suggests that adenylate cyclase activation is one of the earliest stages in the 
differentiation process, and confirms that the activation of adenylate cyclase 
precedes activation of the endogenous Rpe65 gene, as Rpe65 as well as Cralbp 
expression is inhibited by the inhibition of adenylate cyclase. This suggests that it 
198 
 
is the expression of the human RPE65 gene in the murine BMDCs which initiates 
expression of adenylate cyclase in these cells, and that adenylate cyclase 
expression in turn results in expression of the endogenous Rpe65 and Cralbp 
genes. If expression of the RPE65 gene alone was sufficient to drive the up-
regulation of Rpe65 expression, we would expect to observe no inhibition of Rpe65 
expression in ILV-RPE65-treated cells exposed to the adenylate cyclase inhibitors.  
Although we observed significant similarities between the murine and human 
BMDCs in response to pharmacological activation of adenylate cyclase, murine 
and human BMDCs did differ in response to the soluble adenylate cyclase inhibitor, 
KH7. In murine BMDCs, KH7 unexpectedly inhibited expression of Cralbp. KH7 
was expected to have no effect on expression of these genes due to the fact that 
the initial study implicated adenylate cyclases 1, 3, and 5 in the cellular 
programming process, which are all transmembrane adenylate cyclases. While the 
inhibition resulting from KH7 exposure was not as great as that observed when 
cells were treated with transmembrane adenylate cyclase inhibitors NKY 80 and 
BPIPP, the inhibition was significant, indicating that soluble adenylate cyclase may 
also play a role in murine BMDC programming. In contrast, in human BMDCs, 
inhibition of the soluble adenylate cyclase did not inhibit expression of CRALBP, 
indicating that there may be a difference in the number of adenylate cyclases 
involved in murine BMDC differentiation in comparison with human BMDC 
differentiation. 
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Figure 5.5 
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Figure 5.5. Adenylate Cyclase Inhibitors Block Expression of Rpe65 and 
Cralbp mRNA in ILV3-RPE65-Infected Cells. Murine (lin-/Sca1+) or human 
(CD34+) BMDCs were infected with ILV3-RPE65 at an MOI of 50 with or without 
inhibitors BPIPP or KH7. Control cells were not infected with virus. Expression of 
RPE65 from the vector, and mouse Rpe65 and Cralbp mRNA and human CRALBP 
mRNA were measured 4 hours after infection as previously described (Chapter 3). 
All cells infected with ILV3-RPE65 expressed RPE65, with a ~26-fold, ~25 fold, 
and ~27-fold increase in RPE65 mRNA observed in ILV3-RPE65, ILV3-
RPE65+BPIPP, and ILV3-RPE65+KH7-treated cells respectively (p<0.05). In 
mouse BMDCs, cells treated with ILV3-RPE65 alone expressed Rpe65 and Cralbp 
mRNA ~5- and ~4-fold over control respectively (p<0.05). These levels reduced to 
~1 and ~0.8 fold when BPIPP was added (p<0.05), and to ~2 and ~3-fold when 
KH7 was added. In human BMDCs, CRALBP mRNA was expressed ~4-fold over 
control when cells were infected with ILV3-RPE65 alone (p<0.05). This reduced to 
~1-fold when BPIPP was added (p<0.05). In the presence of KH7, ILV3-RPE65-
treated human BMDCs expressed CRALBP ~5-fold over control (p<0.05).  
(*=p<0.05; n(per experiment=3; n(experiments)=3).  
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Murine BMDCs Programmed with Adenylate Cyclase Activators are Not 
Recruited to the RPE in Retinal Degeneration Murine Models 
 
As we confirmed the role of adenylate cyclase in activating endogenous RPE-
associated genes in vitro, and observed similar levels of activation of these genes 
following treatment with Forskolin and Rolipram as observed in murine BMDCs 
programmed with ILV-RPE65 and IDLV-RPE65, it was thought that murine BMDCs 
exposed to Forskolin and Rolipram would also be recruited to and regenerate 
damaged RPE in the sodium iodate and SOD2-KD models of retinal degeneration.  
Due to the critical timing of injection of cells infected with the RPE65 vectors, we 
first attempted to determine the best time of injection for BMDCs exposed to 
Forskolin.  Murine BMDCs exposed to 10 µmol/l Forskolin began expressing both 
the murine Rpe65 and Cralbp genes within one hour post-exposure, with a ~4.2-
fold and ~3.5-fold increase in expression of these genes compared with untreated 
cells (p<0.05) (Figure 5.6A). Similar fold changes were observed consistently from 
1 hour to 3 days in culture with 10 µmol/l Forskolin, with an increase in Rpe65 
expression from ~4-fold to ~6-fold between 2 and 3 days (p<0.05) but no significant 
increase in Cralbp expression (Figure 5.6A). Cells were injected into sodium iodate 
mice 8 hours after IP injection of sodium iodate, after 1 hour, 1 days, or 2 days of 
culture with 10 µmol/l Forskolin. Cells treated with Forskolin alone expressed 
Rpe65 ~4-fold over the control, and Cralbp ~2.4-fold. Cells treated with Rolipram 
demonstrated a ~3-fold increase in expression of Cralbp and a ~4-fold increase in 
expression of Rpe65. Cells treated with both Forskolin and Rolipram demonstrated 
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a ~3-fold increase in Cralbp expression and a ~4.4-fold increase in Rpe65 
expression (Figure 5.6B). 
 
We did not observe GFP+ cells in the RPE layer in mice injected with BMDCs 
exposed to Forskolin at 1 hour, 1 day, or 2 days of culture with Forskolin (Figure 
5.6C). Mice were sacrificed 7 days after injection. No GFP+ cells were observed 
in the RPE layer in mice injected with naïve BMDCs (Figure 5.6C). In contrast, 
several GFP+ cells were found in the RPE layer of mice injected with ILV3-RPE65, 
pictured here as a positive control. While some patches of green can be observed 
in the flat mounted RPEs of mice injected with BMDCs exposed to Forskolin for 1 
hour or 1 day, these areas do not appear to be GFP+ cells. Instead, the green 
patches are likely to be autofluorescent particles occurring as a result of the 
sodium iodate induced RPE damage.  
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Figure 5.6 
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Figure 5.6. Forskolin and Rolipram-Treated Murine BMDCs Do Not Preserve 
Retinal Morphology in Murine Models of Retinal Degeneration.  
 
Murine Lin-/Sca1+ BMDCs were isolated from the whole bone marrow of GFP+ 
C57BL6/J mice and treated with 10 µmol/l Forskolin. Cells were kept in culture for 
1h and 1-3 days after Forskolin treatment, and injected via tail vein 1h, 1d, and 2d 
after Forskolin treatment into wild type C57BL6/J mice, which had received 
100mg/kg sodium iodate 1 day prior to injection with cells (50k cells/mouse). (A) 
Rpe65 and Cralbp mRNA levels were measured in murine BMDCs treated with 
Forskolin at each injection time point (1 hour, and 1-3 days) to confirm gene 
expression in cells injected into Sodium Iodate mice. Prior to treatment with 
Forskolin, cells did not express Rpe65 or Cralbp. At 1 hour post-exposure to 
Forskolin, cells Rpe65 mRNA was increased ~4-fold over control, and Cralbp ~3-
fold (p<0.05). ~3-fold increase in Cralbp mRNA was consistent at each time point, 
and Rpe65 mRNA was expressed ~4-fold over control at all time points apart from 
3 days, at which Rpe65 expression increased to ~6-fold over control (p<0.05). (B) 
Flat mounted RPE/Choroid layers were examined by confocal microscopy for 
expression of GFP+ cells at each time point. In contrast to the large numbers of 
GFP+ cells observed in sodium iodate mice injected with ILV3-RPE65-treated 
cells, no expression of GFP was observed in any of the eyes from mice injected 
with Forskolin-treated BMDCs at any of the time points. Areas of green 
fluorescence were determined to be autofluorescent, not cellular, in nature and are 
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consistent with areas of autofluorescence observed in damaged RPE.  (*=p<0.05. 
n=3) 
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Discussion 
 
Programming BMDCs to RPE-like cells for therapeutic intervention in retinal 
degeneration with drugs instead of a LV vector approach is an attractive possibility 
due to the increased safety of the treatment. While we believe IDLV-based 
approaches are significantly safer than the previously used ILV approach,[13, 216] 
the use of a drug is more so, and may not only be cheaper and easier as a 
mechanism for programming cells, but also more likely to be quickly approved for 
use in human clinical trial. Forskolin is already FDA approved for treatment of 
conditions such as heart disease and glaucoma,[325] and Rolipram, while 
discontinued for its original purpose as an antidepressant, is also FDA approved 
and has been shown to be safe in human clinical trials.[326] Additionally, the 
drug(s) are used only to program the cells and are not injected along with the cells, 
unlike the LV approach, where the viral genome remains in the cells given back to 
the animal/patient. Where patients are not being directly exposed to the agent used 
for programming, the potential for dangerous side effects is significantly reduced. 
For this reason, further developing the BMDC-programming approach with 
Forskolin/Rolipram is advantageous and may allow for treatment of humans earlier 
than cells derived from the ILV/IDLV approach.  
 
As Forskolin/Rolipram-treated cells express the same markers of programming as 
ILV3/IDLV3-RPE65-treated cells, Rpe65/RPE65 and Cralbp/CRALBP, and as 
inhibition of expression of these mRNAs is inhibited on exposure to cAMP 
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inhibitors whether cells were treated with virus or drug(s), we are confident that the 
mechanism by which the cells express these mRNAs is the same. Expression of 
Rpe65/RPE65 in particular indicates that the Forskolin/Rolipram-treated cells are 
at least beginning to differentiate into an RPE-like cell as this gene is specific to 
RPE cells and would not be expected to be expressed in the absence of 
programming to this cell type. The lack of Forskolin/Rolipram-treated BMDC 
migration to and regeneration of damaged RPE in both the sodium iodate and 
SOD2-KD retinal degeneration models, in our opinion, suggests that the ideal time 
point for treatment and subsequent injection of BMDCs may differ significantly from 
that used for ILV3/IDLV3-RPE65-treated cells. As shown in Chapter IV, cells 
cultured for 16 hours after ILV3-RPE65 infection are also not recruited to and do 
not regenerate RPE in these models; however, this did not mean that ILV3-RPE65-
treated cells were incapable of doing so. The problem was not with the cells, but 
the timing of the injection, as the cells are recruited and do regenerate RPE when 
injected immediately after infection. This highlighted the critical importance of 
selecting the optimum time point after treatment for injection. We therefore do not 
believe that the lack of migration and regeneration with Forskolin/Rolipram-treated 
cells at this stage in the study indicates that this treatment is not appropriate for 
generating therapeutic BMDCs. Instead, we think that identifying the best time at 
which to inject the cells following exposure to the drug(s) will result in BMDC repair 
of the RPE comparable to that achieved with ILV3-RPE65.  
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The one critical difference between cells programmed with ILV3/IDLV3-RPE65 
and cells programmed with Forskolin is the timeline of endogenous Rpe65 and 
Cralbp mRNA expression. While these genes are found to be activated within 4 
hours of infecting cells with ILV3/IDLV3-RPE65, their expression is detected within 
just one hour of exposure to Forskolin. In fact, when used in Förster resonance 
energy transfer (FRET) applications for in vitro imaging of biosensor activity, 
Forskolin activates cAMP pathways within 30 seconds of being added to the cells, 
with emission reaching its highest at just 2 minutes after Forskolin is added.[327] 
Comparatively, this activation is considerably faster than activation observed with 
the vector-transduced cells. As observed with the vector-transduced cells, there is 
a critical time window for injection which is most likely related to the time point at 
which endogenous genes become activated and, as treating the cells with 
Forskolin/Rolipram results in the expression of these genes at different times in 
comparison with the vector-transduced cells, it is likely that this time point will be 
different from the time point used with the vector-transduced cells.  
 
When vector-transduced cells are injected into mice, they are effective only when 
they are injected at the time point where adenylate cyclase pathways are thought 
to have been activated or are in the process of being activated, but robust 
expression of Rpe65 and Cralbp mRNA has yet to occur – vector-infected cells, 
when lysed immediately after infection, do not exhibit expression of these mRNAs, 
which occurs at the 2-3 hour time point after injection. In contrast, cells 
programmed with Forskolin/Rolipram already express Rpe65 and Cralbp, even 
209 
 
when injected just one hour after treatment. We believe this difference in timing of 
expression is the key to understanding how to make functional BMDCs using 
Forskolin/Rolipram. Essentially, we hypothesize that pharmacologically-activated 
BMDCs may be too differentiated by the time they are injected into the mice, 
limiting their ‘homing’ capacity.  
 
As expression of Rpe65 and Cralbp increases over time, expression of the BMDC 
markers Sca-1 decreases. Appendix 2). The most obvious explanation for cells not 
being recruited to the RPE after systemic injection would be that they have become 
too differentiated along a non-hematopoietic lineage and have lost expression of 
the markers that BMDCs require to be able to circulate in the blood and not be 
filtered out of the system. The cells may also begin to lose expression of markers 
involved in recruitment to the RPE after they become differentiated. While we have 
not measured CXCR4 expression, it is possible that the cells also lose expression 
of CXCR4 as they differentiate, which would significantly impair their ability to be 
recruited to and be retained in the retina following injection.[217] Future studies will 
focus on identifying the BMDC marker expression profile in comparison with the 
Forskolin/Rolipram activation timeline, in order to identify a time point at which the 
cells express the right markers for both differentiating into RPE-like cells, and 
migrating to the RPE from the bloodstream. It may be necessary to add the drug(s) 
directly to the cells immediately before injection into mice, which would make the 
treatment slightly riskier as the drugs would be injected along with the cells, but as 
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both have been shown to be safe in small doses, we do not expect that the amount 
of drug required to differentiated the cells would have an effect in vivo.  
 
Overcoming this limitation would allow for rapid treatment of retinal degeneration, 
minimizing the amount of time the cells are required to be maintained ex vivo. This 
is beneficial, as it has been shown that maintaining cells ex vivo in ambient oxygen 
alters their phenotype and reduces the number of cells capable of engrafting.[328] 
In summary, pharmacological activation of adenylate cyclase and subsequent 
inhibition of this activation in both Forskolin/Rolipram-treated cells and ILV-RPE56 
treated cells confirms the role of adenylate cyclase in the programming of BMDCs 
to RPE-like cells, via activation of the endogenous RPE65/Rpe65 and 
CRALBP/Cralbp mRNA expression. Modifications to the treatment and injection 
process may allow the use of pharmacologically differentiated cells in vivo. 
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CHAPTER VI: DISCUSSION AND FUTURE DIRECTIONS 
 
The lack of therapeutically viable options for intervention in dry AMD is a significant 
concern, [12] as the prevalence of the disorder is increasing and expected to 
continue to increase, as life expectancy and human exposure to environmental 
factors which contribute to the development of the disorder increases. [1-4, 9, 329] 
There is a critical need for a therapy which can be given early in the progression 
of the disease to prevent, or at least delay, the development of geographical 
atrophy and loss of neural retinal integrity in dry AMD patients. [13, 216] No matter 
how effective an RPE replacement strategy is, there will be no preservation of 
central vision if the treatment is applied so late in the progression of the disorder 
that the neural retina, in particular the photoreceptors, along with the choroid, are 
already damaged.  
 
Some of the main disadvantages in stem cell-based therapies which have been 
trialed in dry AMD – late-stage treatment, invasive cell delivery, and a lack of 
adequate ‘spreading’ of cells from the site of injection – can be overcome by 
delivering the cells systemically, avoiding the invasive protocols which limit cellular 
delivery to late-stage disease in adult RPE, iPSC and ESC-derived transplant 
strategies. [13, 216]  Other disadvantages, such as the potential or iPSC and ESC-
derived cells to become tumorigenic or form teratomas, [211] can be addressed by 
using an adult stem cell as the cell of origin, as adult stem cells lack the potential 
to become any cell type. BMSCs combine these two solutions in providing a cell 
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type that can be injected directly into the bloodstream, and which is also very 
unlikely to be tumorigenic in itself.  
 
BMDCs can be differentiated into RPE-like cells which regenerate RPE and 
preserve vision in retinal degeneration mice. [13, 216]  Here, we have expanded 
this approach to eliminate the need for an integrating lentiviral vector (ILV) in the 
production of RPE-like cells from BMDCs, avoiding any potential concerns 
associated with the integration of lentiviral vector particles into coding or regulatory 
regions of the genome. [330] We have generated an integrase-defective lentiviral 
vector (IDLV)-based system for programming BDMCs to RPE-like cells, including 
the development a method for optimizing the infection of BMDCs with this vector. 
Not only are IDLVs capable of programming murine BMDCs to RPE-like cells, 
infection with this vector also initiates programming of human BMDCs to RPE-like 
cells as evidenced by the cells’ expression of CRALBP shortly after infection. 
Critically, RPE-like cells derived from BMDCs using the IDLV vector are as capable 
of regenerating the RPE and preserving visual function as cells programmed using 
the ILV, confirming that integration and permanent expression of the human 
RPE65 gene from the infecting vector is not required for the programming of 
BMDCs to RPE-like cells. Finally, we have confirmed the role of adenylate cyclase 
in the process of BMDC programming to RPE-like cells, showing that adenylate 
cyclase activation is both necessary and sufficient for generating RPE-like cells 
from BMDCs.  
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Together, our studies provide invaluable insight into methods by which RPE-like 
cells can be derived from BMDCs without taking unnecessary risks in the use of 
ILVs, improving safety for human clinical trial. We have further confirmed that our 
previously published protocols [13, 216]  for regenerating RPE function in vivo. To 
the best of our knowledge, this study is not only the first example of the use of a 
single IDLV being used to program an adult stem cell in vitro, but also the first to 
produce a new cell type from a lineage not usually generated by the cell of origin 
that acts as an effective tissue regeneration therapy when delivered in vivo. It is 
also the first evidence that human BMDCs can be programmed to become RPE-
like cells, which is vital for the use of BMDC-derived RPE in human clinical trials.  
Several experiments are required to further assess the mechanisms by which 
differentiated BMDCs are recruited to and integrate into the RPE layer. Previously, 
we have conducted an experiment in which RPE65 vector-transduced GFP+ 
BMDCs were injected into wild-type C57BL6/J mice, followed by harvest of the 
eye, lung, liver, spleen, and bone marrow 1 day, 7 days, and 28 days after injection. 
[13] Organs were then homogenized and qRT-PCR was used to determine the 
level of expression of GFP in each organ. While GFP expression was observed in 
all tissues 1 day after injection, by 7 days, GFP was detectable only in the spleen. 
By 28 days, expression was found only in the eye. This raises questions as to the 
mechanism behind which cells are recruited to the eye, as RPE65-transduced GFP 
cells are present in the eye of wild-type mice, whereas in our retinal degeneration 
studies involving the SOD2-KD model, the GFP+ cells are recruited predominantly 
to the injured eye and not to the eye which has not received SOD2-KD injury. This 
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suggests that the programmed cells are recruited to the eye in the absence of 
injury, but that the localization of the cells is specifically and significantly enhanced 
by the presence of injury at the RPE. One possible mechanism for this would be 
the relative expression levels of CXCR4 in the BMDCs and SDF-1 in the RPE cells, 
since it is known that BMDCs express CXCR4 and that the recruitment of cells to 
specific areas will be enhanced by the expression in those tissues of SDF-1. A 
comparison of SDF-1 expression in the presence and absence of injury to the 
retina would allow for determination of whether or not an upregulation of SDF-1 in 
the presence of injury could enhance the recruitment of the cells to the injured eye, 
and this may be confirmed by inhibiting SDF-1 in the and determining the effect on 
the recruitment of BMDCs. Additionally, measuring the expression level of CXCR4 
in null vs. RPE65-programmed BMDCs may provide insight into how the CXCR4 
pathway enhances the natural ability of the cells to be recruited to the eye in injury. 
If CXCR4 is upregulated in RPE65-programmed BMDCs in comparison with the 
null cells, this may account for the enhanced ability of the cells to be recruited to 
the RPE layer.  
 
Further experiments to compare the role of injury with the role of the cells ability to 
be recruited to the eye specifically could compare the presence of RPE65-
programmed BMDCs in, for example, the lung, liver, or spleen at the time points 
previously analyzed when those organs are injured as opposed to the injury being 
located in the eye. A lack of recruitment of these cells to other organs in the 
presence of injury would provide evidence to confirm that the recruitment to the 
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eye in our models, and, consequently, the reparative capabilities of the cells, is 
specific to the RPE. This may be important in the application of these cells in 
human clinical trials, as if the recruitment is not eye-specific, it would be important 
to determine that any off-target migration to other organs would not be detrimental 
to the patient. Long-term mouse studies evaluating RPE65-programmed cells in 
tissues other than the retina would be required to rule this out should these cells 
be recruited to other injured organs, including the isolation and characterization of 
cells localizing to other organs and histopathological analysis for the presence of 
changes in the organs.  
 
It is worth noting that studies involving adult stem cells have, in the past, been 
associated with cell fusion to existing cells as opposed to the cells themselves 
providing a therapeutic effect, [331] and that we have previously determined that 
our BMDC-derived RPE-like cells do not fuse to existing RPE by using XY-FISH. 
[216] Lack of cell fusion indicates that the cells themselves are functioning as RPE 
cells in vivo. It does not, however, rule out the possibility that the cells are 
supporting and protecting existing RPE after they have integrated. It is entirely 
possible that the cells not only help preserve the retina by performing RPE cell 
functions, but also act to protect the existing RPE cells from further degeneration. 
This would be advantageous, as it is not clear that the BMDC-derived RPE-like 
cells are any more capable of cell division than native, terminally differentiated 
RPE in the RPE layer – an ability to protect and support existing RPE would result 
in longer-term preservation of vision or delay in the progression of dry AMD.  
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Our primary goal is to establish the outlined therapy for use in human clinical trials. 
Preliminary data showing preservation of vision in mice treated with human BMDC-
derived RPE-like cells generated with ILV3-RPE65 (Godoy et al., personal 
communication) is encouraging; however, several issues need to be addressed 
prior to moving toward human clinical trials. Firstly, evaluation of human BMDC-
derived RPE-like cells in a larger animal is necessary for a number of reasons, 
including determination of the number of cells required for RPE regeneration and 
preservation of vision in a larger animal.  
 
The mouse retinal area is approximately 15.6mm2, [332] whereas a human eye is 
~1025mm2. [333] Based on the cell number used in this study, we inject 
approximately 3300 BMDC-derived RPE-like cells per mm2 of retinal area in the 
mouse. To get the equivalent cell number in humans, 3.3 million cells would 
therefore be required. This is an extremely high cell number considering that only 
~150k CD34+ cells could be obtained from patient peripheral blood. Bringing more 
invasive techniques, such as bone marrow harvest, into the equation is not optimal, 
and it would be better for patients if such invasive methods could be avoided. 
Mobilization of CD34+ cells into the bloodstream using G-CSF and subsequent 
collection by apheresis is less invasive than bone marrow harvest, but has been 
found in rare cases to result in pulmonary complications. [334] Evaluating the 
therapy in a larger animal prior to use in humans may allow for this complication 
to be minimized, through injections of smaller numbers of cells to identify the 
lowest number necessary for visual recovery. It is possible that a number 
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significantly lower than 3.3 million will be required, based on the recovery of vision 
we have observed in mice treated with 5k cells. [216] Potentially, 300k or fewer 
cells may be sufficient. This would allow for the recovery of cells from peripheral 
blood of patients, keeping the invasiveness of the procedure at a minimum. In the 
event that a smaller cell number fails to adequately regenerate the RPE and 
preserve vision, other options for obtaining large numbers of cells are available. 
For example, it has been shown that CD34+ hematopoietic progenitor cells can be 
obtained from iPSCs, [335] which would be a viable alternative, as long as a 
screening mechanism was used to ensure the iPSC generation process had not 
generated cells with the potential to become tumorigenic. [212]   
 
Studies on non-human primates are critical for another reason – the presence of 
a macula. [336] Murine models are appropriate for evaluating the ability of cells to 
regenerate RPE, but as mice do not have a macula, these models do not 
accurately represent human AMD, where the primary site of degeneration is 
around the macular region. Especially in the sodium iodate model, RPE damage 
is widespread across the entire RPE area, and in both this model and the SOD2-
KD model, it is difficult to pinpoint any specific areas of RPE injury that the cells 
are recruited to. We can say that the injury promotes recruitment of the cells to the 
RPE layer as we find significant cell numbers in the injured eye in mice injected 
with the cells in comparison with the non-injured eye in the same mouse. We do 
not, however, know if focal areas of injury in the SOD2-KD model specifically 
recruit cells to that area or if the cells will spread across the RPE regardless of 
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where the RPE is most damaged. In human dry AMD, in order for the therapy to 
have the maximum effect on preservation of vision, we hypothesize that the 
majority of the recruited cells would need to localize around the macular region in 
order to protect that area of the retina from degeneration. Even if the cells also 
protect existing RPE, localization in this area is likely to be critical for sustained 
maintenance of central vision in dry AMD patients. Developing a model of retinal 
degeneration in a non-human primate would allow for testing the therapy in an 
animal that has a macula, if a model could be generated that affects that macular 
region in a similar way to human dry AMD, would determine whether or not the 
cells are likely to be recruited to the area of the RPE that requires the most 
regeneration and protection in dry AMD.   
 
In addition to optimizing the therapy for a larger animal, there is also the potential 
for enhancing the therapeutic value of adult BMDCs in dry AMD by generating 
photoreceptor cells in addition to RPE-like cells for systemic injection. The 
photoreceptors are the most affected by dry AMD after the RPE cells, as the loss 
of function of RPE cells during the development of the disorder has a significant 
effect on the function of the photoreceptors. Replacing damaged RPE is only going 
to be effective if the overlying photoreceptors are still functional. While we are 
focusing on developing a therapy which can be delivered early in the progression 
of dry AMD, patients may not be diagnosed until some photoreceptor damage has 
already occurred, and in these cases, it would be advantageous to be able to 
regenerate photoreceptors at the same time as regenerating the RPE. 
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Theoretically, if BMDCs can be programmed to one non-hematopoietic retinal cell 
type, generating a second cell type should also be possible. In practice, it may be 
considerably more difficult to generate photoreceptors from BMDCs than it is to 
generate RPE-like cells. The reason for this is that, when programming BDMCs to 
RPE-like cells, we are not necessarily giving the cells a new function, but exploiting 
a capability they already have. Indeed, the naïve BMDCs’ ability to be recruited to 
and regenerate RPE without any manipulation, albeit at a low level, is likely to be 
the reason why it is possible to generate our cells from BMDCs in the first place. 
[216] Other stem cell types, such as iPSC and ESC, have been differentiated into 
RPE cells with relative ease, indicating that non-retinal stem cells may be innately 
predisposed to being able to differentiate into RPE. That being said, however, with 
the right genes, it is not beyond possibility that photoreceptor cells could be 
generated from BMDC, and the significant advantage to the overall therapy that 
delivering both RPE and photoreceptor cells would provide makes it worthwhile to 
try to generate these cells in addition to RPE. 
 
Another potential future direction is the use of BMDC-derived RPE-like cells as a 
preventive measure in patients identified as being at high risk for developing dry 
AMD. While not particularly viable with the current knowledge on the genetic basis 
for dry AMD development, as our understanding of the genetic components of the 
disorder increase, it may be possible in future to identify people at risk of 
developing the disorder before they develop it, and, in such cases, it may be 
beneficial to give the cells before any loss of vision occurs. We have demonstrated 
220 
 
that the cells are capable of migrating to the eye in a wild-type mouse, and that 
while they are present in all of the organs immediately after delivery, they 
preferentially localize to the eye and the spleen in the first 28 days post-injection. 
If cells that localize to the spleen can be retained there and then, at the onset of 
retinal injury, become recruited to the retina, injecting cells before significant retinal 
injury may provide a ‘pool’ of cells capable of regenerating that damage. This 
would be a relatively easy theory to test, as the cells could be given 1 week to 28 
days prior to SOD2-KD injury to determine whether or not having the cells present 
prior to injury would be sufficient to promote their migration and repair of the 
damage.  
 
Finally, early application of BMDC-derived RPE-like cells may also be applicable 
in inherited retinal disorders, for example, retinitis pigmentosa (RP) or leber 
congenital amaurosis – especially where the underlying cause of these disorders 
in a patient is mutations in the RPE65 gene, which occurs in approximately 2% 
and 16% of cases. [337] Early identification through prenatal screening for these 
disorders would allow for rapid intervention at birth, utilizing autologous CD34+ 
cord blood cells as a cell source. Injecting RPE-like cells derived from these cord 
blood cells within the first few weeks of life may be sufficient to preserve vision 
before it is lost, particularly if BMDC-derived photoreceptor cells can be given at 
the same time. An IDLV-based approach would be unlikely to function for this 
application, however. Due to mutations in the existing RPE65 gene, an ILV would 
be advantageous over an IDLV for these diseases as it would be performing a 
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second role in addition to programming the cells – replacing, and hopefully 
compensating for, a mutated gene. With the endogenous Rpe65 activation in 
murine BMDCs following infection with RPE65-vectors occurring after adenylate 
cyclase activation, endogenous RPE65 or at least sustained RPE65 expression 
from the ILV is likely to be required for the cells to be reparative and maintained in 
RP or LCA.  
 
Conclusion 
 
In conclusion, we have (Figure 1): 
(a) Generated an IDLV-based approach for reprogramming BDMCs to 
RPE-like cells which are recruited to and preserve vision in mouse 
models of retinal degeneration. 
(b) Improved the infection efficiency of IDLVs for short-term transgene 
expression in applications which only require transient expression. 
(c) Demonstrated that human BDMCs can be programmed to an RPE-like 
cell. 
(d) Confirmed the role of adenylate cyclase activation in BMDC 
programming to RPE-like cells. 
 
 
 
 
 
222 
 
Figure 6.1 
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Figure 6.1. A Summary of the Current Study.  
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APPENDICES 
 
Appendix 1:  Plasmid Sequences 
GeneArt RPE65  
TCTAGAGCTAGCACCGGTAtgtctatccaggttgagcatcctgctggtggttacaagaaactgtttgaaactgtggagga 
Actgtcctcgccgctcacagctcatgtaacaggcaggatacccctctggctcaccggcagtctccttcgatgtgggccag 
Gactctttgaagttggatctgagccattttaccacctgtttgatgggcaagccctcctgcacaagtttgactttaaagaa 
Ggacatgtcacataccacagaaggttcatccgcactgatgcttacgtacgggcaatgactgagaaaaggatcgtcataac 
Agaatttggcacctgtgctttcccagatccctgcaagaatatattttccaggtttttttcttactttcgaggagtagagg 
Ttactgacaatgcccttgttaatgtctacccagtgggggaagattactacgcttgcacagagaccaactttattacaaag 
Attaatccagagaccttggagacaattaagcaggttgatctttgcaactatgtctctgtcaatggggccactgctcaccc 
Ccacattgaaaatgatggaaccgtttacaatattggtaattgctttggaaaaaatttttcaattgcctacaacattgtaa 
Agatcccaccactgcaagcagacaaggaagatccaataagcaagtcagagatcgttgtccaattcccctgcagtgaccga 
ttcaagccatcttacgttcatagttttggtctgactcccaactatatcgtttttgtggagacaccagtcaaaattaacct 
gttcaagttcctttcttcatggagtctttggggagccaactacatggattgttttgagtccaatgaaaccatgggggttt 
ggcttcatattgctgacaaaaaaaggaaaaagtacctcaataataaatacagaacttctcctttcaacctcttccatcac 
atcaacacctatgaagacaatgggtttctgattgtggatctctgctgctggaaaggatttgagtttgtttataattactt 
atatttagccaatttacgtgagaactgggaagaggtgaaaaaaaatgccagaaaggctccccaacctgaagttaggagat 
atgtacttcctttgaatattgacaaggctgacacaggcaagaatttagtcacgctccccaatacaactgccactgcaatt 
ctgtgcagtgacgagactatctggctggagcctgaagttctcttttcagggcctcgtcaagcatttgagtttcctcaaat 
caattaccagaagtattgtgggaaaccttacacatatgcgtatggacttggcttgaatcactttgttccagataggctct 
gtaagctgaatgtcaaaactaaagaaacttgggtttggcaagagcctgattcatacccatcagaacccatctttgtttct 
cacccagatgccttggaagaagatgatggtgtagttctgagtgtggtggtgagcccaggagcaggacaaaagcctgctta 
tctcctgattctgaatgccaaggacttaagtgaagttgcccgggctgaagtggagattaacatccctgtcacctttcatg 
gactgttcaaaaaatcttgatcaTGTACAGGATCCGCGGCCGCgcagaggaagtcttctaacatgcggtgacgtggagga 
gaatcccggcccttccgCTCGAGGAATTCAAGCTTGTCGAC 
Multiple Cloning Site 
TTTCTGTTCTGCGCCGTTACAGATCCAAGCTGTGACCGGCGCCTACTCTAGAACCGGTGCCACCGAATT
CTGTACAATTT 
AAATGCGGCCGCGAGGGCAGAGGAAGTCTTCTAACATGCGGTGACGTGGAGGAGAATCCCGGCCCTG
GATCCCTTCCGGA 
ATGGAGAGCGACGAGAGCGGCCTGCCCGCCATGGAGATCGAGTGCCGCATCACCG 
pCDH-RPE65 (For ILV3-RPE65 and IDLV3-RPE65) 
acgcgtgtagtcttatgcaatactcttgtagtcttgcaacatggtaacgatgagttagcaacatgccttacaaggagaga 
aaaagcaccgtgcatgccgattggtggaagtaaggtggtacgatcgtgccttattaggaaggcaacagacgggtctgaca 
tggattggacgaaccactgaattgccgcattgcagagatattgtatttaagtgcctagctcgatacaataaacgggtctc 
tctggttagaccagatctgagcctgggagctctctggctaactagggaacccactgcttaagcctcaataaagcttgcct 
tgagtgcttcaagtagtgtgtgcccgtctgttgtgtgactctggtaactagagatccctcagacccttttagtcagtgtg 
gaaaatctctagcagtggcgcccgaacagggacctgaaagcgaaagggaaaccagagctctctcgacgcaggactcggct 
tgctgaagcgcgcacggcaagaggcgaggggcggcgactggtgagtacgccaaaaattttgactagcggaggctagaagg 
agagagatgggtgcgagagcgtcagtattaagcgggggagaattagatcgcgatgggaaaaaattcggttaaggccaggg 
ggaaagaaaaaatataaattaaaacatatagtatgggcaagcagggagctagaacgattcgcagttaatcctggcctgtt 
agaaacatcagaaggctgtagacaaatactgggacagctacaaccatcccttcagacaggatcagaagaacttagatcat 
tatataatacagtagcaaccctctattgtgtgcatcaaaggatagagataaaagacaccaaggaagctttagacaagata 
gaggaagagcaaaacaaaagtaagaccaccgcacagcaagcggccactgatcttcagacctggaggaggagatatgaggg 
acaattggagaagtgaattatataaatataaagtagtaaaaattgaaccattaggagtagcacccaccaaggcaaagaga 
agagtggtgcagagagaaaaaagagcagtgggaataggagctttgttccttgggttcttgggagcagcaggaagcactat 
gggcgcagcGtcaatgacgctgacggtacaggccagacaattattgtctggtatagtgcagcagcagaacaatttgctga 
gggctattgaggcgcaacagcatctgttgcaactcacagtctggggcatcaagcagctccaggcaagaatcctggctgtg 
gaaagatacctaaaggatcaacagctcctggggatttggggttgctctggaaaactcatttgcaccactgctgtgccttg 
gaatgctagttggagtaataaatctctggaacagattTggaatcacacgacctggatggagtgggacagagaaattaaca 
attacacaagcttaatacactccttaattgaagaatcgcaaaaccagcaagaaaagaatgaacaagaattattggaatta 
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gataaatgggcaagtttgtggaattggtttaacataacaaattggctgtggtatataaaattattcataatgatagtagg 
aggcttggtaggtttaagaatagtttttgctgtactttctatagtgaatagagttaggcagggatattcaccattatcgt 
ttcagacccacctcccaaccccgaggggacccgacaggcccgaaggaatagaagaagaaggtggagagagagacagagac 
agatccattcgattagtgaacggatctcgacggtATCGGTtaacttttaaaagaaaaggggggattggggggtacagtgc 
aggggaaagaatagtagacataatagcaacagacatacaaactaaagaattacaaaaacaaattacaaaattcaaaattt 
tatcgatactagtggatctgcgatcgctccggtgcccgtcagtgggcagagcgcacatcgcccacagtccccgagaagtt 
ggggggaggggtcggcaattgaacgggtgcctagagaaggtggcgcggggtaaactgggaaagtgatgtcgtgtactggc 
tccgcctttttcccgagggtgggggagaaccgtatataagtgcagtagtcgccgtgaacgttctttttcgcaacgggttt 
gccgccagaacacagctgaagcttcgaggggctcgcatctctccttcacgcgcccgccgccctacctgaggccgccatcc 
acgccggttgagtcgcgttctgccgcctcccgcctgtggtgcctcctgaactgcgtccgccgtctaggtaagtttaaagc 
tcaggtcgagaccgggcctttgtccggcgctcccttggagcctacctagactcagccggctctccacgctttgcctgacc 
ctgcttgctcaactctacgtctttgtttcgttttctgttctgcgccgttacagatccaagctgtgaccggcgcctacTct 
agAGCTAGCACCGGTAtgtctatccaggttgagcatcctgctggtggttacaagaaactgtttgaaactgtggaggaAct 
gtcctcgccgctcacagctcatgtaacaggcaggatacccctctggctcaccggcagtctccttcgatgtgggccagGac 
tctttgaagttggatctgagccattttaccacctgtttgatgggcaagccctcctgcacaagtttgactttaaagaaGga 
catgtcacataccacagaaggttcatccgcactgatgcttacgtacgggcaatgactgagaaaaggatcgtcataacAga 
atttggcacctgtgctttcccagatccctgcaagaatatattttccaggtttttttcttactttcgaggagtagaggTta 
ctgacaatgcccttgttaatgtctacccagtgggggaagattactacgcttgcacagagaccaactttattacaaagAtt 
aatccagagaccttggagacaattaagcaggttgatctttgcaactatgtctctgtcaatggggccactgctcacccCca 
cattgaaaatgatggaaccgtttacaatattggtaattgctttggaaaaaatttttcaattgcctacaacattgtaaAga 
tcccaccactgcaagcagacaaggaagatccaataagcaagtcagagatcgttgtccaattcccctgcagtgaccgattc 
aagccatcttacgttcatagttttggtctgactcccaactatatcgtttttgtggagacaccagtcaaaattaacctgtt 
caagttcctttcttcatggagtctttggggagccaactacatggattgttttgagtccaatgaaaccatgggggtttggc 
ttcatattgctgacaaaaaaaggaaaaagtacctcaataataaatacagaacttctcctttcaacctcttccatcacatc 
aacacctatgaagacaatgggtttctgattgtggatctctgctgctggaaaggatttgagtttgtttataattacttata 
tttagccaatttacgtgagaactgggaagaggtgaaaaaaaatgccagaaaggctccccaacctgaagttaggagatatg 
tacttcctttgaatattgacaaggctgacacaggcaagaatttagtcacgctccccaatacaactgccactgcaattctg 
tgcagtgacgagactatctggctggagcctgaagttctcttttcagggcctcgtcaagcatttgagtttcctcaaatcaa 
ttaccagaagtattgtgggaaaccttacacatatgcgtatggacttggcttgaatcactttgttccagataggctctgta 
agctgaatgtcaaaactaaagaaacttgggtttggcaagagcctgattcatacccatcagaacccatctttgtttctcac 
ccagatgccttggaagaagatgatggtgtagttctgagtgtggtggtgagcccaggagcaggacaaaagcctgcttatct 
cctgattctgaatgccaaggacttaagtgaagttgcccgggctgaagtggagattaacatccctgtcacctttcatggac 
tgttcaaaaaatcttgatcaTGTACAGGATCCGCGGCCGCgcagaggaagtcttctaacatgcggtgacgtggaggagaa 
tcccggcccttccgCTCGAGGAATTCAAGCTTGtcgacaatcaacctctggattacaaaatttgtgaaagattgactggt 
attcttaactatgttgctccttttacgctatgtggatacgctgctttaatgcctttgtatcatgctattgcttcccgtat 
ggctttcattttctcctccttgtataaatcctggttgctgtctctttatgaggagttgtggcccgttgtcaggcaacgtg 
gcgtggtgtgcactgtgtttgctgacgcaacccccactggttggggcattgccaccacctgtcagctcctttccgggact 
ttcgctttccccctccctattgccacggcggaactcatcgccgcctgccttgcccgctgctggacaggggctcggctgtt 
gggcactgacaattccgtggtgttgtcggggaaatcatcgtcctttccttggctgctcgcctgtgttgccacctggattc 
tgcgcgggacgtccttctgctacgtcccttcggccctcaatccagcggaccttccttcccgcggcctgctgccggctctg 
cggcctcttccgcgtcttcgccttcgccctcagacgagtcggatctccctttgggccgcctccccgcctggtacctttaa 
gaccaatgacttacaaggcagctgtagatcttagccactttttaaaagaaaaggggggactggaagggctaattcactcc 
caacgaaaataagatctgctttttgcttgtactgggtctctctggttagaccagatctgagcctgggagctctctggcta 
actagggaacccactgcttaagcctcaataaagcttgccttgagtgcttcaagtagtgtgtgcccgtctgttgtgtgact 
ctggtaactagagatccctcagacccttttagtcagtgtggaaaatctctagcagtagtagttcatgtcatcttattatt 
cagtatttataacttgcaaagaaatgaatatcagagagtgagaggaacttgtttattgcagcttataatggttacaaata 
aagcaatagcatcacaaatttcacaaataaagcatttttttcactgcattctagttgtggtttgtccaaactcatcaatg 
tatcttatcatgtctggctctagctatcccgcccctaactccgcccagttccgcccattctccgccccatggctgactaa 
ttttttttatttatgcagaggccgaggccgcctcggcctctgagctattccagaagtagtgaggaggcttttttggaggc 
ctagacttttgcagagacggcccaaattcgtaatcatggtcatagctgtttcctgtgtgaaattgttatccgctcacaat 
tccacacaacatacgagccggaagcataaagtgtaaagcctggggtgcctaatgagtgagctaactcacattaattgcgt 
tgcgctcactgcccgctttccagtcgggaaacctgtcgtgccagctgcattaatgaatcggccaacgcgcggggagaggc 
ggtttgcgtattgggcgctcttccgcttcctcgctcactgactcgctgcgctcggtcgttcggctgcggcgagcggtatc 
agctcactcaaaggcggtaatacggttatccacagaatcaggggataacgcaggaaagaacatgtgagcaaaaggccagc 
aaaaggccaggaaccgtaaaaaggccgcgttgctggcgtttttccataggctccgcccccctgacgagcatcacaaaaat 
cgacgctcaagtcagaggtggcgaaacccgacaggactataaagataccaggcgtttccccctggaagctccctcgtgcg 
ctctcctgttccgaccctgccgcttaccggatacctgtccgcctttctcccttcgggaagcgtggcgctttctcatagct 
cacgctgtaggtatctcagttcggtgtaggtcgttcgctccaagctgggctgtgtgcacgaaccccccgttcagcccgac 
cgctgcgccttatccggtaactatcgtcttgagtccaacccggtaagacacgacttatcgccactggcagcagccactgg 
taacaggattagcagagcgaggtatgtaggcggtgctacagagttcttgaagtggtggcctaactacggctacactagaa 
ggacagtatttggtatctgcgctctgctgaagccagttaccttcggaaaaagagttggtagctcttgatccggcaaacaa 
accaccgctggtagcggtggtttttttgtttgcaagcagcagattacgcgcagaaaaaaaggatctcaagaagatccttt 
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gatcttttctacggggtctgacgctcagtggaacgaaaactcacgttaagggattttggtcatgagattatcaaaaagga 
tcttcacctagatccttttaaattaaaaatgaagttttaaatcaatctaaagtatatatgagtaaacttggtctgacagt 
taccaatgcttaatcagtgaggcacctatctcagcgatctgtctatttcgttcatccatagttgcctgactccccgtcgt 
gtagataactacgatacgggagggcttaccatctggccccagtgctgcaatgataccgcgagacccacgctcaccggctc 
cagatttatcagcaataaaccagccagccggaagggccgagcgcagaagtggtcctgcaactttatccgcctccatccag 
tctattaattgttgccgggaagctagagtaagtagttcgccagttaatagtttgcgcaacgttgttgccattgctacagg 
catcgtggtgtcacgctcgtcgtttggtatggcttcattcagctccggttcccaacgatcaaggcgagttacatgatccc 
ccatgttgtgcaaaaaagcggttagctccttcggtcctccgatcgttgtcagaagtaagttggccgcagtgttatcactc 
atggttatggcagcactgcataattctcttactgtcatgccatccgtaagatgcttttctgtgactggtgagtactcaac 
caagtcattctgagaatagtgtatgcggcgaccgagttgctcttgcccggcgtcaatacgggataataccgcgccacata 
gcagaactttaaaagtgctcatcattggaaaacgttcttcggggcgaaaactctcaaggatcttaccgctgttgagatcc 
agttcgatgtaacccactcgtgcacccaactgatcttcagcatcttttactttcaccagcgtttctgggtgagcaaaaac 
aggaaggcaaaatgccgcaaaaaagggaataagggcgacacggaaatgttgaatactcatactcttcctttttcaatatt 
attgaagcatttatcagggttattgtctcatgagcggatacatatttgaatgtatttagaaaaataaacaaataggggtt 
ccgcgcacatttccccgaaaagtgccacctgacgtctaagaaaccattattatcatgacattaacctataaaaataggcg 
tatcacgaggccctttcgtctcgcgcgtttcggtgatgacggtgaaaacctctgacacatgcagctcccggagacggtca 
cagcttgtctgtaagcggatgccgggagcagacaagcccgtcagggcgcgtcagcgggtgttggcgggtgtcggggctgg 
cttaactatgcggcatcagagcagattgtactgagagtgcaccatatgcggtgtgaaataccgcacagatgcgtaaggag 
aaaataccgcatcaggcgccattcgccattcaggctgcgcaactgttgggaagggcgatcggtgcgggcctcttcgctat 
tacgccagctggcgaaagggggatgtgctgcaaggcgattaagttgggtaacgccagggttttcccagtcacgacgttgt 
aaaacgacggccagtgccaagctg 
 
pCDH-RPE65-MITF (For ILV3-RPE65-MITF and IDLV3-RPE65-MITF) 
CATGCTGGAAATGCTAGAATATAATCACTATCAGGTGCAGACCCACCTCGAAAACCCCACCAAGTACCA
CATACAGCAAG 
CCCAACGGCAGCAGGTAAAGCAGTACCTTTCTACCACTTTAGCAAATAAACATGCCAACCAAGTCCTGA
GCTTGCCATGT 
CCAAACCAGCCTGGCGATCATGTCATGCCACCGGTGCCGGGGAGCAGCGCACCCAACAGCCCCATGG
CTATGCTTACGCT 
TAACTCCAACTGTGAAAAAGAGGGATTTTATAAGTTTGAAGAGCAAAACAGGGCAGAGAGCGAGTGCC
CAGGCATGAACA 
CACATTCACGAGCGTCCTGTATGCAGATGGATGATGTAATCGATGACATCATTAGCCTAGAATCAAGTT
ATAATGAGGAA 
ATCTTGGGCTTGATGGATCCTGCTTTGCAAATGGCAAATACGTTGCCTGTCTCGGGAAACTTGATTGAT
CTTTATGGAAA 
CCAAGGTCTGCCCCCACCAGGCCTCACCATCAGCAACTCCTGTCCAGCCAACCTTCCCAACATAAAAA
GGGAGCTCACAG 
AGTCTGAAGCAAGAGCACTGGCCAAAGAGAGGCAGAAAAAGGACAATCACAACCTGATTGAACGAAGA
AGAAGATTTAAC 
ATAAATGACCGCATTAAAGAACTAGGTACTTTGATTCCCAAGTCAAATGATCCAGACATGCGCTGGAAC
AAGGGAACCAT 
CTTAAAAGCATCCGTGGACTATATCCGAAAGTTGCAACGAGAACAGCAACGCGCAAAAGAACTTGAAAA
CCGACAGAAGA 
AACTGGAGCACGCCAACCGGCATTTGTTGCTCAGAATACAGGAACTTGAAATGCAGGCTCGAGCTCAT
GGACTTTCCCTT 
ATTCCATCCACGGGTCTCTGCTCTCCAGATTTGGTGAATCGGATCATCAAGCAAGAACCCGTTCTTGAG
AACTGCAGCCA 
AGACCTCCTTCAGCATCATGCAGACCTAACCTGTACAACAACTCTCGATCTCACGGATGGCACCATCAC
CTTCAACAACA 
ACCTCGGAACTGGGACTGAGGCCAACCAAGCCTATAGTGTCCCCACAAAAATGGGATCCAAACTGGAA
GACATCCTGATG 
GACGACACCCTTTCTCCCGTCGGTGTCACTGATCCACTCCTTTCCTCAGTGTCCCCCGGAGCTTCCAAA
ACAAGCAGCCG 
GAGGAGCAGTATGAGCATGGAAGAGACGGAGCACACTTGTAagctTGtcgacaatcaacctctggattacaaaatttgtg 
aaagattgactggtattcttaactatgttgctccttttacgctatgtggatacgctgctttaatgcctttgtatcatgct 
attgcttcccgtatggctttcattttctcctccttgtataaatcctggttgctgtctctttatgaggagttgtggcccgt 
tgtcaggcaacgtggcgtggtgtgcactgtgtttgctgacgcaacccccactggttggggcattgccaccacctgtcagc 
tcctttccgggactttcgctttccccctccctattgccacggcggaactcatcgccgcctgccttgcccgctgctggaca 
ggggctcggctgttgggcactgacaattccgtggtgttgtcggggaaatcatcgtcctttccttggctgctcgcctgtgt 
tgccacctggattctgcgcgggacgtccttctgctacgtcccttcggccctcaatccagcggaccttccttcccgcggcc 
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tgctgccggctctgcggcctcttccgcgtcttcgccttcgccctcagacgagtcggatctccctttgggccgcctccccg 
cctggtacctttaagaccaatgacttacaaggcagctgtagatcttagccactttttaaaagaaaaggggggactggaag 
ggctaattcactcccaacgaaaataagatctgctttttgcttgtactgggtctctctggttagaccagatctgagcctgg 
gagctctctggctaactagggaacccactgcttaagcctcaataaagcttgccttgagtgcttcaagtagtgtgtgcccg 
tctgttgtgtgactctggtaactagagatccctcagacccttttagtcagtgtggaaaatctctagcagtagtagttcat 
gtcatcttattattcagtatttataacttgcaaagaaatgaatatcagagagtgagaggaacttgtttattgcagcttat 
aatggttacaaataaagcaatagcatcacaaatttcacaaataaagcatttttttcactgcattctagttgtggtttgtc 
caaactcatcaatgtatcttatcatgtctggctctagctatcccgcccctaactccgcccagttccgcccattctccgcc 
ccatggctgactaattttttttatttatgcagaggccgaggccgcctcggcctctgagctattccagaagtagtgaggag 
gcttttttggaggcctagacttttgcagagacggcccaaattcgtaatcatggtcatagctgtttcctgtgtgaaattgt 
tatccgctcacaattccacacaacatacgagccggaagcataaagtgtaaagcctggggtgcctaatgagtgagctaact 
cacattaattgcgttgcgctcactgcccgctttccagtcgggaaacctgtcgtgccagctgcattaatgaatcggccaac 
gcgcggggagaggcggtttgcgtattgggcgctcttccgcttcctcgctcactgactcgctgcgctcggtcgttcggctg 
cggcgagcggtatcagctcactcaaaggcggtaatacggttatccacagaatcaggggataacgcaggaaagaacatgtg 
agcaaaaggccagcaaaaggccaggaaccgtaaaaaggccgcgttgctggcgtttttccataggctccgcccccctgacg 
agcatcacaaaaatcgacgctcaagtcagaggtggcgaaacccgacaggactataaagataccaggcgtttccccctgga 
agctccctcgtgcgctctcctgttccgaccctgccgcttaccggatacctgtccgcctttctcccttcgggaagcgtggc 
gctttctcatagctcacgctgtaggtatctcagttcggtgtaggtcgttcgctccaagctgggctgtgtgcacgaacccc 
ccgttcagcccgaccgctgcgccttatccggtaactatcgtcttgagtccaacccggtaagacacgacttatcgccactg 
gcagcagccactggtaacaggattagcagagcgaggtatgtaggcggtgctacagagttcttgaagtggtggcctaacta 
cggctacactagaaggacagtatttggtatctgcgctctgctgaagccagttaccttcggaaaaagagttggtagctctt 
gatccggcaaacaaaccaccgctggtagcggtggtttttttgtttgcaagcagcagattacgcgcagaaaaaaaggatct 
caagaagatcctttgatcttttctacggggtctgacgctcagtggaacgaaaactcacgttaagggattttggtcatgag 
attatcaaaaaggatcttcacctagatccttttaaattaaaaatgaagttttaaatcaatctaaagtatatatgagtaaa 
cttggtctgacagttaccaatgcttaatcagtgaggcacctatctcagcgatctgtctatttcgttcatccatagttgcc 
tgactccccgtcgtgtagataactacgatacgggagggcttaccatctggccccagtgctgcaatgataccgcgagaccc 
acgctcaccggctccagatttatcagcaataaaccagccagccggaagggccgagcgcagaagtggtcctgcaactttat 
ccgcctccatccagtctattaattgttgccgggaagctagagtaagtagttcgccagttaatagtttgcgcaacgttgtt 
gccattgctacaggcatcgtggtgtcacgctcgtcgtttggtatggcttcattcagctccggttcccaacgatcaaggcg 
agttacatgatcccccatgttgtgcaaaaaagcggttagctccttcggtcctccgatcgttgtcagaagtaagttggccg 
cagtgttatcactcatggttatggcagcactgcataattctcttactgtcatgccatccgtaagatgcttttctgtgact 
ggtgagtactcaaccaagtcattctgagaatagtgtatgcggcgaccgagttgctcttgcccggcgtcaatacgggataa 
taccgcgccacatagcagaactttaaaagtgctcatcattggaaaacgttcttcggggcgaaaactctcaaggatcttac 
cgctgttgagatccagttcgatgtaacccactcgtgcacccaactgatcttcagcatcttttactttcaccagcgtttct 
gggtgagcaaaaacaggaaggcaaaatgccgcaaaaaagggaataagggcgacacggaaatgttgaatactcatactctt 
cctttttcaatattattgaagcatttatcagggttattgtctcatgagcggatacatatttgaatgtatttagaaaaata 
aacaaataggggttccgcgcacatttccccgaaaagtgccacctgacgtctaagaaaccattattatcatgacattaacc 
tataaaaataggcgtatcacgaggccctttcgtctcgcgcgtttcggtgatgacggtgaaaacctctgacacatgcagct 
cccggagacggtcacagcttgtctgtaagcggatgccgggagcagacaagcccgtcagggcgcgtcagcgggtgttggcg 
ggtgtcggggctggcttaactatgcggcatcagagcagattgtactgagagtgcaccatatgcggtgtgaaataccgcac 
agatgcgtaaggagaaaataccgcatcaggcgccattcgccattcaggctgcgcaactgttgggaagggcgatcggtgcg 
ggcctcttcgctattacgccagctggcgaaagggggatgtgctgcaaggcgattaagttgggtaacgccagggttttccc 
agtcacgacgttgtaaaacgacggccagtgccaagctgacgcgtgtagtcttatgcaatactcttgtagtcttgcaacat 
ggtaacgatgagttagcaacatgccttacaaggagagaaaaagcaccgtgcatgccgattggtggaagtaaggtggtacg 
atcgtgccttattaggaaggcaacagacgggtctgacatggattggacgaaccactgaattgccgcattgcagagatatt 
gtatttaagtgcctagctcgatacaataaacgggtctctctggttagaccagatctgagcctgggagctctctggctaac 
tagggaacccactgcttaagcctcaataaagcttgccttgagtgcttcaagtagtgtgtgcccgtctgttgtgtgactct 
ggtaactagagatccctcagacccttttagtcagtgtggaaaatctctagcagtggcgcccgaacagggacctgaaagcg 
aaagggaaaccagagctctctcgacgcaggactcggcttgctgaagcgcgcacggcaagaggcgaggggcggcgactggt 
gagtacgccaaaaattttgactagcggaggctagaaggagagagatgggtgcgagagcgtcagtattaagcgggggagaa 
ttagatcgcgatgggaaaaaattcggttaaggccagggggaaagaaaaaatataaattaaaacatatagtatgggcaagc 
agggagctagaacgattcgcagttaatcctggcctgttagaaacatcagaaggctgtagacaaatactgggacagctaca 
accatcccttcagacaggatcagaagaacttagatcattatataatacagtagcaaccctctattgtgtgcatcaaagga 
tagagataaaagacaccaaggaagctttagacaagatagaggaagagcaaaacaaaagtaagaccaccgcacagcaagcg 
gccactgatcttcagacctggaggaggagatatgagggacaattggagaagtgaattatataaatataaagtagtaaaaa 
ttgaaccattaggagtagcacccaccaaggcaaagagaagagtggtgcagagagaaaaaagagcagtgggaataggagct 
ttgttccttgggttcttgggagcagcaggaagcactatgggcgcagcGtcaatgacgctgacggtacaggccagacaatt 
attgtctggtatagtgcagcagcagaacaatttgctgagggctattgaggcgcaacagcatctgttgcaactcacagtct 
ggggcatcaagcagctccaggcaagaatcctggctgtggaaagatacctaaaggatcaacagctcctggggatttggggt 
tgctctggaaaactcatttgcaccactgctgtgccttggaatgctagttggagtaataaatctctggaacagattTggaa 
tcacacgacctggatggagtgggacagagaaattaacaattacacaagcttaatacactccttaattgaagaatcgcaaa 
accagcaagaaaagaatgaacaagaattattggaattagataaatgggcaagtttgtggaattggtttaacataacaaat 
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tggctgtggtatataaaattattcataatgatagtaggaggcttggtaggtttaagaatagtttttgctgtactttctat 
agtgaatagagttaggcagggatattcaccattatcgtttcagacccacctcccaaccccgaggggacccgacaggcccg 
aaggaatagaagaagaaggtggagagagagacagagacagatccattcgattagtgaacggatctcgacggtATCGGTta 
acttttaaaagaaaaggggggattggggggtacagtgcaggggaaagaatagtagacataatagcaacagacatacaaac 
taaagaattacaaaaacaaattacaaaattcaaaattttatcgatactagtggatctgcgatcgctccggtgcccgtcag 
tgggcagagcgcacatcgcccacagtccccgagaagttggggggaggggtcggcaattgaacgggtgcctagagaaggtg 
gcgcggggtaaactgggaaagtgatgtcgtgtactggctccgcctttttcccgagggtgggggagaaccgtatataagtg 
cagtagtcgccgtgaacgttctttttcgcaacgggtttgccgccagaacacagctgaagcttcgaggggctcgcatctct 
ccttcacgcgcccgccgccctacctgaggccgccatccacgccggttgagtcgcgttctgccgcctcccgcctgtggtgc 
ctcctgaactgcgtccgccgtctaggtaagtttaaagctcaggtcgagaccgggcctttgtccggcgctcccttggagcc 
tacctagactcagccggctctccacgctttgcctgaccctgcttgctcaactctacgtctttgtttcgttttctgttctg 
cgccgttacagatccaagctgtgaccggcgcctacTCTAGAGctagCACCGGTAtgtctatccaggttgagcatcctgct 
ggtggttacaagaaactgtttgaaactgtggaggaActgtcctcgccgctcacagctcatgtaacaggcaggatacccct 
ctggctcaccggcagtctccttcgatgtgggccagGactctttgaagttggatctgagccattttaccacctgtttgatg 
ggcaagccctcctgcacaagtttgactttaaagaaGgacatgtcacataccacagaaggttcatccgcactgatgcttac 
gtacgggcaatgactgagaaaaggatcgtcataacAgaatttggcacctgtgctttcccagatccctgcaagaatatatt 
ttccaggtttttttcttactttcgaggagtagaggTtactgacaatgcccttgttaatgtctacccagtgggggaagatt 
actacgcttgcacagagaccaactttattacaaagAttaatccagagaccttggagacaattaagcaggttgatctttgc 
aactatgtctctgtcaatggggccactgctcacccCcacattgaaaatgatggaaccgtttacaatattggtaattgctt 
tggaaaaaatttttcaattgcctacaacattgtaaAgatcccaccactgcaagcagacaaggaagatccaataagcaagt 
cagagatcgttgtccaattcccctgcagtgaccgattcaagccatcttacgttcatagttttggtctgactcccaactat 
atcgtttttgtggagacaccagtcaaaattaacctgttcaagttcctttcttcatggagtctttggggagccaactacat 
ggattgttttgagtccaatgaaaccatgggggtttggcttcatattgctgacaaaaaaaggaaaaagtacctcaataata 
aatacagaacttctcctttcaacctcttccatcacatcaacacctatgaagacaatgggtttctgattgtggatctctgc 
tgctggaaaggatttgagtttgtttataattacttatatttagccaatttacgtgagaactgggaagaggtgaaaaaaaa 
tgccagaaaggctccccaacctgaagttaggagatatgtacttcctttgaatattgacaaggctgacacaggcaagaatt 
tagtcacgctccccaatacaactgccactgcaattctgtgcagtgacgagactatctggctggagcctgaagttctcttt 
tcagggcctcgtcaagcatttgagtttcctcaaatcaattaccagaagtattgtgggaaaccttacacatatgcgtatgg 
acttggcttgaatcactttgttccagataggctctgtaagctgaatgtcaaaactaaagaaacttgggtttggcaagagc 
ctgattcatacccatcagaacccatctttgtttctcacccagatgccttggaagaagatgatggtgtagttctgagtgtg 
gtggtgagcccaggagcaggacaaaagcctgcttatctcctgattctgaatgccaaggacttaagtgaagttgcccgggc 
tgaagtggagattaacatccctgtcacctttcatggactgttcaaaaaatcttgatcaTGTACAGGATCCGCGGCCGCgc 
agaggaagtcttctaacatgcggtgacgtggaggagaatcccggcccttccgCTCGAGGaatt 
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Appendix 2: Gene Expression Over Time 
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Appendix 2: Expression of cKit and Sca1 in FACS sorted Lin-Sca1+ cells decreases after RPE65, 
Rpe65 and Cralbp expression is initiated, approximately 2 hours after treatment with ILV3-RPE65 
or IDLV3-RPE65. 
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